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ABBREVIATIONS 
 
αB-STA Non-phosphorylatable αB-   
   crystallin  
αB-STD Pseudophosphorylated αB-   
   crystallin  
αB-WT  Wild-type αB-crystallin    
AGO2  Argonaute 2   
AKT  Protein kinase B  
ANOVA Analysis of variance   
ARCON Accelerated radiotherapy,    
   carbogen, nicotinamide   
ATP  Adenosine Tri-phosphate  
BRCA  Breast Cancer susceptibility gene 
BSA  Bovine Serum Albumine  
CK   Cytokeratin    
CRM1  Chromosome region maintenance  
   1     
DFS  Disease-Free Surviva   
DMEM  Dulbecco's modified Eagle's    
   medium  
DNA  Deoxyribonucleic acid   
DOX  Doxycyclin    
DTT  Dithiothreitol  
EDTA  Ethylenediaminetetraacetic acid  
EGF  Epithelial growth factor   
EGFP  Enhanced Green Fluorescent   
   Protein  
EGFR   Growth factor receptor  
EGTA  Ethylene glycol tetraacetic acid 
EMEM  Eagle's minimal essential medium 
EMT  Epithelial-to-Mesenchymal    
   Transition 
ER   Estrogen receptor 
ER   Endoplasmic reticulum 
ERK1/2 Extracellular regulated protein   
   kinase1/2 
ETS-1  E26 transformation-specific-1 
FBX4  F-Box protein X4 
FCS  Fetal Calf Serum 
GFAP  Glial fibrillary acidic protein 
GST  Glutathione S-transferase 
GTP  Guanosine-5'-triphosphate 
HEPES  4-(2-hydroxyethyl)-1-    
   piperazineethanesulfonic acid 
HER2  Epidermal growth factor receptor 2 
HIF-1  Hypoxia-inducible factor 1  
HNSCC Head and neck squamous cell   
   carcinoma    
HSF1  Heat shock factor 1    
HSP  Heat shock protein     
IGC  Interchromatic granule cluster  
IGF-1R  Insulin-like growth factor 1 receptor   
LEDGF  Lens epithelial derived growth factor  
LRC  Locoregional control    
LRR  Locoregional recurrence  
LUC  Luciferase   
MAPK  Mitogen-activated protein kinase   
MEK  Mitogen-activated protein kinase  
   kinase    
METS  Mitogenic Ets transcriptional   
   suppressor    
MFS  Metastasis-free survival    
MK  Mitogen activated protein kinase- 
   activated protein kinase 
MOPS  3-(N-morpholino)propanesulfonic  
   acid     
MSK1  Mitogen- and stress-activated protein 
   kinase-1    
mTOR  Mammalian Target of Rapamycin  
NAC  N-acetylcysteine   
NADPH Nicotinamide adenine dinucleotide  
   phosphate    
NMR  Nuclear Magnetic Resonance  
NRF2  NF-E2-related factor 2     
pAKT  phospho-AKT       
PBS  phosphate-buffered saline    
PHD  Prolyl hydroxylase     
pERK1/2  phospho-ERK1/2      
pmTOR phospho-mTOR       
POP1  Ribonucleases P/MRP protein subunit 
PR   Progesterone receptor     
RAS  Oncogene protein P21    
ROC  Receiver operating characteristic  
ROS   Reactive oxygen species    
RT-PCR Real-time polymerase chain reaction  
SDS  Sodium dodecyl sulfate    
SF-1  Splicing factor 1     
SMA  Smooth muscle actin     
SMN  Survival motor neuron    
snRNP  Small nuclear ribonucleic particles  
TMA  Tumor microarray      
TRAIL   Tumor necrosis factor-related   
   apoptosis-inducing ligand   
VEGF  Vascular endothelial growth factor  
VHL  Von Hippel-Lindau protein 
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In this thesis, the endeavor to elucidate the steps of cancer formation in which small 
heat shock protein αB-crystallin can intertwine is described. This introductory chapter 
is meant to provide background information on this protein to help understand how it 
can be involved in the development of cancer. Chapter 2 will provide an introduction 
on cancer formation. The emphasis will be on head and neck squamous cell carcinoma 
(HNSCC) and breast cancer, since these two types of cancers are the major research 
subjects in this thesis.  
 
 
1. EVOLUTIONARY ASPECTS OF SMALL HEAT SHOCK PROTEINS  
 
Back in 1894 α-crystallin, now known to be composed of αA- and αB-crystallin, was 
discovered as a structural protein in the mammalian eye lens (1). Differentiated lens 
fiber cells have the unique property, as do erythrocytes, that they lack protein turnover 
due to the absence of cellular organelles, such as nuclei and mitochondria. Yet, these 
cells must remain viable and their proteins must keep their functional integrity. To 
maintain transparency of the lens, aggregation of the ageing lens proteins must be 
avoided. The role of αA- and αB-crystallin, now also called HSPB4 and HSPB5, was 
stepwise unraveled in this process. Around 1973, the sequence of bovine αA- and αB-
crystallin was determined by direct protein sequencing (2;3). Later, in 1982, it was 
realized that αA- and αB-crystallin belong to the family of sHSPs based on 
conspicuous sequence similarities with four Drosophila melanogaster sHSPs (4). Ten 
years later, by virtue of their ability to prevent the aggregation of unfolding proteins, 
αA- and αB-crystallin were recognized as molecular chaperones (5). However, their 
activity is generally considered as ‘chaperone-like’, because of their inability to refold 
proteins with the help of ATP.  
One by one the other human sHSPs were discovered that share conspicuous sequence 
identity with αA- and αB-crystallin. At present, there are ten HSPB family members 
known, called HSPB1-10. These possess the α-crystallin domain as the defining feature 
of their evolutionary relationship (Figure 1 position 113 - 201).  
Outside the α-crystallin domain, sHSPs have a low sequence similarity, although a few 
recurring motifs can be recognized. Noticeable is the “IPI/V” motif, which is localized 
in the C-terminal extension of a number of sHSPs (Figure 1, positions 218 - 220). This 
motif is thought to play both a structural and functional role in these proteins (6). In the 
N-terminal region several sHSPs display a SRLFDQxFG-like motif (Figure 1, 
positions 51 - 59); this motif has been pinpointed as important as well (7). Deleting this 
part affects the higher order assembly of the subunits and structural stability, as well as 
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the chaperone-like activity. The genes encoding HSPB1-10 are scattered over the 
different chromosomes. Only HSPB2 and αB-crystallin form an exception as they are 
arranged as a head-to-head gene pair on chromosome 11 (8). The chromosomal 
dispersal together with the sequence divergence, which amounts to 45 to 85%, suggests 
that the duplications responsible for these multiple genes occurred before the earliest 
divergence of present vertebrates. Indeed, in lower vertebrates orthologs of all 
mammalian sHSPs have been identified, except for HSPB10 (9;10). Based on a 
sequence alignment of human, mouse and chicken sHSPs, a maximum likelihood tree 
has been constructed, which facilitates the comparison of the evolutionary relationships 
between these proteins (Figure 2). It confirms that HSPB4-6 are each other’s closest 
relatives, as are HSPB2 and HSPB3. HSPB9 and HSPB10 are clearly the earliest 
diverging and most deviating sHSPs.  
 
 
Figure 1. Alignment of the human HSP27 (HSPB1), HSPB2, HSPB3, αA-crystallin 
(HSPB4), αB-crystallin (HSPB5), HSP20 (HSPB6), cvHSP (HSPB7), HSPB8, HSPB9 
and HSPB10. ClustalW v1.83 (11) was used to align the sequences at default settings. The 
C-terminal part (residues 200-250) was manually edited using GeneDoc (12). Similarity 
groups used for shading are DN, EQ, ST, KR, FYW and LIVM. Residues in black are 
conserved in 8-10 sequences and those in grey in 6-7. The β-strands that were identified by 
solid state NMR in HSPB5 (13) are indicated below the alignment. The arrowhead 
indicates the structurally and functionally important Arg in the α-crystallin domain. The N-
terminal SRLFDQxFG motif is located at positions 51 to 59, the C-terminal IPI/V motif at 
positions 218 to 220 (14). 
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Figure 2. Maximum Likelihood tree of HSP27 (HSPB1), HSPB2, HSPB3, αA-
crystallin (HSPB4), αB-crystallin (HSPB5), HSP20 (HSPB6), cvHSP (HSPB7), 
HSPB8, HSPB9 and HSPB10. The online PhyML program (http://atgc.lirmm.fr/phyml/ 
(15)) was used to calculate the Maximum Likelihood tree of the human (Hs), mouse (Mm) 
and chicken (Gg) proteins, using 500 bootstrap sets, the WAG model of substitution, 
estimated proportion of invariable sites, estimated gamma correction parameter and a 
BIONJ tree as starting point. The alignment used for this calculation was made with 
ClustalW v1.83 at default settings. 
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2. STRUCTURE OF sHSPs 
 
One of the most notable features of sHSPs is their organization as large oligomeric 
structures. Human sHSPs, such as αB-crystallin, αA-crystallin and HSP27 (HSPB1), 
exhibit a remarkable polydispersity in their oligomeric states. Through interactions 
with themselves or with other sHSPs, homo- and hetero-oligomers can be formed 
containing up to 50 subunits (5;16;17). The quaternary structures are dynamic, which is 
reflected by rapid subunit exchange under native and stress conditions (18;19). The 
subunit exchange is markedly enhanced at high temperature, which may be a key factor 
in preventing protein aggregation during heat denaturation.  
The α-crystallin domain plays a central role in sHSP oligomerization across the 
evolutionary spectrum and is necessary to form the dimeric building blocks of which 
larger oligomeric structures are composed (20;21). Structurally important residues in 
the amino acid sequences of the α-crystallin domain are well conserved, and the 
predicted secondary structure shows a clear conservation of β-strand structures (Figure 
1, (10;13;22;23)). These β-strands assemble into a β-sandwich. 
The α-crystallin domain is surrounded by a hydrophobic N-terminal region and a rather 
short and polar C-terminal extension. The last 10-18 residues of the C-terminal 
extension are highly flexible as determined by NMR studies (24). This extension acts 
as a solubilizer to counteract the hydrophobicity associated with the target protein 
sequestration. Many of these C-terminal extensions contain a short β-strand formed by 
the conserved IPI/V motif. This strand is able to make contact with a hydrophobic 
patch in the α-crystallin domain of a neighboring subunit, which is critical for the 
oligomer formation (20;25) and is important for the functioning of sHSPs (26;27). 
Also, the N-terminal region plays an important role in the stabilization of the assembly 
and the formation of oligomers (28). This likely occurs via hydrophobic contacts 
between the N-terminal regions of the subunits that are buried inside the oligomer (25). 
In the case of αB-crystallin, a model based on NMR observations reveals that the α-
crystallin domain is responsible for dimer formation, that the C-terminal regions are 
responsible for defining hexameric units, and the N-terminal region and α-crystallin 
domain are responsible for higher-order multimerization (28). In addition, 
crystallization studies demonstrated that a highly conserved arginine, position 173 in 
Figure 1, plays an important role in the formation of intermolecular interactions that 
mediate the assembly of higher-order structures and substrate binding. Mutations of 
this residue in human sHSPs are associated with cataract, myopathy and neuropathy. 
Delbecq and Klevit reviewed several studies in which the oligomerization of αB-
crystallin was addressed. Taken together, these studies indicate that αB-crystallin forms 
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oligomers composed of 10-40 monomers. They conclude that αB-crystallin exists as a 
distribution of oligomeric species that include dimers, hexamers, and multiples of 
hexamers, and that the relatively short lifetime and small population of the smaller 
species limit their detection under native conditions (29-31). 
 
 
3. EXPRESSION OF sHSPS 
 
The expression of sHSPs changes during development and may vary depending on the 
local stress conditions. Under non-stress conditions αB-crystallin, HSP27, HSP20 and 
HSPB8 are ubiquitously expressed in most tissues, with a high expression level in 
cardiac and skeletal muscle (32-38). αA-crystallin is abundantly expressed together 
with αB-crystallin in the eye lens (39;40), but is almost undetectable in other tissues 
(33;36;41;42). Interestingly, the expression patterns of the head-to-head located genes 
for HSPB2 and αB-crystallin are not identical, indicating that besides shared, promoter-
preferred transcriptional regulatory elements are present as well (43-45).  
Several, but not all, members of the sHSP family exhibit a pattern of inducible 
expression in response to heat or other physiological stimuli. Heat shock is a 
commonly applied type of stress to determine whether the transcription of a gene is 
promoted by heat shock transcription factor 1 (HSF1). So far, it has been shown that 
αB-crystallin, HSP27 and HSPB8 are heat shock inducible, while no induction has 
been observed for HSPB2, HSPB3, αA-crystallin and HSP20 (46). Many other types of 
stress, such as osmotic or arsenite stress (47), hypoxia/reoxygenation (48), oxidative 
stress (49), exposure to heavy metals (50), and enforced exercise (51;52) can increase 
the expression of different sHSP as well. 
Certain diseases are associated with enhanced sHSP expression, especially 
neurodegenerative disorders and cancer. In brains of Alzheimer’s patients, increased 
expression of αB-crystallin and HSP27 has been observed in the activated glial cells 
close to the pathological lesions (53). Also, high levels of constitutive HSP27 and αB-
crystallin expression have been detected in several cancers, particularly those of 
carcinoma origin (54).  
 
 
4. POST-TRANSLATIONAL MODIFICATIONS 
 
Some, if not most, sHSPs can be phosphorylated, allowing to control their functioning 
by signal transduction pathways (55;56). Most sHSPs have their phosphorylatable 
serine residues localized in the N-terminal region. Phosphorylation of αB-crystallin 
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occurs at S19 by an unknown protein kinase, at S45 by ERK1/2 MAPK and at S59 by 
MK2 (57). In response to a wide variety of stimuli, growth factors, differentiation-
inducing agents, tumor necrosis factor, oxidative stress or heat shock, αB-crystallin is 
rapidly phosphorylated, which modulates its activity (54). Upon phosphorylation the 
distribution of oligomers shifts from mainly large αB-crystallin oligomers toward 
higher levels of smaller oligomeric structures (58;59).  
Moreover, mimicking phosphorylation enhances chaperone activity, preventing the 
aggregation of most of the target proteins that were studied (60). The cellular 
distribution of αB-crystallin can change as well. Phosphorylation of serines 45 and 59 
leads to translocation into the cell nuclei. αB-crystallin is localized here in so-called 
“speckles”, which are nuclear bodies that function as storage compartments for splicing 
factors (61). In response to stress, αB-crystallin is also known to interact with the three 
major cytoskeletal components, i.e. microtubules, intermediate filaments and 
microfilaments (62). Phosphorylation is probably important for these interactions, since 
αB-crystallin phosphorylated at S59 colocalizes with the cytoskeleton components, 
such as vinculin in focal adhesion and desmin in aggregates (63). 
Beside phosphorylation other modifications can occur as well. Deamidation is an 
aging-related process, resulting in the replacement of an amide group by a carboxylate 
group. This introduces a negative charge, which has been shown to affect the 
oligomeric structure and chaperone-like activity of αB-crystallin (64). Other well-
known modifications on α-crystallin are truncation (65;66), oxidation (67), glycation 
(68-71) and racemization/isomerization (72). The structural and functional implications 
of these modifications are not known yet. 
 
 
5. INTERACTIONS WITH UNFOLDING PROTEINS 
 
During unfolding of a protein, hydrophobic residues from the interior will be exposed 
and are responsible for aggregation. These protein aggregates can accumulate over 
time, which may lead to age-related diseases. Progress in understanding the mechanism 
of chaperone function of sHSPs has been achieved mainly by a biochemical approach 
using purified sHSPs and model substrate proteins. The chaperone activity is measured 
by its ability to prevent thermally or chemically induced aggregation of a substrate. 
Aggregation is a late step in the unfolding pathway (Figure 3). By interacting with 
partially unfolded proteins, sHSPs inhibit the aggregation process (25). Both the N-
terminal and C-terminal regions have been postulated to be involved in the chaperone 
function of sHSPs (20). This is based on cross-linking studies with a hydrophobic 
probe or small substrates. Once formed, complexes between substrates and sHSPs are 
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very stable. Electron microscopic images have revealed large complexes, of which the 
morphology depends on the nature of the substrate proteins and the respective sHSPs 
(73). In addition to these large complexes, still larger assemblies of substrate proteins 
and sHSPs have been observed when an excess of non-native proteins is present. In 
patients with aggregation diseases large accumulations of sHSPs with protein 
aggregates have been observed. Diseases associated with αB-crystallin containing 
aggregates are, Rosenthal fibers in Alexander disease (74), Lewy bodies in Parkinson's 
disease (75) and inclusion bodies in myopathies (76). In these situations, the 
incorporation of sHSPs into protein aggregates is believed to facilitate the reactivation 
or degradation of substrates. Although the critical role of sHSPs in conferring stress 
tolerance to cells is well established (77), their role in cellular protein refolding is less 
clear. The binding capacity can reach one substrate protein per sHSP subunit, 
indicating that sHSPs can be a major contributor to the chaperoning capacity of a cell. 
sHSP chaperone activity does not require ATP, and release of the bound substrate with 
subsequent refolding can be accomplished through interaction with HSP70 (78;79). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Model for the chaperone functioning of sHSPs under stress conditions. 
Unfolding of native proteins can lead to (insoluble) aggregations. Partially unfolded 
proteins can be bound by sHSPs, keeping them in a soluble state, which is accessible for 
HSP70 and HSP40. These ATP-dependent chaperones can refold the protein to its native 
state (14). 
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Studies in Escherichia coli and Saccharomyces cerevisiae revealed the involvement of 
a cooperative cellular chaperone network connected to the sHSP-substrate complexes 
comprised of HSP70-HSP40 (80-83) (Figure 3 ). 
 
 
6. INTERACTIONS WITH PARTNER PROTEINS 
 
Interaction between proteins is a key element in building structures and functional 
protein complexes. These interactions are often transient, and are essential for the 
activities associated with biological processes. αB-crystallin interacts with other sHSPs 
to form mixed oligomeric complexes and with unrelated partners to fulfill a broad 
range of functions, which makes this protein very versatile. Here we focus on four 
important functions, involving hetero-oligomer formation, cytoskeletal organization, 
apoptosis and protein degradation. 
 
 
6.1. INTERACTIONS BETWEEN sHSPS 
 
In muscle cells, seven sHSPs are abundantly expressed (Figure 4). In these cells, 
hetero-oligomers of sHSPs may form and fulfill specific functions (84). A number of 
studies describe such mixed sHSP complexes, for example complexes containing αB-
crystallin/HSP27 (85) and αB-crystallin/HSP20 (86). Not much is known about the 
occurrence, composition and dynamics of hetero-oligomeric sHSP complexes in vivo, 
and whether particular compositions are preferred above others. This is in part caused 
by the difficulty to avoid subunit exchange after cell lysis, which makes it difficult to 
quantify subunit ratios. Furthermore, the affinity of their interactions is variable and 
can be regulated in a way that will affect the size of the oligomers (87).  
Well-known factors that influence the interaction between different sHSPs are 
phosphorylation (88) and temperature (89;90). The changes occurring in composition 
and size of hetero-oligomers may alter the accessibility of particular sites within the 
complex and could be a way to influence the functioning of sHSPs in the cellular 
environment. As explained, the expression of sHPSs can vary extensively between 
different cells types and therefore it is unclear if these interactions are muscle cell 
specific or more broadly occurring. 
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Figure 4. Interactions between the seven sHSPs expressed in muscle cells. Several 
complexes can be formed through interactions of sHSPs with themselves (homomeric 
interaction) or with other sHSPs (heteromeric interaction). 1: homomeric interaction HSP27 
(HSPB1) (91), 2: homomeric interaction HSPB2, homomeric interaction αB-crystallin 
(HSPB5) and interaction between HSPB2 and HSPB3 (87), 3: homomeric interaction αB-
crystallin (HSPB5) and interaction between HSP27 (HSPB1) and αB-crystallin (HSPB5) 
(92), 4: interaction between αB-crystallin (HSPB5) and HSP20 (HSPB6) (93), 5: 
homomeric interaction HSPB6 (59), 6: interaction between αB-crystallin (HSPB56 and 
HSPB8 and interaction between HSP20 (HSPB6) and HSPB8 (94), 7: homomeric 
interaction HSPB8, interaction between cvHSP (HSPB7) and HSPB8, interaction between 
HSP27 (HSPB1) and HSPB8 and interaction between HSPB2 and HSPB8 (95), 8: 
interaction between HSP27 (HSPB1) and HSPB8 (96), 9: interaction between HSPB6 and 
HSP27 (HSPB1) (90), 10: interaction between αB-crystallin (HSPB5) and HSP27 (HSPB1) 
(97), 11: interaction between HSPB2 and HSPB8 (98), 12: interaction between αB-
crystallin (HSPB5) and HSP27 (HSPB1) (14;17).  
 
 
6.2. INTERACTIONS WITH THE CYTOSKELETON 
 
sHSPs binds and thereby modulates the structure of the cytoskeleton, an activity which 
is linked to their protective function. αB-crystallin, as well as HSP27, are able to 
associate with actin (99). The interaction appears to be vital for the stability of the actin 
network and is important for cardiac and skeletal muscle development (100). 
Moreover, αB-crystallin associates with intermediate filaments, especially type III 
filaments such as vimentin (101), desmin (102) and glial fibrillary acidic protein 
(GFAP) (103) and regulates the assembly of intermediate filaments and assists in their 
recovery from stress by preventing untimely filament–filament interactions that would 
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otherwise lead to aggregation. The missense mutation R120G in αB-crystallin, which 
reduces the chaperone-like activity (104), leads to accumulation of desmin-positive 
sarcomeric inclusions (105). αB-crystallin also plays a critical role in Alexander 
disease to prevent aggregation of GFAP and the formation of Rosenthal fibers (106). In 
the absence of stress, αB-crystallin interacts directly with tubulin and microtubule-
associated proteins to promote microtubule assembly and under stress protects against 
microtubule depolymerization (107-109). This action is dependent on the oligomeric 
state of αB-crystallin (110). 
 
 
6.3. INTERACTION WITH APOPTOSIS-INDUCING PROTEINS 
 
Apoptosis is a controlled way of cell death and several stimuli can trigger this process. 
There are two pathways leading to apoptosis: the intrinsic (mitochondrial) pathway and 
the extrinsic (death receptor) pathway. Increased expression of sHSPs during a stress 
response correlates with better cell survival after the stress, which might be an effect of 
the inhibition of the apoptotic process. αB-crystallin interacts with pro-apoptotic 
factors interfering with their function and therefore leading to inhibition of the intrinsic 
pathway (111). In vitro, αB-crystallin is capable of binding procaspase 3 cleavage 
products (112) and thus may inhibit the intrinsic apoptosis pathway in vivo (113). 
Posttranslational modifications are important as well for the protective function of αB-
crystallin, as phosphorylation of S45 and S59 protects against C2-ceramide and 
staurosporine-induced cell death (114). 
It is clear that αB-crystallin and also other sHSPs aid in cell survival in several 
different ways. However, the significance and physiological importance of each 
interaction in the regulation of the apoptotic process is still not well understood and 
needs further investigations.  
 
 
6.4. INTERACTION WITH THE DEGRADATION MACHINERY 
 
sHSPs have been implicated in the ubiquitin-proteasome pathway, a process in which 
ubiquitin ligases mark substrate proteins for degradation by the proteasome. This is 
executed by covalent addition of multiple ubiquitin molecules. αB-crystallin can 
interact with F-Box protein X4 (FBX4), which forms an E3 ubiquitin ligase, together 
with Skp1 and Cullin1 (115). One of the targets of this FBX4/αB-crystallin E3 ligase is 
phosphorylated cyclin D1 (116). This protein accounts for the G1 to S phase transition 
in the cell cycle and its degradation leads to diminished cell proliferation. Thus by 
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interacting with FBX4, αB-crystallin may interfere with cell growth. αB-crystallin can 
also bind to one of the fourteen subunits of the 20S proteasome, possibly guiding the 
substrate to the proteasome (117). 
 
 
7. INVOLVEMENT OF sHSPS IN DISEASE 
 
As molecular chaperones, sHSPs protect protein structure and activity, thereby 
counteracting the deleterious effects of disease processes. The expression of various 
sHSPs is therefore upregulated under different pathological conditions. sHSPs guard 
against ischemic and reperfusion injury caused by myocardial infarction or stroke, 
prevent cataract in the mammalian eye lens and protect against aggregation and/or 
toxicity of α-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease and 
amyloid in Alzheimer’s disease. The exact role of sHSPs in these diseases might be 
linked to their chaperone activity in providing a first line of defense against misfolded 
proteins (118-121), and in modulating the aberrant protein interactions that trigger 
pathogenic cascades. 
On the other hand, mutated sHSPs contribute to cell malfunctioning. For instance, 
mutants of sHSPs are implicated in diseases such as myofibrillar myopathy, 
cardiomyopathy, neuropathies and cataract. These pathologies result from the 
misfolding and progressive aggregation of the mutated sHSP, although the molecular 
mechanism is likely to be different for each type of disease (54;122). The myofibrillar 
myopathy associated R120G mutation in αB-crystallin has been found to modify the 
properties of αB-crystallin, such as oligomerization and in vitro chaperone-like activity 
(104), and to increase its affinity to desmin (123). This mutation in αB-crystallin 
results in misfolding and progressive aggregation, and subsequent association with 
desmin filaments to form αB-crystallin /desmin/amyloid-positive aggresomes (124). 
The D109H mutation found in a family with five affected individuals, results in the 
same clinical phenotype as the R120G mutation (125). Interestingly, molecular 
modelling shows that D109 and R120 interact with each other during dimerization of 
αB-crystallin, which might explain why these mutations give the same phenotype. 
Several members of the HSPB family have been implicated in cancer development, of 
which αB-crystallin and HSP27 are most well studied. αB-crystallin can act as an 
oncoprotein in breast cancer and its expression is correlated with a poor clinical 
outcome (126). High expression induces neoplastic changes and invasive properties in 
human mammary epithelial cells, which are inhibited by αB-crystallin phosphorylation. 
Phosphorylation affects oligomerization and anti-apoptotic activities of αB-crystallin. 
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Remarkably, αB-crystallin does not increase the tumorigenic potential under all 
circumstances. In fact, the protein can reduce cancer progression by forming, together 
with FBX4, an E3 ligase able to ubiquitinate and subsequently degrade cyclin D1 (see 
6.4) (116). Cyclin D1 is a well-known oncoprotein, and decrease in αB-crystallin levels 
likely lead to elevated cyclin D1 levels, which may drive tumor formation. Studies by 
Lin and co-workers show that in a subset of breastcancer-derived cell lines the 
expression of αB crystalline is decreased, which indeed coincided with cyclin D1 
stabilization (116). 
The expression of sHSPs is also involved in another aspect of cancer biology. sHSP 
expression is associated with cellular resistance to cytostatic anticancer drugs 
(127;128). Some of these drugs, in particular cisplatin (129), vincristine and colchicine 
(108) have been demonstrated to enhance αB-crystallin and HSP27 expression, leading 
to even higher resistance to these drugs. Thus, high expression of sHSPs may impair 
the efficiency of the clinical treatments using chemotherapeutic agents and could 
ultimately affect the survival of the patient. 
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Title: Clara Jacobi 
Image from the History of Medicine (NLM) 
Copyright Statement: The National Library of Medicine believes this item 
to be in the public domain. 
 
Clara Jacobi was a Dutch woman who, in 1689, had a tumor 
removed from her neck. 
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In this thesis the research is focused on two types of solid tumors; head and neck 
squamous cell carcinoma (HNSCC) and breast cancer. This chapter will provide an 
introduction on how solid tumors are generally formed and describes the major 
characteristics of these two kinds of tumors. Moreover, metastasis formation and the 
presence of hypoxic regions in solid tumors will be discussed. 
 
 
1. SOLID TUMORS 
 
A tumor is formed when cells exhibit uncontrolled cell division. If the tumor is benign, 
the lump of cells can often be removed and in most cases does not regrow. If the tumor 
is able to intrude and destroy adjacent tissues, it is termed malignant and cancerous 
(130). 
There are different kinds of cancer, depending on the type of cell from which the 
cancer originates. Carcinomas begin in epithelial cells of the skin or in endothelial 
cells that cover internal organs. Sarcomas develop from bone, muscle, cartilage, fat, 
muscle, blood vessels or connective or supportive tissue. Lymphoma and leukemia start 
in the blood-forming (hematopoietic) cells. There are central nervous system cancers, 
which begin in the brain or spinal cord. Blastoma originates from precursor cells and 
usually occurs in children. 
A solid tumor, the type of tumors on which this chapter will be focused, consists of two 
distinct compartments: the parenchyma, which are the neoplastic cells and the stroma, 
which is comprised of nonmalignant supporting tissue, connective tissue, inflammatory 
cells and blood vessels (131).  
High throughput sequencing data reveal that numerous mutations are involved in 
tumorigenesis (132-134). All kinds of point mutations, translocations, amplifications 
and deletions may contribute to cancer development (132-134). Using bioinformatic 
analysis, it has become clear that many core signaling pathways and processes are 
affected by these mutations (135). Most cells require alterations on at least six 
important areas of cell signaling and functioning, which collectively make 
transformation to a cancer cell feasible: self-sufficiency in growth signaling, 
insensitivity to anti-growth signaling, evasion of programmed cell death, limitless 
replication, sustained angiogenesis and tissue invasion and metastasis (Figure 1) (136). 
All these alterations uncouple cell growth from extracellular stimuli (137;138) and 
cells obtain characteristics that promote growth and cell survival, ultimately leading to 
evolution of a tumor (139;140). The affected genes can be subdivided into two 
categories. The first category is formed by the tumor suppressor genes, which become 
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inactivated upon so called loss-of-function mutations. Normally, these genes encode 
for proteins that function in the inhibition of the cell cycle or inhibit proliferation, like 
p53 and pRb (141;142). The other category consists of the proto-oncogenes, which 
after ‘gain of function’ mutations become oncogenes. Example are the cell cycle 
regulator cyclin D1 and Epidermal Growth Factor Receptor 2 (HER2, also known as 
HER2/neu or ERBB2), an epidermal growth factor receptor able to activate several 
signaling pathways (143;144). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Physiological alterations required for cellular transformation into a 
cancerous cell. Cells need to become self-sufficient in growth signaling, insensitive to 
antigrowth signaling, unable to die by apoptosis and perform limitless replications, 
stimulate sustained angiogenesis and ultimately able to invade tissues to form metastasis. 
Figure is based on (136). 
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Mutations usually increase the activity of the encoded protein or increase expression of 
the gene. Novel mutations can arise for example due to errors during DNA replication 
or mutations can be acquired via exposure to a broad range of environmental and 
occupational carcinogens (145;146). The accumulation of mutations also drives tumor 
progression, meaning that cancers can become more and more malignant over time 
(147;148) (Figure 2). 
 
 
2. HNSCC AND BREAST CANCER 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide and accounts for 6% of all cancers (149;150). Although prognosis gradually 
improved over the past 40 years, the overall 5 year survival rate is still only around 
50%. Most important risk factors for the development of HNSCC are tobacco use, 
alcohol consumption (151) and viral infections, most notably with HPV (152;153). 
Genetic predisposition plays a role as well (154).  
Several oncogenic mutations specific for oral cancer, a subtype of HNSCC, have been 
established. An effect of these mutations can be an elevated production of growth 
factor TGF-α, which binds to epidermal growth factor receptor (EGFR, also termed 
HER1) (155-157). Also, EGFR itself can be constitutive activated by mutations, like 
deletion of the N-terminal ligand-binding domain, deletion of the C-terminus, 
preventing downregulation after ligand binding or overexpression (158-162). Also 
intracellular messengers (like the RAS family members) and transcription factors (for 
example cyclin D1) are altered. Moreover, mutations in tumor suppressor genes like 
p53, p16 and doc-1 have been described (157;163). 
Breast cancer is a leading cause of death from cancer among women. Using gene 
expression profiling, the heterogeneous group of breast cancer tumors can be divided in 
several subsets, of which the most well-known are normal breast-like, luminal A and 
B, HER2-enriched and basal-like breast tumors (164). An immunohistochemical 
difference between these groups can be found in expression of the estrogen receptor 
(ER), progesterone receptor (PR) and HER2 receptor (Table 1). The group of breast 
cancers lacking the expression of the three receptors, ER, PR and HER2, but with 
overexpression of for example EGFR, is referred to as triple negative. These tumors 
often show the basal-like gene expression pattern, including expression of basal-like 
marker CK5/6 and smooth muscle actin (SMA) and this type accounts for 15% of all 
breast cancer cases. The different tumor subtypes vary in their prognosis and is the 
worst for patients with the triple negative/basal-like subtype (165).  
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Figure 2. Cellular transformation leading to formation of a malignant tumor. Due to 
DNA replication errors and effects of exogenous carcinogens, mutations can arise 
(initiation, 2, black nucleus). If a cell is able to repair the mutation, the cell is again 
unaffected (DNA repair, 1, all nuclei have the normal grey phenotype). If the mutation is 
not repaired and inactivates a tumor suppressor gene or activates a proto-oncogene, a 
phenotype can arise causing uncontrolled replication of the affected cell, leading to solid 
tumor formation (promotion, 3). Ultimately, genomic instability can lead to the 
accumulation of even more mutations, leading to a tumor showing genomic heterogeneity 
between cells (progression, 4) and presenting more malignant behavior (metastasis). Figure 
is adapted from (148). 
 
 
Many mutations are described to be present in breast cancer tissue. In 80% of the 
familial hereditary breast cancers, BRCA1 or BRCA2 are affected. These proteins are 
functioning in the DNA damage response pathway and malfunctioning causes 
susceptibility to an instable genome (166). Also mutations of signal transduction 
mediators (oncogenes as mTOR and RAS, cell cycle modulators as cyclin D1 and 
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tumor suppressor genes p53, p27 and PTEN) have been described (167). 
Overexpression of EGFR has been described as well, especially in the basal-like 
subtype (Table 1), only overexpression is not as common as for example in HNSCC 
(168). 
 
Table 1. Receptor status of different breast cancer subtypes (168).  
Breast cancer subtype Receptor 
Luminal A ER+ and/or PR+, HER2- 
Luminal B ER+ and/or PR+, HER2+ 
Normal breast-like ER-, PR-, HER2- 
Basal-like ER-, PR-, HER2-, EGFR+* 
HER2-enriched ER-, PR-, HER2+ 
* Expression of basal-like markers 
 
 
3. METASTASIC MECHANSIMS OF SOLID TUMORS  
 
Some types of cancer cells are prone to spread to other parts of the body through the 
blood and lymph systems. This process is termed metastasis formation (130). Organs to 
which solid tumors preferentially spread and in which secondary tumors are generally 
formed are the lungs, liver, brain and bone. Both HNSCC and breast cancer are prone 
to metastasis formation (169). Generally, many steps are necessary for cell spreading to 
occur from the primary tumor site to a distant site. This process is known as the 
metastatic cascade. First, the so-called Epithelial-to-Mesenchymal Transition (EMT) 
occurs. During EMT, epithelial cells acquire characteristics similar to less specialized 
mesenchymal cells (170;171). Secondly, tumor cells become dissociated from the 
tumor. Normally, cells would undergo anoikis, which is cell death induced by 
inappropriate loss of cell adhesion. Hence, anoikis suppression is required for tumor 
cells to be able to metastasize to distant sites (172;173). As a third step, neighboring 
tissue is invaded. In many tumors, a basal lamina separates nests of tumor cells from 
stroma and at sites where the lamina is incomplete, often tumor invasion occurs (174). 
Thus, tumor cells must acquire the ability to invade and migrate (130). Many proteins 
are involved in the process of cell migration, and in metastasizing tumors mutations in 
the genes encoding for example integrins, which are transmembrane receptors that 
mediate the attachment between cells and their surroundings, can be found (175-177). 
The fourth step entails intravasation into pre-existing and newly formed blood and 
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lymph vessels. Normally, angiogenesis is rare and occurs mainly during wound healing 
and the female reproductive cycle. The growth of new vessels is controlled by a 
balance of angiogenic activators and angiogenic inhibitors (130;178;179). During the 
“angiogenic switch”, upon which a tumor activates vascularisation, this balance is 
disturbed (137). A major player in angiogenesis is vascular endothelial growth factor 
(VEGF) (180). Tumor cells are transported to distant sites in the body through blood- 
or lymph vessels (fifth step). In the sixth step of the metastatic cascade, cells 
extravasate from vessels. In the seventh and final step, outgrowth of metastases occurs 
(130). There are differences between the different types of cancer regarding the 
propensity to metastasize, the extent of metastasis and the sites to which tumors 
metastasize. The last few years there has been much focus on the discovery of gene 
targets that regulate metastasis or can act as biomarkers for metastasis formation. 
 
 
4. HYPOXIC REGIONS AND REACTIVE OXYGEN SPECIES IN SOLID TUMORS 
 
When a tumor reaches a size of 1-2 mm, tumor formation is hampered due to the 
limitation of diffusion of O2 and nutrients. If growth occurs beyond this limit without 
formation of new blood vessels, another phenomenon arises, which is the development 
of hypoxic regions within these tumors. Hypoxia is a condition in tissues were oxygen 
pressure is less than 5 to 10 mmHg (0.66 – 1.32% O2) (181).  
The best-characterized hypoxia response pathway is via hypoxia-inducible factor-1 
(HIF-1). HIF-1 consists of the constitutively expressed HIF-1β and HIF-1α, of which 
the latter is regulated in an oxygen dependent way. In normoxic areas of the tumor, 
prolyl hydroxylases (PHD) modify Pro-402 and Pro-564 of HIF-1α in a reaction that 
uses O2 as a substrate. Hydroxylated HIF-1α interacts with the Von Hippel-Lindau 
protein (VHL). This protein is part of an E3 ubiquitin ligase complex, of which binding 
ultimately leads to proteasomal degradation of HIF-1α (182).  
In hypoxic regions, HIF-1α is stabilized by suppressed breakdown and subsequently 
transported to the nucleus, where it dimerizes with HIF-1β, forming the HIF-complex. 
This binds to hypoxia response element (5’-G/ACGTG-3’) with help of coactivator 
CBP/p300. Binding of HIF-1 to CBP/p300 is regulated by the factor inhibiting HIF-1 
(FIH-1), which uses O2 as a substrate to hydroxylate HIF-1α at Asn-803, thereby 
preventing the binding to CBP/p300 (181). Targets of HIF-1 signaling can be divided 
into the categories: glucose transporters and glycolysis, angiogenesis, survival and 
proliferation (183). The presence of hypoxia is correlated to worse clinical outcome 
(184-186) and is associated with therapeutic resistance and metastatic progression 
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(183;187-193). Moreover, HIF-1α is overexpressed in many cancers (182). There are 
two different kinds of hypoxia: acute and chronic. Chronic hypoxia arises when the 
vasculature provides limited blood flow capacity. Acute hypoxia arises, when enough 
blood vessels are present only these are leaking or partially blocked, thereby preventing 
O2-rich blood from reaching the inner part of the tumor (181). Multiple studies have 
shown that the blood flow in tumors can be irregular. This is responsible for hypoxia 
and reoxygenation phases, which is called intermittent hypoxia (194-198). Tumor cells 
exposed to cyclic hypoxia/reoxygenation showed much greater upregulation of 
metastasis-related genes (187), thus not only hypoxia itself, but reoxygenation as well 
can have detrimental effects.  
In vivo studies have demonstrated that hypoxia/reoxygenation transitions are associated 
with transient increased levels of reactive oxygen species (ROS) (199;200). Underlying 
molecular mechanisms are not completely characterized yet. Both the respiratory 
system of the mitochondria, as well as NADPH oxidases have been implicated as 
sources of elevated ROS levels in situations of hypoxia/reoxygenation (201). Other 
mechanisms could lead to ROS formation as well. In the middle of a hypoxic region, 
often a necrotic centre is present (181;202), especially in HNSCC, which may 
stimulate ROS formation (202). Elevation of ROS levels has an important role in tumor 
development (203;204). Moderate increase in ROS levels that, lethal to a cell, lead to 
enhanced DNA oxidation. As a result, genetic instability and accumulation of 
oncogenic mutations in proto-oncogenes, tumor suppressor genes, and other genes will 
occur, leading to dysfunction and neoplastic cell transformation and/or further tumor 
progression (203) (Figure 2).  
 
 
5. CANCER TREATMENT OPTIONS 
 
To assess the prognosis of the patient, tumors are pathologically classified. For a long 
time been this was mainly based on histopathologic classification where characteristics 
seen upon light microscopy of biopsy specimens are studied (205). Another well-
known classification method to predict tumor progression is tumor staging using the 
TNM system. Staging attempts to measure the extent of tumor spread within a patient 
on the basis of parameters as the size of the primary tumor (T), the degree of spread to 
lymphnodes (N) and the presence of distant metastasis (M) (206), though these 
methods do have shortcomings. A different TNM scale is required for every type of 
tumor and scoring is subjective and not always reproducible. Moreover, tumors are 
heterogeneous, thus a risk of sampling error exists for the histopathological 
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classification. Also, as a result of tumor progression, predictions of tumor behavior are 
not straightforward (147). Therefore there is a need of biomarkers, which can help in 
determining prognosis and customizing anti-cancer treatment as well.  
For patients with solid tumors surgery and radiotherapy are the most effective 
treatment options. These are often combined with systemic treatments such as 
chemotherapy and targeted therapies. Although these treatment combinations are 
frequently associated with significant toxicity rates, the quality of life of cancer 
patients has increased thanks to more advanced radiotherapeutic techniques as well as 
organ-preservation protocols (207;208). 
Using radiotherapy, cell death is mainly induced by direct ionization of DNA or 
indirectly by radiation-induced ROS formation; these include hydroxyl radicals, 
superoxide anion radicals and other molecules such as hydrogen peroxide. Additional 
destructive radicals are formed through various chemical interactions (209-211). 
One important cause of radiation resistance is the occurrence of hypoxia, as oxygen is 
essential for the generation of ROS and thus the cell damaging effects (212). Therefore, 
hypoxic regions in solid tumors are 2 to 3 times more radio-resistant than well-
oxygenated tumor cells (186). To increase treatment options, several approaches are 
used to take hold of the hypoxic tumor regions. To raise tumor oxygen levels, oxygen 
enhanced gas mixtures and pharmacologic modification of blood flow are used, for 
example using "accelerated radiotherapy, carbogen, nicotinamide" (ARCON) therapy 
(213). Moreover, specific killing of hypoxic tumor cells could be achieved by hypoxia-
selective cytotoxins, like tirapazamine (214).  
To further improve treatment, targeted drugs were developed and implemented in 
combination with radiotherapy. Monoclonal antibodies are used, which through several 
mechanisms raise a response against cancer cells. A well-known example is cetuximab, 
an EGFR-specific human/mouse chimeric antibody. The affinity of this antibody to the 
receptor is much higher than the affinity of the endogenous ligands, thereby blocking 
EGF-based cellular signaling and leading to receptor internalization (215;216). EGFR 
is a member of the epidermal receptor (HER)/Erb-B family, which contain tyrosine 
kinase domains able to activate two pathways: RAS-Raf-MEK1/2-ERK1/2 and RAS-
PI3K-Akt-mTor (Figure 3). Ultimately, blocking signaling can influence cell 
proliferation, apoptosis, angiogenesis and metastasizing potential (217). Another 
receptor that often is targeted by drugs is the vascular endothelial growth factor 
receptor (VEGFR). VEGF and VEGFR are associated with tumor progression, changes 
in microvessel density, development of lymphnode metastasis, distant metastasis and 
treatment failure. Thus, interference in signaling mediates a broad anti-tumorigenic 
response (218). 
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Figure 3. Ras-Raf-MEK1/2-ERK1/2 and PI3K-Akt-mTor pathways. Dysregulation of 
growthfactor receptors (EGFR, HER2, VEGFR and IGF-1R) and/or downstream kinases 
(RAS, Raf-1, MEK1/2, ERK1/2, PI3K, Akt and mTOR) or tumor suppressor genes (PTEN 
or p53) can result in uncontrolled cell growth and proliferation. Figure is adapted from 
(219). 
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6. OUTLINE OF THIS THESIS 
 
Using a semi- quantitative method of analysis, Chin and co-workers showed that small 
heat shock protein αB-Crystallin is a promising biomarker in HNSCC, predicting lower 
disease-free survival rates for patients with tumors expressing high levels of αB-
Crystallin (220). Interestingly, in another study that was performed semi- quantitatively 
in HNSCC biopsies by Boslooper and co-workers, these results were not confirmed 
(221). Results from both these semi-quantitative studies are difficult to compare, 
therefore, in Chapter 3 other approaches are followed to determine whether αB-
crystallin expression in HNSCC is correlated with worse prognosis. αB-crystallin 
expression in HNSCC biopsies is studied in a computer-aided quantitative way, where 
percentage of αB-crystallin-positive surface was calculated per biopsy. A division is 
made between low and high αB-crystallin expression. These data are correlated to 
patient data regarding local and regional recurrence and distant metastasis formation to 
find which specific component in cancer formation is affected by αB-crystallin 
expression. Moreover, siRNA mediated knockdown of αB-crystallin in HNSCC cell 
lines is used to determine the effect of αB-crystallin expression on VEGF secretion and 
cell motility, which both are linked to metastasis formation.  
As described in the introduction, in most solid tumors areas are present containing 
hypoxic-stressed cells. Since aB-crystallin can become upregulated by several types of 
stress, an analysis was performed of the relationship between the presence of hypoxia 
in HNSCC tumors and αB-crystallin expression. Findings are described in Chapter 4. 
Also the influence of hypoxia on αB-crystallin mRNA and protein expression levels in 
HNSCC cell lines is studied and it is determined whether hypoxia-stimulated ROS 
generation plays a role in αB-crystallin induction during hypoxia/reoxygenation. 
Furthermore, it is investigated whether αB-crystallin, as chaperone protein, is able to 
enhance survival of cells exposed to hypoxic stress.  
In Chapter 5 the correlation of αB-crystallin expression with several signaling 
molecules is studied, including pERK1/2, pAKT, pmTOR, EGFR and IGF-1R 
(Chapter 2, Figure 3) in a breast tumor tissue microarray. These molecules are known 
to be involved in cancer formation, thus an interaction of αB-crystallin with these 
signaling pathways could be of importance. Also the correlation of αB-crystallin 
expression with triple negativity, thus the absence of ER, PR and HER2 expression, 
and expression of basal markers CK5/6 and SMA is studied. To determine whether αB-
crystallin directly effects the expression of pERK1/2 and ERK1/2, the influence of αB-
crystallin knockdown on ERK1/2 expression levels and phosphorylation levels are 
studied in a triple negative breast cancer cell line.  
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αB-Crystallin is mainly a cytoplasmic protein, but can accumulate in the nucleus when 
it is phosphorylated at specific positions. However, it is not known how αB-crystallin 
enters the nucleus and whether the protein has a nuclear function. Chapter 6 is focused 
on these two aspects. The nuclear chaperoning activity of αB-crystallin is measured by 
its ability to refold heat-shock denatured nuclear luciferase in HeLa cells. Yeast two-
hybrid screening shows that (especially pseudophosphorylated) αB-crystallin interacts 
with the C-terminus of Gemin3, which is part of the SMN complex. Using an in vitro 
and in situ nuclear import assay it is determined whether the nuclear import of αB-
crystallin is facilitated by the SMN complex. 
Finally, in Chapter 7 a discussion on findings in the research chapters and suggestions 
for further research is provided. 
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ABSTRACT 
 
αB-crystallin is able to modulate vascular endothelial growth factor (VEGF) secretion. 
In many solid tumors VEGF is associated with angiogenesis, metastasis formation and 
poor prognosis. We set out to assess whether αB-crystallin expression is correlated 
with worse prognosis and whether this is related to VEGF secretion and cell motility in 
head and neck squamous cell carcinoma (HNSCC). αB-crystallin expression was 
determined immunohistochemically in tumor biopsies of 38 HNSCC patients. 
Locoregional control (LRC) and metastasis-free survival (MFS) of the patients were 
analyzed in relation to αB-crystallin expression. Additionally, the effects of αB-
crystallin knockdown on VEGF secretion and cell motility were studied in vitro. 
Patients with higher staining fractions of αB-crystallin exhibited a significantly shorter 
MFS (Log-Rank test, p < 0.005). Under normoxic conditions αB-crystallin knockdown 
with two different siRNAs in a HNSCC cell line reduced VEGF secretion 1.9-fold and 
2.1-fold, respectively. Under hypoxic conditions, a similar reduction of VEGF 
secretion was observed, 1.9-fold and 2.2-fold, respectively. The effect on cell motility 
was assessed by a gap closure assay, which showed that αB-crystallin knockdown 
decreased the rate by which HNSCC cells were able to close a gap by 1.5- to 2.0-fold. 
Our data suggest that αB-crystallin expression is associated with distant metastases 
formation in HNSCC patients. This association might relate to the chaperone function 
of αB-crystallin in mediating folding and secretion of VEGF and stimulating cell 
migration. 
 
 
BACKGROUND 
 
The small heat shock protein αB-crystallin (HspB5) is expressed in several types of 
cancer, including head and neck squamous cell carcinomas (HNSCC) (220;221) and 
breast carcinomas (126;222;223). The expression is often correlated with a poor 
prognosis, but the reason for this is not fully understood (54;224). αB-crystallin plays a 
role in many different cellular processes such as proliferation, cell migration and 
apoptosis (54;126;225). The expression of this protein is increased during various 
stresses, like heat shock and oxidative stress (14). A well-known function of αB-
crystallin is molecular chaperoning, allowing the prevention of aggregation of proteins 
(14). Recently, it has been shown that αB-crystallin chaperones the hypoxia-induced 
VEGF protein to the endoplasmic reticulum, leading to more properly folded and thus 
secreted VEGF (226;227). VEGF is a major player involved in tumor angiogenesis 
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(228) and increased VEGF secretion is often correlated with metastasis formation (229) 
and worse outcome for the patient (230). 
HNSCC is the sixth most common cancer worldwide and accounts for 6% of all 
cancers (150). The majority of these patients are treated with radiotherapy, alone or in 
combination with surgery or chemotherapy (231). Based on the improved 
understanding of the molecular pathways underlying HNSCC, targeted drugs (e.g. 
EGFR-specific antibodies) and other modifications have been implemented in 
treatment protocols (231). However, only a subset of patients profit from these 
combined modality strategies. Therefore, there is a great demand for biomarkers to 
customize treatment. 
In the present study the value of αB-crystallin as a biomarker in HNSCC was 
investigated. αB-crystallin expression levels were immunohistochemically determined 
in HNSCC biopsies and correlated with clinicopathological characteristics and 
outcome. Moreover, the effect of knockdown of αB-crystallin on VEGF secretion and 
cell migration was studied. 
 
 
METHODS 
 
Patients 
Biopsy material from a cohort of HNSCC patients with stage II to IV primary 
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx was 
used. The inclusion criteria of patients with HNSCC have been described before (232). 
Approval from the ethics committee of Radboud University Nijmegen Medical Centre 
was obtained and all patients provided written informed consent. Of 13 patients no 
biopsy materials were left and were excluded from this study. The median duration of 
follow-up for all patients was 29 months and for surviving patients 85 months. During 
follow-up, LRC and MFS were registered. 
 
Immunohistochemical staining of αB-crystallin of HNSCC biopsies 
Oral cavity tumor sections (233) were incubated with 100-fold diluted polyclonal 
rabbit αB-crystallin antiserum (38) and subsequently stained with diaminobenzidine 
(DAB) according to a standard protocol. Sections of the 38 available biopsies (5 μm) 
were mounted on poly-L-lysine coated slides, fixed for 10 minutes in acetone at 4°C 
and rehydrated in PBS. The sections were incubated overnight at 4°C with 100-fold 
diluted αB-crystallin antiserum (38) and subsequently incubated for 30 minutes at 37°C 
with 600-fold diluted goat-α-rabbit-FabCy3 (Jackson Immuno Research Laboratories 
Inc) in PBS, for 45 minutes at 37°C with 10-fold diluted endothelium antibody PAL-E 
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(Euro Diagnostica BV) in PAD, for 60 minutes at 37°C with 100-fold diluted chicken-
α-mouse Alexa647 (Molecular probes) in PBS and finally for 5 minutes at room 
temperature with 0.5 ng/ml Hoechst (Sigma) in PBS. Between the incubation steps, 3 
times 2 minutes washing steps in PBS were performed. The sections were mounted 
using fluorostab (ProGen Biotechnik GmbH). 
 
Image acquisition 
Scanning of the tumor sections was performed with a fluorescence microscope 
(Axioskop, Zeiss) and a computer-controlled motorized stepping stage, using IP-lab 
software (Scanalytics) (234). Each section was completely scanned for αB-crystallin 
staining. The resulting grey scale images were subsequently binarized. Thresholds 
were set just above the background staining for each staining. Manually, the total 
tumor area was contoured, excluding surrounding tissue, large necrotic areas and 
artifacts. The percentage of αB-crystallin was determined as the tumor area positive for 
αB-crystallin relative to the total tumor area. 
 
Cell culture, siRNA treatment, hypoxia exposure and VEGF secretion 
measurement 
The HNSCC cell line, UT-SCC-5 (described in (235)), was maintained in DMEM + 
Glutamaxtm (Invitrogen) supplemented with 10% fetal calf serum (Gibco-BRL) in a 
standard humidified 37°C incubator. At 40% confluency, cells were transfected using 
Lipofectaminetm 2000 Reagent according to the manufacturers’ protocol (Invitrogen). 
The siRNAs used were si-Luciferase (siRNA LUC) as negative control, sequence: 
CGUACGCGGAAUACUUCGAdTdT, si-αB-crystallin1 (siRNA αB1) sequence: 
GCACCCAGCUGGUUUGACAdTdT and si-αB-crystallin2 (siRNA αB2) sequence: 
CCCUGAGUCCCUUCUACCUdTdT. After 5 hours, cells were reseeded (9.0x103 
cells in 0.3 cm2 wells in 12-fold, for VEGF secretion measurements, and 2.5x105 cells 
in 10 cm2 wells in 4-fold, for RNA expression measurements (see below)). Hypoxia 
treatment was performed 24 hours after siRNA transfection cells in a humidified 37°C 
H35 Hypoxystation (Don Whitley Scientific) with 0.1% O2. Cells cultured under 
normoxic (6-fold) and hypoxic (6-fold) conditions were maintained for 48 hours. The 
culture media of the samples were collected and VEGF levels were determined using a 
quantitative enzyme-linked immunosorbent assay (ELISA). The details of this assay 
have been described previously by Span and coworkers (236). The assay is based on 
the combination of four polyclonal antibodies raised in four different animal species, 
duck, chicken, rabbit and goat, and are employed in a sandwich assay format. The 
assay measures VEGF165 and VEGF121, the main isoforms of VEGF. There is no cross-
reactivity with VEGF B, VEGF C and VEGF D (236;237). 
207528-L-bw-Schootbrugge
αB-CRYSTALLIN STIMULATES VEGF SECRETION AND TUMOR CELL 
MIGRATION AND CORRELATES WITH ENHANCED DISTANT METASTASIS IN 
HEAD AND NECK SQUAMOUS CELL CARCINOMA 
 
44 
 
Gap closing assay 
The HNSCC cell line UT-SCC-15 (235) was transfected with siRNA as described 
above. Twenty-four hours after transfection, cells were seeded at 1.0x105 cells per side 
of the Culture-Inserts (Ibidi, N = 6 per condition). For quantitative RT-PCR, 0.5x106 
cells were seeded in parallel in 10 cm2 wells (N = 5). 24 Hours later cells were washed 
with PBS, fresh medium was added and the insert was removed. Time lapse imaging 
was performed for 24 hours in a microscope stage incubator (Oko-Lab) on a Nikon 
DiaPhot microscope equipped with a Hamamatsu C8484-05G digital camera. Images 
were taken every 10 min using TimeLapse Software (Oko-Lab), version 2.7, with a 
10x objective. Analysis of gap closing was performed using TScratch (238). 
 
RNA analysis by quantitative PCR 
Total RNA from UT-SCC-5 and UT-SCC-15 cell lysates was extracted using standard 
Trizol isolation. After DNAse I treatment (Amplification grade, Invitrogen) mRNAs 
were reverse transcribed using oligo(dT) primers and the Reverse Transcription System 
(Promega) according to manufacturer’s protocol starting with 1 μg of RNA in a total 
volume of 20 μl. Subsequently quantitative PCR reactions were performed with 10 μl 
Power SYBR Green (Applied BioSystems), 5 μM of primers and 2 μl cDNA in a total 
volume of 20 μl. The sequence of the used αB-crystallin primers is: 5’-
ATCTTCTTTTGCGTCGCCAG-3’ and 5’-TTCCCCATGGTGTCTGAGC-3’, and of 
the GAPDH primers: 5’-GATTGAGGTGCATGGAAAAC-3’ and 5’-
AGGACCCCATCAGATGACAG-3’. The fluorescent signal intensities were recorded 
with the ABI Prism 7000 system (Applied Biosystems). Samples were kept for 10 
minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. 
Data analysis was performed with 7000 System SDS software (Applied BioSystems). 
 
Statistics 
Statistical analyses were performed using Graphpad Prism 5.00 software. To test for 
differences in αB-crystallin expression using binary patient data, the unpaired t-test 
was used. For survival analyses, receiver operating characteristic (ROC) curves were 
made to determine the cut-off value with the highest sensitivity and specificity for 
discriminating between patients with or without locoregional recurrence (LRR) or 
distant metastasis with at least 24 months of follow-up or an LRR or distant metastatic 
event before that. Survival rates were calculated starting at the date of diagnosis. The 
Kaplan-Meier method and the log-rank test were used to test for differences in LRC 
and MFS rates in all patients. P-values below 0.05 were considered a priori to indicate 
a significant difference. Differences in VEGF secretion and gap closure speed were 
tested using One-way ANOVA and Tukey’s Multiple Comparison Test. 
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RESULTS 
 
The presence of αB-crystallin in the tumors was analyzed by immunohistological 
staining. In most tumors cells αB-crystallin could be detected. In stromal cells, no or 
only very low levels of nuclear staining were found (Figure 1a). The αB-crystallin 
expression was determined in 38 primary HNSCC biopsies, which were histologically 
confirmed to contain tumor tissue (232). The characteristics of the tumors at the time 
point of biopsy collection are listed in Table 1. To quantify the fraction of the tumor 
section expressing αB-crystallin, fluorescently labeled secondary antibodies were used 
and the images were analyzed with a digital image analysis system. Only, the tumor 
area was used for the analysis by excluding the surrounding stromal tissue, large 
necrotic areas and artifacts. The results showed that the αB-crystallin expressing tumor 
areas varied from 0 to 69%. Examples of biopsies having marginal and extensive αB-
crystallin expression are shown in Figure 1b and c. 
 
αB-crystallin expression in HNSCC biopsies is associated with distant 
metastasis 
Patients with at least 24 months of event-free follow up or with a locoregional 
recurrence (LRR) or distant metastatic event before 24 months were dichotomized in 
groups with and without LRR (N = 16 and N = 12, respectively), or with and without 
metastasis (N = 17 and N = 10, respectively). Figure 2 shows that the mean percentage 
of the tumor area expressing αB-crystallin was not significantly different between 
biopsies from patients with or without LRR (Figure 2a). However, the mean percentage 
of the tumor area expressing αB-crystallin was significantly higher in biopsies from 
patients who developed distant metastasis during follow up as compared to those 
without (two-tailed unpaired t-test, p < 0.05, Figure 2b). The highest sensitivity and 
specificity for discriminating between patients with or without metastasis was 
determined by receiver operating characteristic (ROC) curve to be at a cut-off value of 
20%. At this cut-off value the Kaplan-Meier estimates for LRC did not show any 
significant differences (Figure 2c), and the same result was obtained with other cut-off 
values (results not shown). For MFS a significant difference was observed (Log-Rank, 
p < 0.005, Figure 2d), which was especially clear after 22 months; at that time point 
MFS was 86% for the patients with relatively low fractions of tumor area expressing  
αB-crystallin, whereas this was only 36% for the patients with extensive αB-crystallin 
expression in the tumors. These results suggest that the levels of αB-crystallin 
expression inversely correlate with MFS. 
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Table 1. Characteristics of 38 head and neck squamous cell carcinomas 
 
Characteristics Number of biopsies 
Site of tumor 
 
Oral cavity 1 
Hypopharynx 12 
Larynx 15 
Oropharynx 10 
T classification 
 
1 1 
2 13 
3 16 
4 8 
N classification 
 
0 10 
1 10 
2 18 
M classification 
 
0 38 
Differentiation grade 
 
1 2 
2 21 
3 14 
Unknown 1 
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Figure 1. Immunohistochemical staining of tumor tissues with polyclonal anti-αB-
crystallin antibody. DAB staining of three oral cavity tumor sections. Tumor cells are 
indicated with T, surrounding stromal cells with S (a). Immunofluorescent staining of 
biopsies with low αB-crystallin expression (red, b left panel) and high αB-crystallin 
expression (red, c left panel) and the corresponding Hoechst stainings (blue, b and c right 
panels). Blood vessels are indicated in white. 
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Figure 2. Relation between αB-crystallin expression and locoregional recurrence and 
metastasis. αB-crystallin expression per biopsy and the mean αB-crystallin expression of 
each group with standard error of the mean (SEM) in biopsies from patients without or with 
locoregional recurrence (a) or metastasis (b) and Kaplan-Meier analysis of locoregional 
control (c) and metastasis-free survival (d) for patients with high (>20% of tumor area) and 
low (<20% of tumor area) αB-crystallin expression. TA: Tumor area, ns: not significant. 
 
 
αB-crystallin expression enhances VEGF secretion  
The recently reported involvement of αB-crystallin in VEGF production prompted us 
to investigate the effects of αB-crystallin expression on VEGF secretion by HNSCC 
cells. For these experiments the HNSCC cell line UT-SCC-5 was used and the levels of 
αB-crystallin were reduced by siRNA-mediated knock-down. Two distinct αB- 
crystallin siRNAs, αB1 and αB2, resulted in a 1.3-fold and 1.8-fold reduction of αB-
crystallin mRNA levels, respectively (Figure 3a). Downregulation of αB-crystallin 
significantly decreased VEGF secretion (1.9-fold and 2.1-fold reduction, respectively). 
Since hypoxia leads to elevated VEGF production, we next assessed the effects of αB-
crystallin knock-down under hypoxic conditions. Indeed, VEGF secretion appeared to 
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be increased in UT-SCC-5 cells by hypoxia (Figure 3b, 1.6-fold) and also under these 
conditions αB-crystallin depletion resulted in decreased VEGF expression (1.9-fold 
and 2.2-fold reduction, respectively). These results show that αB-crystallin expression 
can affect VEGF secretion both at normoxia and hypoxia. 
 
 
 
Figure 3. Influence of αB-crystallin knock-down on VEGF secretion. Knockdown of 
αB-crystallin mRNA expression in UT-SCC-5 cells by two different siRNAs, αB1 and αB2, 
compared to negative control siRNA LUC (Luciferase) as measured by quantitative PCR 
(a). VEGF secretion levels in UT-SCC-5 cells transfected with the αB1, αB2 or LUC 
siRNA under normoxic and hypoxic conditions determined by ELISA (b). Statistical 
analysis was performed using One-way ANOVA and Tukey’s Multiple Comparison Test. 
*** P < 0.001, ** 0.001 < P < 0.01, * 0.01 < P < 0.05; a.u: absorbance units 
 
 
Effect of αB-crystallin expression on cell migration 
The association of αB-crystallin expression with metastasis may also be due to effects 
on cell motility (126). To investigate whether motility of HNSCC cells is affected by 
reduced αB-crystallin a gap closure assay was applied. Since the UT-SCC-5 cells were 
easily damaged during gap preparation, disturbing migration, the related cell line UT-
SCC-15 was used. Also in this HNSCC cell line αB-crystallin mRNA levels could be 
reduced by siRNA-mediated knock-down, although the efficiency appeared to be much 
higher than that in the UT-SCC-5 cells (Figure 4a). Depletion of αB-crystallin resulted 
in decreased gap closure rates compared to mock treated cells (Figure 4b). The cell 
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migration rate was reduced 2.0-fold and 1.5-fold after treatment with the siRNA αB1 
and αB2, respectively (Figure 4c). 
 
 
DISCUSSION 
 
Here, we show that αB-crystallin expression in HNSCC tumors correlates with MFS, 
but not with LRC. Clues for the mechanism by which αB-crystallin might affect distant 
metastasis formation in patients were obtained by the depletion of αB-crystallin in 
HNSCC cell lines, which showed that both VEGF secretion and cell motility were 
decreased when αB-crystallin expression was reduced. Previously, two studies have 
addressed the prognostic value of αB-crystallin in HNSCC. Chin and coworkers have 
shown that αB-crystallin is a marker for poor prognosis (220), which is substantiated 
by our data. However, they noted that none of the patients lacking αB-crystallin had 
LRR, while 37% of the patients with tumors stained positive for αB-crystallin had 
LRR. In the current study, the difference in prognosis was mainly caused by a higher 
rate of distant metastasis in the high αB-crystallin group and not by a difference in 
LRR. Boslooper and colleagues did not find αB-crystallin to be a prognostic marker for 
HNSCC (221). These researchers observed the highest concentrations of αB-crystallin 
in the centre of tumor cell nests and not the more diffuse localization observed in this 
study and the study of Chin and coworkers (220). This difference in αB-crystallin 
localization may have been caused by a difference in staining procedure and could be 
the reason why this study led to a different conclusion. αB-crystallin was also found to 
be associated with a poor prognosis in several other types of cancers, such as breast 
cancer (126;222;223;239;240) and was downregulated in a breast cancer cell line by 
breast cancer metastasis suppressor 1, which specifically suppresses metastasis (241). 
αB-crystallin is a molecular chaperone able to prevent protein aggregation and can 
confer protection to cells under stress conditions. αB-crystallin inhibits apoptosis in 
response to different anti-cancer agents, such as DNA-damaging drugs, TNFα and Fas 
ligand (54) and has been shown to be a predictor of resistance to chemotherapy (242). 
However, since our data do not support an association of αB-crystallin expression with 
local recurrence after treatment of the patients, the cytoprotective activity is likely not 
the sole reason why αB-crystallin is associated with poor prognosis. Metastasis 
formation occurs via a series of steps, also known as the “metastatic cascade” (130). 
One of the factors associated with metastatic spread is VEGF (243;244). Several 
studies have demonstrated roles for αB-crystallin in VEGF-dependent angiogenesis 
(245;246). Tumor vasculature in αB-crystallin-deficient mice displays high levels of  
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Figure 4. Influence of αB-crystallin knock-down on cell migration determined with 
gap closure assay. Knockdown of αB-crystallin mRNA expression in UT-SCC-15 cells by 
two different siRNAs, αB1 and αB2, compared to negative control siRNA LUC 
(Luciferase) as measured by quantitative PCR (a). Representative micrographs of the gap 
closure by UT-SCC-15 cells after 0 and 180 minutes at 10x magnification (b). Relative gap 
size between 0 and 180 minutes of UT-SCC-15 cells transfected with the αB1, αB2 or LUC 
siRNA (c). Statistical analysis was performed using One-way ANOVA and Tukey’s 
Multiple Comparison Test. *** P < 0.001, * 0.01 < P < 0.05. 
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endothelial apoptosis and decreased vessel formation. αB-crystallin has been shown to 
associate with VEGF-A (the most well-known member of the VEGF protein family) 
(225;246) and colocalizes with VEGF at the endoplasmic reticulum (227). 
Furthermore, VEGF-A expression remained low in αB-crystallin-deficient mice during 
retinal revascularization after artificially-induced retinopathy (226). Here we have 
shown that in a HNSCC cell line αB-crystallin is also involved in secretion of VEGF 
and in this way may influence tumorigenic blood vessel formation and metastasis 
formation in HNSCC. For the growth of metastatic tumors in lymph nodes 
neoangiogenesis is not absolutely needed (247;248), which might explain why no 
correlation was found between αB-crystallin expression and LRC. Migration-
associated proteins may also correlate with worse outcome, as has been shown for 
patients with squamous cell carcinoma of the tongue (249). αB-crystallin can affect cell 
migration as well. Overexpression of αB-crystallin led to higher cell motility in several 
studies (126;239;250). Here we have shown that depletion of αB-crystallin decreased 
the motility of UT-SCC cells, indicating also in these types of cells αB-crystallin may 
affect cell migration. VEGF also plays a role in cell migration (251), potentially by 
enhancing invadopodia formation (252). The effect of αB-crystallin on cell migration 
may thus be mediated by VEGF, although other mechanisms are also possible, as for 
example by the influence of αB-crystallin on actin filaments dynamics (252;253). 
Further research is needed to reveal the molecular mechanisms by which αB-crystallin 
affects cell migration. 
 
 
CONCLUSIONS 
 
High αB-crystallin expression is associated with metastasis formation in HNSCC but 
not with locoregional recurrence. αB-crystallin could be a useful biomarker to help 
fine-tune treatment, possibly by targeting αB-crystallin-induced VEGF secretion or cell 
motility. Validation in a larger HNSCC cohort is required to confirm the significance 
of this finding. 
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ABSTRACT 
 
The presence of hypoxia in head and neck squamous cell carcinoma (HNSCC) is 
associated with therapeutic resistance and increased risk of metastasis formation. αB-
crystallin (HspB5) is a small heat shock protein, which is also associated with 
metastasis formation in HNSCC. In this study, we investigated whether αB-crystallin 
protein expression is increased in hypoxic areas of HNSCC biopsies and analyzed 
whether hypoxia induces αB-crystallin expression in vitro and in this way may confer 
hypoxic cell survival. In 38 HNSCC biopsies, the overlap between 
immunohistochemically stained αB-crystallin and pimonidazole-adducts 
(hypoxiamarker) was determined. Moreover, expression levels of αB-crystallin were 
analyzed in HNSCC cell lines under hypoxia and reoxygenation conditions and after 
exposure to reactive oxygen species (ROS) and the ROS scavenger N-acetylcysteine 
(NAC). siRNA-mediated knockdown was used to determine the influence of αB-
crystallin on cell survival under hypoxic conditions. In all biopsies αB-crystallin was 
more abundantly present in hypoxic areas than in normoxic areas. Remarkably, 
hypoxia decreased αB-crystallin mRNA expression in the HNSCC cell lines. Only after 
reoxygenation, a condition that stimulates ROS formation, αB-crystallin expression 
was increased. αB-crystallin mRNA levels were also increased by extracellular ROS, 
and NAC abolished the reoxygenation-induced αB-crystallin upregulation. Moreover, 
it was found that decreased αB-crystallin levels reduced cell survival under hypoxic 
conditions. We provide the first evidence that hypoxia stimulates upregulation of αB-
crystallin in HNSCC. This upregulation was not caused by the low oxygen pressure, 
but more likely by ROS formation. The higher expression of αB-crystallin may lead to 
prolonged survival of these cells under hypoxic conditions. 
 
 
BACKGROUND 
 
In solid tumors, hypoxic regions can be present when cells are exposed to an oxygen 
pressure below 5 to 10 mmHg (0.66 – 1.32% O2) (181). Hypoxia can be a result of 
insufficient oxygen transportation to remote parts of a tumor, caused by deficient blood 
vessel formation (chronic, diffusion-limited hypoxia) or leaking or partially blockage 
of blood vessels (acute, perfusion-limited hypoxia) (181). Hypoxia might be 
intermittent when the blood flow is restored after temporary vascular shutdown, which 
can result in a cycling pattern of hypoxia and reoxygenation (194;196;197). The 
presence of hypoxic regions in the tumor is detrimental for the patient, since hypoxic 
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tumor cells are associated with therapeutic resistance and metastatic progression 
(187;188;254). Despite the low oxygen levels, hypoxia is also associated with the 
presence of reactive oxygen species (ROS) (199;200;255). As ROS are conventionally 
thought to be cytotoxic and mutagenic, they could lead to cancer progression and might 
be one of the reasons why the presence of hypoxia is as a bad prognostic factor (256). 
αB-crystallin is a small heat shock protein, which can bind to partially unfolded 
proteins, thereby keeping them in a soluble state to prevent their aggregation (54;224). 
It may protect cells from death induced by accumulation of unfolded proteins (257). 
Furthermore, αB-crystallin may confer stress resistance to cells by inhibiting the 
processing of the pro-apoptotic protein caspase-3 (258). Besides being mainly 
expressed in eye lens and muscle tissues (259), αB-crystallin can also be found in 
several types of cancer, among which head and neck squamous cell carcinoma 
(HNSCC) (220;260;261) and breast carcinomas (126;222;262). αB-crystallin 
expression is associated with metastasis formation in HNSCC and in breast carcinomas 
(14;223) and in other types of cancer, expression is often correlated with poor 
prognosis as well (54;224). The expression of αB-crystallin can be increased during 
various stresses, like heat shock, osmotic stress or exposure to heavy metals (14). 
Moreover, in tissues from newborn piglets, αB-crystallin has been shown to be 
upregulated by hypoxia (263;264). In this study, we analyzed whether the expression 
of αB-crystallin protein is affected in hypoxic regions of HNSCC’s and whether αB-
crystallin knockdown influences cell survival under hypoxic stress. 
 
 
METHODS 
 
Patients 
Biopsy material of 38 HNSCC patients with stage II to IV primary squamous cell 
carcinoma of the oral cavity, oropharynx, hypopharynx or larynx was used (not all 
biopsies of the available cohort could be used due to the lack of material) (232;261). 
Two hours before biopsies were taken (1 per patient), patients received 500 mg/m2 
body surface of the hypoxia marker pimonidazole (intravenously, dissolved in 100 ml 
0.9% NaCl) over 20 minutes. The obtained biopsies were snap-frozen and stored in 
liquid nitrogen until immunohistochemical processing. Approval from the ethics 
committee of Radboud University Nijmegen Medical Centre was obtained and all 
patients provided written informed consent. 
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Immunohistochemisty 
Sections of the biopsies (5 μm) were mounted on poly-L-lysine coated slides, fixed for 
10 minutes in acetone at 4 °C and rehydrated in PBS. The sections were incubated 
overnight at 4 °C with 100-fold diluted αB-crystallin antiserum (38) and subsequently 
incubated for 30 minutes at 37 °C with 600-fold diluted FabCy3 goat-α-rabbit IgG 
(Jackson Immuno Research Laboratories Inc) in PBS for 45 minutes at 37 °C with 10-
fold diluted endothelium antibody PAL-E (Euro Diagnostica BV) in Primary Antibody 
Diluent (PAD, Dako) and for 60 minutes at 37 °C with 100-fold diluted Alexa 647 
chicken-α-mouse IgG (Molecular probes) in PBS. For visualization of the 
pimonidazole adducts, the sections were stained with 1000-fold diluted rabbit-α-
pimonidazole (gift from Dr. James A. Raleigh, University of North Carolina), diluted 
in PAD for 30 minutes at 37 °C and subsequently stained with 600-fold diluted Alexa 
488 donkey-α-rabbit IgG (Molecular probes) in PBS 30 minutes at 37 °C. During the 
latter step only the rabbit antibodies directed to pimonidazole were stained (265). 
Between the incubations, 3 times 2 minutes washing steps in PBS were performed. The 
sections were mounted using fluorostab (ProGen Biotechnik GmbH). 
 
Image acquisition 
Scanning of the biopsy sections was performed with a fluorescence microscope 
(Axioskop, Zeiss) and a computer-controlled motorized stepping stage, using IP-lab 
software (Scanalytics), as described previously (266). Each section was completely 
sequentially scanned for αB-crystallin, pimonidazole and blood vessel staining at 100x 
magnification. The resulting composite grey scale images were converted to binary 
images for further analysis. Thresholds were set just above the background staining for 
each individual staining. The total tumor area was contoured manually, excluding 
nontumor tissue, large necrotic areas and artifacts. The percentage of αB-crystallin in 
the normoxic area was determined as the pimonidazole-negative tumor area containing 
αB-crystallin relative to the total pimonidazole-negative tumor area. The percentage of 
αB-crystallin in the hypoxic area was determined as the tumor area positive for αB-
crystallin and pimonidazole relative to the total pimonidazole-positive area. 
 
αB-crystallin mRNA expression upon hypoxia 
The HNSCC cell line UT-SCC-5 (described in (235)), maintained in DMEM + 
GlutaMAX (Invitrogen) supplemented with 10% fetal calf serum (Gibco-BRL) was 
seeded on 6-wells plates, 0.5x106 cells per well, N = 4 per time point, and transferred 
after 24 hours from a standard humidified 37 ºC incubator to a humidified 37 ºC H35 
hypoxystation (Don Whitley Scientific) with 0.1% O2. Samples were harvested after 0–
22 hours of hypoxic incubation for quantitative RNA analysis. 
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αB-Crystallin mRNA expression upon hypoxia, reoxygenation and N-
acetylcysteine 
The HNSCC cell lines UT-SCC-5 and UT-SCC-15 (described in (235)), maintained in 
DMEM + GlutaMAX supplemented with 10% fetal calf serum, were seeded in 6-wells 
plates, 0.3x106 cells per well, N = 4 per condition, and transferred after 24 hours from a 
standard humidified 37 ºC incubator to a H35 hypoxystation with 0.1% O2 (Don 
Whitley Scientific), or maintained in a standard incubator. Normoxic and hypoxic 
samples were harvested after 48 hours for quantitative RNA analysis. The 
reoxygenation samples were transferred after 24 hours of hypoxic incubation to a 
standard incubator again for 24 hours and subsequently harvested. To reduce ROS, 
cells were incubated after 24 hours of hypoxia or normoxia with 0.05 mM NAC 
(Sigma). After NAC was added, the reoxygenation samples were transferred from the 
hypoxystation to a standard humidified 37 ºC incubator and incubated for 24 hours and 
subsequently harvested. 
 
αB-crystallin protein expression upon hypoxia and reoxygenation 
The UT-SCC-5 cell line was seeded in T25 flasks, 0.9x106 cells per flask, N = 3 for 
the normoxic condition and N = 4 for the hypoxic and reoxygenation condition, and 
incubated for 5 hours in a standard humidified 37ºC incubator. The cells were 
transferred to the hypoxystation maintained at 0.1% or kept in the standard incubator 
and harvested after 48 hours. The reoxygenation samples were transferred after 24 
hours of hypoxic incubation to the standard incubator again for 24 hours and 
subsequently harvested. The cells were harvested in 2% sodium dodecyl sulfate 
(Gibco), heated for 5 minutes at 100 °C and sonicated 5x 30 seconds on and 30 seconds 
off with Bioruptor (Diagenode). The protein concentrations were determined with BCA 
Protein Assay Kit (Thermo Scientific) according to manufacturer’s protocol. Protein 
samples (60 μg/sample) were separated by electrophoresis on a 12.5% polyacrylamide 
gel and transferred to a nitrocellulose membrane (Protran). The membranes were 
blocked with 5% Elk (Campina) in PBS for an hour and washed 3 times for 10 minutes 
with PBS + 0.0025% v/v Nonidet P-40. The membranes were incubated for an hour 
with the 200-fold diluted monoclonal mouse-α-human-αB-crystallin (RIKEN) and 
6000-fold diluted mouse-α-human-γ-tubulin as reference (Sigma-Aldrich) diluted in 
0.025% w/v Nonidet P-40 and completed with 2% Elk in PBS. After washing, blots 
were incubated for 1 hour with a 6000-fold dilution of IRDye 800CW goat-α-mouse 
IgG (LI-COR). The proteins were visualized with the Odyssey scanner (LI-COR). 
Analysis was performed using Odyssey 2.1 software. 
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αB-crystallin mRNA expression upon H2O2-induced oxidative stress 
UT-SCC-5 cells were seeded in 6-wells plates, 0.5x106 cells per well; N = 4 per 
concentration maintained in DMEM + GlutaMAX supplemented with 10% fetal calf 
serum. After 24 hours, cells were incubated with 0 mM (mock), 0.3 mM, 1.5 mM or 
3.0 mM H2O2 for 1 hour after which they were incubated again in normal medium and 
harvested after 7 hours for quantitative RNA analysis. 
 
Hypoxia survival upon siRNA-mediated knock-down of αB-crystallin 
4.4 x106 UT-SCC-5 cells were seeded in a T175 culture flask and maintained in 
DMEM + GlutaMAX supplemented with 10% fetal calf serum. After 24 hours, cells 
were transfected with siRNA using Lipofectamine 2000 Reagent according to 
manufacturers’ protocol (Invitrogen). The siRNA’s were directed against luciferase 
(siRNA LUC, sequence: CGUACGCGGAAUACUUCGAdTdT) and EGFP (si-EGFP, 
sequence: CGAGAAGCGCGAUCACAUGdTdT) as negative controls and αB-
crystallin (si-αB1, sequence: GCACCCAGCUGGUUUGACAdTdT, si-αB2 sequence: 
CCCUGAGUCCCUUCUACCUdTdT and si-αB3, sequence: 
CCGGAUCCCAGCUGAUGUAdTdT). After 5 hours, cells were reseeded 4.0x104 
cells/well in 96-wells plates (6-fold per condition) and 1.25 x105 cells/well in 6-wells 
plates (4-fold per condition). The next day, the cells in the 96-wells plates were washed 
twice with PBS and DMEM (supplemented with GlutaMAX, 1 mM sodiumpyruvate 
and 10% fetal calf serum) was added containing 0 mM or 5 mM Glucose (Dextrose 
D(+), Invitrogen). After one hour, cells were kept in the standard incubator or 
transferred to the H35 hypoxystation maintained at 0.1% O2 and incubated for 24 
hours. All 96-wells plates were subsequently incubated in the standard incubator for 
3.5 hours and washed twice with PBS and incubated for two hours in 10-fold diluted 
Cell Counting Kit-8 solution (Sigma-Aldrich) in Optimem (Invitrogen). The 
absorbance at 450 nm was measured using an ELISA-reader (Tecan). The cells in the 
6-wells plates were harvested 48 hours after siRNA transfection for quantitative RNA 
analysis to determine the efficiency of αB-crystallin mRNA knockdown. 
 
RNA analysis by quantitative RT-PCR 
Total RNA from the harvested UT-SCC-5 and UT-SCC-15 cells was extracted using 
standard Trizol isolation. After DNAse I treatment (Amplification grade, Invitrogen) 
mRNAs were reverse transcribed using oligo(dT) primers and the Reverse 
Transcription System (Promega) according to manufacturer’s protocol starting with 1 
μg of RNA in a final volume of 20 μl. Subsequently, quantitative PCR (qPCR) 
reactions were performed with 10 μl Power SYBR Green (Applied BioSystems), 5 μM 
primers and 2 μl cDNA in a final volume of 20 μl. The used primer sequences for αB-
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crystallin are: ATCTTCTTTTGCGTCGCCAG and TTCCCCATGGTGTCTGAGC, 
and for GAPDH: GATTGAGGTGCATGGAAAAC and 
AGGACCCCATCAGATGACAG. The fluorescent signal intensities were recorded 
with the ABI Prism 7000 system (Applied Biosystems). Samples were kept for 10 
minutes at 95 °C, followed by 40 cycles of 15 seconds at 95 °C and 1 minute at 60 °C. 
Data analysis was performed on the CFX96 (Biorad). Analysis was performed with 
CFX Manager Software (Biorad). 
 
Statistics 
Statistical analyses were performed using Graphpad Prism 5.00 software. Statistical 
analysis was performed using One-way ANOVA and Tukey’s Multiple Comparison. 
 
 
RESULTS 
 
αB-crystallin protein is increased in the hypoxic areas of HNSCC biopsies 
The expression of αB-crystallin protein was analyzed in the hypoxic and normoxic 
regions present in sections of HNSCC biopsies of 38 different patients. To detect the 
hypoxic regions, the hypoxia marker pimonidazole was used. Figure 1 shows a 
representative binarized staining of αB-crystallin and pimonidazole (Figure 1a and 1b). 
Most of the hypoxic areas (Figure 1c, depicted in green) are located in tumor areas at 
larger distance from blood vessels (Figure 1c, depicted in blue). Interestingly, areas 
showing αB-crystallin expression (Figure 1c, depicted in red) are largely overlapping 
with hypoxic areas, though αB-crystallin can be detected in normoxic areas as well. By 
digital analysis of the scanned images the percentages of αB-crystallin-positive areas in 
the normoxic tumor areas and in the hypoxic tumor areas were determined for each 
biopsy. In case hypoxia does not affect αB-crystallin expression, the percentages of 
αB-crystallin-positive areas present in normoxic and hypoxic areas would be similar 
(Figure 2, grey line). However, as shown in Figure 2, the percentages of αB-crystallin-
positive areas were found to be higher in the hypoxic than in the normoxic areas in all 
analyzed HNSCC biopsies. 
 
αB-crystallin expression is upregulated by reoxygenation, not hypoxia 
The increased presence of αB-crystallin in the hypoxic areas might be the result of two 
different processes: a stress-induced upregulation of αB-crystallin and/or a longer 
survival of the cells expressing αB-crystallin. It has been shown that hypoxia 
stimulates upregulation of αB-crystallin in piglet stomach, colon and heart tissue 
(263;264). For this reason we first tested whether hypoxic incubation is able to increase 
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Figure 1. Immunofluorescent staining of human HNSCC for αB-crystallin, 
pimonidazole-modified proteins and PAL-E. Shown is a representative biopsy section. 
The fluorescent grey scale images were binarized, resulting in black and white images for 
αB-crystallin staining and pimonidazole-modified proteins staining, indicating the hypoxic 
areas (a and b). The merged image with αB-crystallin staining (assigned red), pimonidazole 
staining (assigned green) and PAL-E blood vessel staining (assigned blue) shows a 
substantial overlap between αB-crystallin and hypoxic regions. Hypoxic regions are mostly 
located in areas at greater distance from vessels (c). 
 
 
αB-crystallin mRNA expression levels of HNSCC cell lines by using quantitative RT- 
PCR. The HNSCC cell line UT-SCC-5 was maintained for 22 hours under 0.1% O2 
conditions and every 2 hours (except t = 12 hours), αB-crystallin mRNA expression 
levels were determined. Surprisingly, αB-crystallin mRNA levels were found not to be 
upregulated, but actually 2.3-fold downregulated after 22 hours (Figure 3, P < 0.001), 
which suggests that the increased expression of αB-crystallin in the hypoxic areas of 
HNSCC is not directly caused by low oxygen levels. Reoxygenation can also lead to 
αB-crystallin upregulation, as has been shown in cultured optic nerve astrocytes (48). 
Since in some areas hypoxia can be intermittent, resulting in periods with higher 
oxygen (194;196;197), we assessed the effect of reoxygenation on αB-crystallin 
expression. Consistent with the previous experiment, after 48 hours of hypoxic 
incubation, αB-crystallin mRNA expression was downregulated in UT-SCC-5 as well 
as in the HNSCC cell line UT-SCC-15 (Figure 4). However, upon reoxygenation, αB-
crystallin expression levels were significantly higher than in the cells which were only 
incubated under normoxic conditions. A similar response was also observed in HeLa 
cells (data not shown), indicating that this might be a general response. Next we tested 
if a similar effect of the reoxygenation could be found on the protein level. For this we 
could only use the UT-SCC-5 cell line, since αB-crystallin expression in UT-SCC-15  
(a) (b) (c) 
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Figure 2. αB-crystallin expression is increased in hypoxic areas. The symbols represent 
the relative amount of αB-crystallin staining in the normoxic areas and in the hypoxic areas 
for each individual HNSCC. Equal staining of αB-crystallin in the normoxic and hypoxic 
areas would be according to the grey line. 
 
 
cells was too low to allow detection by western blotting. After 48 hours of hypoxic 
conditions, αB-crystallin protein levels were decreased 2.0-fold (Figure 5, p < 0.001) 
and upon reoxygenation the αB-crystallin level was raised 1.5-fold compared to the 
hypoxic level (p < 0.01). Although the level after reoxygenation did not reach the level 
observed at normoxic conditions (p < 0.01), these results show that also the αB-
crystallin protein was upregulated upon reoxygenation after hypoxia. 
 
αB-crystallin mRNA overexpression during reoxygenation is induced by ROS 
Reoxygenation stimulates the production of ROS (267), which at a high concentration 
is stressful for cells. As a reaction, cells can protect themselves by increasing the level 
of stress proteins (48). To test whether ROS induces αB-crystallin expression in 
HNSCC cells, UT-SCC-5 cells were treated with H2O2. The cells were incubated for 1 
hour with a H2O2 concentration series between 0 and 3.0 mM H2O2 and subsequently 
harvested after 7 hours (Figure 6). At the protein level no effect could be detected, 
because the protein expression was too low to allow accurate measurement by western 
blotting (data not shown). However, a significant increase in αB-crystallin mRNA  
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Figure 3. Relative αB-crystallin mRNA expression during hypoxia. αB-crystallin 
mRNA expression levels in UT-SCC-5 cells after incubation in a humidified 37 ºC H35 
hypoxystation at 0.1% O2 for the indicated time points. αB-crystallin mRNA expression 
levels were assessed via RT-qPCR (N = 4) *** p < 0.001, ** 0.001 < p < 0.01 
 
 
expression could be observed at 1.5 mM and 3.0 mM H2O2, compared to incubation 
with mock (P < 0.001). Next, it was tested whether induction of αB-crystallin upon 
reoxygenation can be reduced with the ROS scavenger NAC. UT-SCC-5 cells were 
incubated without and with NAC during normoxia, hypoxia and reoxygenation. 
Without NAC, αB-crystallin mRNA levels were again downregulated during hypoxia 
and upregulated during reoxygenation, as expected (Figure 7). In the presence of NAC, 
the hypoxia-induced αB-crystallin mRNA downregulation remained the same, whilst 
the upregulation upon reoxygenation was reduced 1.7-fold, compared to reoxygenation 
without NAC. These results suggest that the ROS produced upon reoxygenation is at 
least in part responsible for the upregulation of αB-crystallin in UT-SCC-5 cells. 
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Figure 4. Relative αB-crystallin mRNA levels after hypoxia and reoxygenation. αB-
crystallin mRNA levels in UT-SCC-5 and UT-SCC-15 cells under 48 hours normoxia (N), 
hypoxia (H, 0.1% O2) and after reoxygenation (R, 24 hours 0.1% O2/24 hours normoxia). 
αB-crystallin mRNA expression levels were assessed via RT-qPCR (N = 4). *** p < 0.001, 
** 0.001 < p < 0.01, * 0.01 < p < 0.05. 
 
 
αB-crystallin knockdown leads to diminished cell survival under hypoxic and 
hypoglycemic stress 
Next, it was investigated whether cells expressing αB-crystallin were able to survive 
longer under hypoxic conditions. In hypoxic areas, not only a shortage in oxygen, but 
hypoglycemia as well is a physiological stressor (268). Since glucose is able to protect 
cells under hypoxic conditions (269) and glucose is the main energy source required 
for HNSCC cell survival (270;271), medium without glucose was used as an additional 
stress condition. Reduction of αB-crystallin expression in UT-SCC-5 cells was 
obtained by siRNA-mediated knockdown. Cells with normal and reduced levels of αB-
crystallin were exposed to a hypoxic oxygen level of 0.1% for 24 hours, after which the 
survival was determined by analyzing the cell number with Cell Counting Kit-8. The 
knockdown of αB-crystallin was performed with 3 different siRNAs and compared 
with 2 different control siRNAs (Figure 8a). Under normoxic conditions in the 
presence of 5 mM glucose, knockdown of αB-crystallin did not significantly alter cell 
survival, although with all three siRNAs a trend in survival reduction was observed 
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(Figure 8b). Hypoxic stress in the presence of 5 mM glucose, led to a significant lower 
cell survival, compared to normoxic conditions (67% for siEGFP and siLUC). Cell 
survival could be further reduced significantly, by knockdown of αB-crystallin (57% 
for si-αB1 and 58% for si-αB2 and si-αB3). Under normoxic conditions, 0 mM glucose 
led to lower cell survival rates (66% for siEGFP and 63% for si-LUC), which was  
 
 
Figure 5. Relative αB-crystallin protein levels after hypoxia and reoxygenation. αB-
crystallin protein expression levels in UT-SCC-5 cells under 48 hours normoxia (N), 
hypoxia (H, 0.1% O2) and after reoxygenation (R, 24 hours 0.1% O2/24 hours normoxia). 
αB-crystallin protein expression was analyzed of 3–4 independent incubations via western 
blotting (a) and quantified (b). ***p < 0.001, ** 0.001 < p < 0.01. 
(a) 
(b) 
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Figure 6. Relative αB-crystallin mRNA levels upon H2O2-incubation. Relative αB-
crystallin mRNA levels in UT-SCC-5 cells after incubation with 0.0 mM (mock), 0.3 
mM, 1.5 mM or 3.0 mM H2O2 for 1 hour and 7 hours of recovery. αB-crystallin mRNA 
expression levels were assessed via RT-qPCR (N = 4). *** p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of the ROS-scavenger NAC on αB-crystallin mRNA levels during 
reoxygenation. UT-SCC-5 cells after incubation with mock or NAC under 48 hours 
normoxia (N), hypoxia (H, 0.1% O2) and after reoxygenation (R, 24 hours 0.1% O2/24 
hours normoxia).** 0.001 < p < 0.01, * 0.01 < p < 0.05. 
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further reduced as well after knockdown of αB-crystallin (57% for si-αB1 and 55% for 
si-αB2 and si-αB3). Combining hypoxic as well as hypoglycemia stress was 
detrimental resulting in 0% cell survival. Since all 3 different αB-crystallin siRNAs 
gave similar results, it is very unlikely that these observations are due to off-targets 
effects. These results show that reduction of the αB-crystallin level decreases the 
survival of hypoxia-exposed and glucose-deprived cells. 
 
 
DISCUSSION 
 
In the current study, we show that more αB-crystallin protein is present in hypoxic 
HNSCC tumor areas than in normoxic areas. Since an increased αB-crystallin 
expression might be the result of a stress-induced transcriptional upregulation, we 
investigated whether hypoxic stress is able to induce αB-crystallin expression in 
HNSCC cell lines. Remarkably, under hypoxic conditions αB-crystallin mRNA 
expression was found to be downregulated in UT-SCC-5 and UT-SCC-15 cells. It is 
not clear how αB-crystallin is downregulated, but this could be due to a general 
transcription shutdown caused by epigenetic modifications (272;273). Only after 
reoxygenation, a significant upregulation of αB-crystallin mRNA in the HNSCC cell 
lines was found. The same trend was observed at the protein level. The upregulation of 
αB-crystallin has also been observed in other cell types and by different forms of 
reoxygenation stress, such as chemical ischemic/recovery stress and 
ischemic/reperfusion injury (274;275), although from those studies it appeared that the 
upregulation of αB-crystallin is not a general mechanism since not all cell types show 
this effect (274). The reoxygenation-induced upregulation of αB-crystallin also fits 
with the studies performed with the piglets, where hypoxia-induced αB-crystallin 
upregulation was detected (263;264). In these studies piglets were maintained in a 
hypoxic chamber for either 1 or 4 hours and were allowed to recover over periods of 1 
to 68 hours under normoxic condition and thus underwent a period of reoxygenation. 
The reoxygenation-induced upregulation of αB-crystallin mRNA is at least partially 
caused by ROS, based on the inhibitory effect of the ROS-scavenger NAC (Figure 7). 
Despite the low level of oxygen, significant levels of ROS can be present in hypoxic 
areas and thus can be responsible for the induction of αB-crystallin expression. ROS- 
levels in hypoxic areas can be increased by moments of reoxygenation due to 
intermittent, perfusion-limited hypoxia (200) or produced by necrotic cells which are 
often present in hypoxic tumor areas (202;268;276;277). Also ROS can be produced by 
a synergistic effect of oncogenic-induced stimulation of increased mitochondrial 
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Figure 8. Knockdown of αB-crystallin expression reduces hypoxia and hypoglycemia 
survival. Expression of αB-crystallin mRNA in UT-SCC-5 cells was reduced by three 
different αB-crystallin siRNAs (αB1, αB2 and αB3). LUC and EGFP were used as negative 
control siRNAs (a). Survival of siRNA-treated UT-SCC-5 cells under normoxic (N) and 
hypoxic (H, 0.1% O2 for 24 hours) conditions in the presence of 5 mM or 0 mM glucose 
(b). Cell survival was assessed via a colorimetric assay using cell counting kit-8. The 
optical density (O.D.) of siEGFP-treated cells was set at 100%. *** p < 0.001, ** 0.001 < p 
< 0.01, * 0.01 < p < 0.05. 
(a) 
 
(b) 
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capacity and low oxygen levels, which causes an ineffective functioning of 
mitochondrial respiratory complexes (255). For this a hypoxia-induced downregulation 
of thioredoxin reductase 1 seems to be important in maintaining high levels of ROS 
under hypoxic conditions (278). As mentioned earlier, some normoxic areas may also 
contain significant levels of αB-crystallin. These local αB-crystallin expressions might 
be explained by intermittent hypoxia as well. As shown by Bennewith and colleagues a 
substantial proportion of tumor cells can go through cycles of hypoxia and normoxia 
(279;280). If the intervals of hypoxia are too short or if pimonidazole is not present at 
the hypoxic moments, erroneously no staining by this marker will be detected 
(279;280). Nevertheless, αB-crystallin induced by the ROS formed during the 
reoxygenation periods might still be present. 
αB-crystallin is a stress protein which may enhance cell survival upon ROS exposure, 
as shown for H2O2 treated mouse retinal pigment epithelium cells (281). Based on 
knockdown experiments, we showed that αB-crystallin is able to play a role in the 
survival of cells coping with hypoxia and glucose-deprivation stress as well. It is thus 
possible that the αB-crystallin present in hypoxic tumor areas plays a role in tumor cell 
survival during hypoxic stress (268;282). This protective activity of αB-crystallin may 
further increase the number of αB-crystallin-positive cells in hypoxic tumor areas. In 
summary, the relative higher levels of αB-crystallin in HNSCC hypoxic tumor areas 
might be caused by a combination of ROS-induced αB-crystallin upregulation and an 
enhanced survival of αB-crystallin-positive cells exposed to this stress. 
The enhanced expression of αB-crystallin in HNSCC may have a negative effect on the 
prognosis of the patient. We have recently found that αB-crystallin expression is 
associated with distant metastases formation in HNSCC patients (261). This 
association might relate to the chaperone function of αB-crystallin in mediating folding 
and secretion of VEGF. αB-crystallin is able to bind misfolded vascular endothelial 
growth factor (VEGF), leading to enhanced VEGF secretion (226;227). VEGF is 
specifically upregulated by hypoxia-inducible factor 1 (HIF1) and is important for 
tumor vascularization. VEGF induction is thus a mechanism to alleviate hypoxic 
circumstances (228;283). Cycling hypoxia-induced VEGF expression has been shown 
to increase pulmonary metastasis formation in mice (284). Since αB-crystallin can 
increase hypoxic cell survival and can help in the (re)folding of hypoxia-induced 
VEGF expression, αB-crystallin expression could ultimately increase the risk of 
hypoxic tumors to become metastasis-prone (285). Furthermore, by increasing hypoxic 
cell survival αB-crystallin may also decrease the sensitivity of a tumor to cancer 
treatments, such as radiation or other cancer treatments, as shown by the effect of αB-
crystallin on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as well 
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as cisplatin-induced apoptosis in human ovarian cancer cells (286). Because of its 
potential to interfere with anti-tumor therapies, αB-crystallin might be a promising 
target for anti-cancer treatment. 
 
 
CONCLUSIONS 
 
Enhanced αB-crystallin expression in HNSCC and also in other kind of tumors 
correlates with poor prognosis of the patients. The underlying stress that induces αB-
crystallin expression in HNSCC was not known. Here we show that αB-crystallin is 
most abundantly present in the hypoxic areas of the tumor, likely caused by ROS 
stress. The increased expression of αB-crystallin may lead to prolonged survival of 
hypoxic cells, thereby protecting those cells which are most resistant against cancer 
treatments. 
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ABSTRACT 
 
αB-crystallin is regarded as a biomarker for triple negative/basal-like breast cancer. In 
normal breast cells overexpression of αB-crystallin leads to neoplastic-like changes, 
which likely relates to enhanced expression of phosphorylated ERK1/2 (pERK1/2). In 
this study, we investigated whether αB-crystallin expression is correlated to pERK1/2 
expression in breast cancer. In a balanced tissue microarray the expression of αB-
crystallin and pERK1/2 kinase were determined immunohistochemically, together with 
triple negativity and basal-like markers CK5/6 and SMA and the signaling molecules 
pAKT, pmTOR, EGFR and IGF-1R. αB-crystallin expression significantly correlated 
with triple negativity and basal-like markers CK5/6 and SMA (Pearson Chi-square test 
p=0.004, p=0.001, p<0.001, respectively). A significant correlation was observed with 
pERK1/2 expression (p=0.002). siRNA-mediated knockdown of αB-crystallin in triple 
negative breast cell line MDA-MB468 did not show an effect on pERK1/2 expression 
levels, indicating that lowering the level of αB-crystallin does not reduce pERK1/2 
expression. Our results confirm that αB-crystallin can be used as a biomarker for triple 
negative and/or basal like breast cancer. The expression of αB-crystallin correlates with 
pERK1/2 expression in breast cancer tissue suggesting that therapies targeting αB-
crystallin might be considered for treatment of triple negative or basal-like breast 
cancer. 
 
 
INTRODUCTION 
 
Breast cancer consists of a heterogeneous group of tumors with varying histological 
appearances and prognoses (164). Using gene expression profiling, breast cancer can 
be categorized in several subsets, of which the most well known are normal breast-like, 
luminal A and B, epidermal growth factor receptor 2 (HER2)-enriched, and basal-like 
breast tumors (164;287). Because of the clinically aggressive nature, basal-like breast 
cancers have the worst prognosis (287).  
Triple negative breast cancers are defined by the absence of immunohistochemical 
staining for estrogen receptor (ER), progesterone receptor (PR) and HER2. This tumor 
type accounts for 15% of all breast cancer cases (288). Around 75% of the triple 
negative cases have the basal-like gene expression profile showing expression of, 
amongst other markers, high-molecular weight basal cytokeratins (CKs) and smooth 
muscle actin (SMA) (166;289-291).  
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Expression of αB-crystallin, a molecular chaperone able to interfere with several 
cellular processes resulting in cell maintenance under stress conditions (77;122;257), is 
enhanced in triple negative and basal breast cancer, and is a marker for poor prognosis 
(126;166;222;223;292). αB-crystallin may directly contribute to malignant progression 
as overexpression of wild type αB-crystallin in MCF-10A immortalized mammary 
epithelial cells leads to the formation of abnormal mammary acini and induction of 
neoplastic changes (126). Constitutive overexpression of αB-crystallin in MCF-10A 
cells was found to upregulate expression of extracellular regulated protein kinase1/2 
(ERK1/2) and phospho-ERK1/2 (pERK1/2), AKT and phospho-AKT (pAKT). Only 
inhibition of the ERK1/2 pathway could oppose the abnormal acini formation induced 
upon αB-crystallin overexpression. In cell lines and tumor models, AKT and/or 
ERK1/2 are implicated in cancer progression and metastasis formation (293). 
However, it is not known whether αB-crystallin expression in breast tumors is 
correlated to enhanced activity of these kinases. Therefore, we have studied whether 
endogenous αB-crystallin expression levels in breast tumors are correlated with the 
expression of phosphorylated, thus activated, forms of ERK1/2, AKT and mTOR in 
breast cancer tissue and with the expression of epidermal growth factor receptor 
(EGFR) and insulin-like growth factor 1 receptor (IGF-1R), which can activate these 
kinases (294;295). Furthermore, the direct effect of αB-crystallin depletion on 
pERK1/2 expression was studied in vitro, using siRNA mediated knockdown of αB-
crystallin. 
 
 
MATERIAL AND METHODS 
 
Patients 
The study population was selected from a cohort of breast cancer patients that was 
surgically treated between January 1991 and December 1996 at the University Medical 
Centre St. Radboud. Selection criteria were: no axillary lymph node invasion, no 
adjuvant systemic treatment, and at least 5 years follow up or an earlier recurrence 
during follow-up (296;297). In order to increase the power of our analysis, we designed 
a TMA with a high percentage of triple negatives and approximately equally sized 
groups of breast cancer subtypes were obtained. This ultimately led to a cohort of 122 
patients. As approved by the institutional review board and according to national law, 
coded tumor tissues were used. 
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Immunohistochemistry on breast cancer TMAs  
Immunohistochemical analyses were performed on 4 µm thick formalin-fixed, 
paraffin-embedded human tissue micro array (TMA), containing sections of human 
breast tumors. The specifications for each IHC assay are listed in Table 1. The tissue 
sections were deparaffinized in xylol and rehydrated through a graded ethanol into 
water series. All sections were pretreated with a 10 mM citrate buffer (pH 6.0) in a 
microwave oven for 3 minutes at 800W, followed by 10 minutes at 180W. After 
cooling for 1.5 hours at room temperature (RT), slides were washed in distilled water. 
To block endogenous peroxidase activity slides were treated with 3% hydrogen 
peroxide in distilled water for 10 minutes at RT followed by washing in distilled water 
and Tris buffered saline (TBS). The primary antibodies were diluted in 1% BSA-TBS 
and applied overnight in a humidified chamber at 4°C. The following day, the sections 
were washed with TBS and incubated with PowerVision (ImmunoLogic) for 30 
minutes at RT. Subsequently, the sections were washed with TBS and the antibody 
binding was visualized by incubating 5 minutes at RT with PowerVision DAB (3,3’-
diaminobenzide) (ImmunoLogic). After rinsing in distilled water, the sections were 
counterstained with  
 
 
Table 1. Antibodies used for immunohistochemical staining 
Antigen Antibody Dilution Control tissue 
αB-crystallin mAb mouse IgG (RIKEN Cell Bank) 1/1600 Kidney 
SMA mAb mouse IgG (#A2547, SIGMA) 1/30000 Muscle 
CK5/6 mAb mouse IgG (#M7237, DAKO) 1/40 Skin 
EGFR pAb rabbit IgG (#sc-03, Santa Cruz) 1/50 Placenta 
 
IGF-1R 
 
pAb rabbit IgG, (#3027,  
Cell Signaling Technology) 1/250 
Squamous cell carcinoma  
and mamma carcinoma 
pAKT mAb rabbit IgG (#3787,  
Cell Signaling Technology) 
1/100 Squamous cell carcinoma 
and mamma carcinoma 
pmTOR mAb rabbit IgG (#2976,  Cell Signaling Technology) 1/50 Mamma carcinoma 
pERK1/2 
mAb rabbit IgG, (#4376,  
Cell Signaling Technology) 1/100 Melanoma 
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Mayer’s hematoxylin solution, dehydrated through graded ethanol, cleared in xylol and 
enclosed with Permount (Fisher Scientific). Control tissues were used as a positive 
control for each IHC assay as listed in Table 1. Negative control included substitution 
of the primary antibody with 1% BSA-TBS. 
 
Scoring of IHC results 
Scoring of the stainings was performed by eye according to a scoring system where a 
score of ‘0’ is a negative staining and ‘1’ is positive staining. Cut-off points were 
determined for each staining. For pAKT, pERK1/2, pmTOR, EGFR en IGF-1R any 
observable staining was regarded as positive, for CK5/6 and SMA above 5% and for 
αB-crystallin above 15% of the cells expressing the protein were regarded as positive 
staining. 
 
Statistical Analysis 
Analysis of results was done in SPSS 16.0 using the Pearson Chi-square test.  
 
Cell culture of triple negative cell lines 
MDA-MB231, MDA-MB436 and MDA-MB468 cells were seeded into T25 flasks and 
maintained in DMEM + Glutamaxtm (Invitrogen) supplemented with 10% fetal calf 
serum (Gibco-BRL). At 80% confluency, the cells were harvested and, after 
trypsinization and two times washing with PBS, 40 μl 2% sodium dodecyl sulfate 
(SDS, Gibco) was added. Samples were twice heated for 5 minutes at 100°C and 
sonicated for 10 minutes (1 minute cycles, 30 seconds on, 30 seconds off, Bioruptor®, 
Diagenode). The samples were stored at -20oC.  
 
αB-crystallin knockdown in triple negative breast cancer cells 
7.75*105 MDA-MB468 cells were seeded into T25 flasks, N = 2 per condition and 
maintained in DMEM + Glutamaxtm (Invitrogen) supplemented with 10% fetal calf 
serum (Gibco-BRL). After 24 hours, confluency was 40% and cells were transfected 
with 1.25 ng siRNA/flask using Lipofectaminetm 2000 Reagent according to 
manufacturers’ protocol (Invitrogen). One mock transfection and five different 
siRNA’s were used: Mock transfection using MQ, two negative control siRNAs: si-
EGFP (CGAGAAGCGCGAUCACAUGdTdT) and si-LUC 
(CGUACGCGGAAUACUUCGAdTdT), and three αB-crystallin specific siRNA’s: si-
αB1 (GCACCCAGCUGGUUUGACAdTdT), si-αB2 
(CCCUGAGUCCCUUCUACCUdTdT) and si-
αB3(CCGGAUCCCAGCUGAUGUAdTdT). The medium was refreshed 5 hours after 
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transfection. Forty-eight hours after transfection, the cells were harvested, and protein 
was isolated as described above. The samples were stored at -20 oC.  
 
Western blotting 
The protein concentrations of the lysates were determined with BCA Protein Assay Kit 
(Thermo Scientific) according to manufacturer’s protocol. Protein samples were 
separated by electrophoresis on a 12.5% SDS-polyacrylamide gel and transferred to a 
nitrocellulose membrane (Protran). The membranes were blocked with 5% non-fat dry 
milk (Elk, Campina) in 1x PBS for an hour and washed 3 times for 10 minutes with 1x 
PBS + 0.0025% v/v Nonidet P-40. The membranes were incubated with the 
monoclonal mouse-anti-human-αB-crystallin antibody (undiluted, RIKEN), mouse-
anti-human-gamma-tubulin as reference (1:3000, Sigma-Aldrich), mouse-anti-human-
ERK1/2 (1:200, Cell Signaling) and rabbit-anti-human-phospho-ERK1/2 (1:200, Cell 
Signaling) diluted in 0.025% w/v Nonidet P-40 and completed with 2% Elk in 1x PBS. 
After washing, blots were incubated for 1 hour with a 6000-fold diluted goat-anti-
mouse IRDye® 800CW (LI-COR) and 6000-fold diluted goat-anti-rabbit IRDye® 
680CW (LI-COR). The proteins were visualized with the Odyssey scanner (LI-COR). 
Analysis was performed using Odyssey 2.1 software. 
 
 
RESULTS 
 
αB-crystallin expression is correlated with triple negative and basal-like 
markers  
In this study, a balanced breast cancer tissue TMA was used of which 69% of the 
sections were negative for ER expression, 81% were negative for PR expression, 70 % 
were negative for HER2 expression and 43% were triple negative. Endogenous αB-
crystallin expression was assessed by immunohistochemistry and 39% of the sections 
were scored positive. αB-crystallin expression appeared to correlate with triple 
negativity (Table, 2, p = 0.004), and not or less well with the lack of expression of one 
the three receptors per se (ER p = 0.103, PR p = 0.859 and HER2 p = 0.018). 
Moreover, a correlation was found with basal-like markers SMA (p < 0.001), and 
CK5/6 (p = 0.001) (Table 2). These results suggest that αB-crystallin is a good 
biomarker for triple negative tumors and/or basal-like tumors. 
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Table 2. Tumor markers and kinases correlated with αB-crystallin expression in a 
balanced breast cancer TMA  
 
Tumor marker N= 
αB-crystallin 
p-value 
Negative Positive 
Triple negativity 113   0.004 
Yes  22 27  
No  46 18  
ER 113   0.103 
Negative  43 35  
Positive  25 10  
PR 113   0.859 
Negative  55 37  
Positive  13 8  
HER2 115   0.018 
Negative  43 37  
Positive  27 8  
SMA 111   <0.001 
Negative  69 29  
Positive  0 13  
CK5/6 113   0.001 
Negative  42 13  
Positive  27 31  
EGFR 120   0.563 
Negative  35 20  
Positive  38 27  
IGF-1R 113   0.455 
Negative  41 23  
Positive  28 21  
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Tumor marker N= αB-crystallin p-value 
Negative Positive 
pAKT 89   0.648 
Negative  27 15  
Positive  28 19  
pmTOR 108   0.291 
Negative  22 10  
Positive  44 32  
pERK1/2 105   0.002 
Negative  31 7  
Positive  34 33  
 
 
αB-crystallin expression is correlated with pERK1/2 expression  
As constitutive overexpression of αB-crystallin in the immortalized mammary 
epithelial cell line MCF-10A was found to upregulate expression of pERK1/2 and 
pAKT (13), we determined whether a correlation does exist between αB-crystallin and 
pAKT and pERK1/2 in the TMA. Besides pERK1/2 and pAKT, also pmTOR, which is 
an AKT substrate was analyzed and IGF-1R and EGFR, which both are able to activate 
the pERK1/2 and pAKT pathways (16;17) (Table 2). Remarkably, only pERK1/2 
expression showed significant correlation with αB-crystallin expression (p = 0.002), 
whereas pAKT (p = 0.648), pmTOR (p = 0.291), IGF-1R (p = 0.455) and EGFR (p = 
0.563) did not.  
 
 
αB-crystallin depletion does not affect pERK1/2 
The results described above suggest that αB-crystallin may directly or indirectly affect 
pERK1/2 expression. To investigate the effects of a reduction of αB-crystallin 
expression on pERK1/2, triple negative breast cell lines MDA-MB231, MDA-MB436 
and MDA-MB468, were selected for αB-crystallin knock-down experiments. All three 
cell lines showed expression of pERK1/2 and ERK1/2, but αB-crystallin was only 
detected on Western blot in MDA-MB468 cells (Figure 1). Therefore, αB-crystallin 
was depleted in MDA-MB468 cells, which was done by transfection with three 
different αB-crystallin-specific siRNAs. As controls, mock-transfected cells and cells 
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transfected with unrelated siRNAs (si-LUC and si-EGFP) were included. Although αB-
crystallin levels were successfully reduced (Figure 2a), the results show that reduction 
of αB-crystallin in the triple negative breast cell line MDA-MB468 did not detectably 
affect total pERK1/2 levels (Figure 2b).  
 
 
 
 
 
Figure 1. αB-crystallin expression in three cell lines derived from triple-negative 
breast tumors. Western blot analysis of αB-crystallin, ERK1/2 and pERK1/2 expression in 
the three triple negative breast cancer cell lysates MDA-MB231, MDA-MB436 and MDA-
MB468. α-γ-Tubulin was used as loading control. 
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Figure 2. pERK 1/2 and ERK1/2 expression upon αB-crystallin depletion. siRNA-
mediated αB-crystallin knockdown was performed in MDA-MB468 and analyzed by 
western blotting using an antibody to αB-crystallin. pERK1, pERK2, ERK1 and ERK2 
expression was detected by using anti-pERK1/2 and anti-ERK1/2 antibodies. α-γ-Tubulin 
was used as a loading control (a). Quantification of total pERK1/2 expression levels, 
relative to γ-Tubulin expression. The bars in the graph are the mean of the two adjacent 
samples on Western blots (b).  
(a) 
(b) 
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DISCUSSION 
 
Here we describe how, in human breast cancer tissues, αB-crystallin is related to triple 
negativity and the basal-like markers CK5/6 and SMA. This relation of αB-crystallin 
with basal-like breast cancers is in line with other studies, that also reported that αB-
crystallin is related to poor prognosis in breast cancer (126;166;222;223;292). EGFR, 
which is also often used as a basal-like marker (290), did not correlate with αB-
crystallin in our study, which is contrary to the findings described by Tsang and 
coworkers (292). This discrepancy, however, might be explained by the lack of a well-
documented standard assay for this marker protein (298). 
Patients with triple negative breast cancers have a poor prognosis (287), partly as 
particular treatments are not available for these patients. Anti-breast cancer treatments 
targeting the estrogen, progesterone or HER2 receptors are ineffective in triple negative 
breast cancers that do not express these receptors. Other strategies in cancer treatment 
involve the use of small molecule kinase inhibitors, which target the intracellular 
downstream signaling pathways (299). Assessing which kinases are specifically 
enhanced in triple negative breast cancers might therefore reveal new targets for 
treatment using kinase inhibitors in these tumors. For triple negative tumors, increased 
activation of the AKT and ERK1/2 pathways has been described (300), suggesting that 
targeting these pathways might be beneficial in the treatment of triple negative breast 
cancer. Disruption of the RAS/RAF/MEK/ERK1/2 pathway could be an alternative 
strategy in particular breast cancer subtypes (301;302). Alternatively, proteins or 
mechanisms involved in the upregulation of these kinases might be a potential target 
for alternative treatment options. Reportedly, αB-crystallin could have an effect on the 
aggressiveness of tumor cells via upregulation of the AKT or ERK1/2 signaling 
pathways (126). The correlation, observed in the present study, between αB-crystallin 
and pERK1/2 expression suggests that αB-crystallin expression specifically influences 
the ERK1/2 pathway and not the AKT pathway, which is in agreement with the 
observations of Moyano and coworkers (126). However, in the triple negative cell line 
MDA-MB468 knockdown of αB-crystallin did not detectably change pERK1/2 
expression. Moyano and coworkers reported an upregulation of pERK2 in MCF-10A 
breast cells upon αB-crystallin overexpression in MCF-10A breast cells (126) (pERK1 
is not expressed in this cell line (301)) and thus downregulation of at least pERK2 was 
expected upon siRNA treatment. Why αB-crystallin knockdown did not show an effect 
on ERK1/2 phosphorylation is not clear. Since αB-crystallin is a heat shock protein 
which expression is specifically enhanced during stress situations, it is possible that 
αB-crystallin affects pERK1/2 expression only when the protein is overexpressed. The 
correlation of αB-crystallin with triple negative tumors and ERK1/2 suggests that 
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therapies targeting αB-crystallin might be considered for treatment of triple negative or 
basal-like breast cancers. Our data suggest that not αB-crystallin downregulation but 
preventing αB-crystallin upregulation might be an option for such an alternative 
treatment.  
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ABSTRACT 
 
The human small heat shock protein αB-crystallin (HspB5) is a molecular chaperone 
which is mainly localized in the cytoplasm. A small fraction can also be found in 
nuclear speckles, of which the localization is mediated by successional phosphorylation 
at Ser-59 and Ser-45. αB-crystallin does not contain a canonical Nuclear Localization 
Signal sequence and the mechanism by which αB-crystallin is imported into the 
nucleus is not known. Here we show that after heat shock pseudophosphorylated αB-
crystallin mutant αB-STD, in which all three phosphorylatable serine residues (Ser-19, 
Ser-45 and Ser-59) were replaced by negatively charged aspartate residues, is released 
from the nuclear speckles. This allows αB-crystallin to chaperone proteins in the 
nucleoplasm, as shown by the ability of αB-STD to restore nuclear firefly luciferase 
activity after a heat shock. With the help of a yeast two-hybrid screen we found that 
αB-crystallin can interact with the C-terminal part of Gemin3 and confirmed this 
interaction by co-immunoprecipitation. Gemin3 is a component of the SMN complex, 
which is involved in the assembly and nuclear import of U-snRNPs. Knockdown of 
Gemin3 in an in situ nuclear import assay strongly reduced the accumulation of αB-
STD in nuclear speckles. Furthermore, depletion of SMN inhibited nuclear import of 
fluorescently labeled recombinant αB-STD in an in vitro nuclear import assay, which 
could be restored by the addition of purified SMN complex. These results show that the 
SMN-complex facilitates the accumulation of hyperphosphorylated αB-crystallin in 
nuclear speckles, thereby creating a chaperone depot enabling a rapid chaperone 
function in the nucleus in response to stress. 
 
 
INTRODUCTION 
 
αB-Crystallin is a member of the small heat shock protein (sHSP) family and is 
regarded as a molecular chaperone with an important role in cellular protection against 
diverse stress stimuli (77;122;257;258;303). This is consistent with its high expression 
in stress-sensitive tissues, like eye lens and muscle (304). There are numerous 
examples of its protective function, varying from protecting cytoskeletal components to 
preventing cell death in general (305;306). The primary mode of action is to keep 
partially unfolded substrate proteins in a folding-competent state, allowing quick 
recovery after stress stimuli (78). αB-crystallin can be phosphorylated at three different 
sites: Ser-19, for which the kinase is not known, and Ser-45 and Ser-59, which are 
phosphorylated by p44/42 mitogen-activated protein kinase and MAP kinase activated 
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protein kinase 2, respectively (56). Different forms of stress, like heat shock and 
oxidative ischemic stress, may increase the phosphorylation of αB-crystallin, especially 
at Ser-59. Ser-19 and Ser-45 are preferentially phosphorylated during the mitotic phase 
of the cell cycle (57;303). Phosphorylation of αB-crystallin induces conformational 
changes which affect the interaction with substrate proteins (307). The changes in αB-
crystallin increase the chaperone activity by preventing heat shock- and reduction-
induced aggregation of target proteins, although for some substrates the chaperone 
activity might be decreased depending on the nature and concentration of the substrates 
(56;60;307;308). 
Previously, we and others have found that a small subset of the αB-crystallin 
population can be found in the nucleus, where it predominantly is localized in nuclear 
speckles (309-312). These nuclear speckles, also known as interchromatin granule 
clusters (IGCs), are thought to be sites for storage and recycling of splicing factors 
(313). The subnuclear localization of αB-crystallin is modulated by differential 
phosphorylation of Ser-45 and Ser-59, as demonstrated by the substitution of these 
serine residues by negatively charged aspartate residues to mimic phosphorylation, or 
by non-phosphorylatable alanine residues, as well as by immunocytochemical staining 
with antibodies directed to endogenously phosphorylated αB-crystallin (311). In 
interphase cells, phosphorylation at Ser-59 is required for nuclear import, whilst 
phosphorylation at Ser-45 is crucial for nuclear speckle localization (311). 
Furthermore, nuclear import of αB-crystallin might be facilitated by the Survival Motor 
Neuron (SMN) complex, as suggested by the interaction and co-localization of 
(pseudo)phosphorylated αB-crystallin with a subunit of this complex (311). The SMN 
complex is involved in the biogenesis and nuclear import of small nuclear 
ribonucleoparticles (snRNPs) (314;315) and contains, in addition to SMN, at least 
seven other proteins, named Gemin2-8 (316). 
The highly regulated nuclear import of αB-crystallin and its specific subnuclear 
localization suggest that this protein has a nuclear function in addition to its activities 
in the cytoplasm. Here we show that upon heat shock pseudophosphorylated αB-
crystallin moves from the nuclear speckles to the nucleoplasm, allowing protection of a 
broad range of nuclear proteins, and we identified the SMN complex as an important 
factor that facilitates the nuclear import of αB-crystallin.  
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MATERIALS AND METHODS 
 
Cell culture, plasmids, transfections and two-hybrid screen 
HeLa cells were grown at 37°C in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with 10% fetal calf serum (FCS; PAA laboratories), 100 
units/ml penicillin and 200 μg/ml streptomycin, in the presence of 5% CO2 in a 
humidified 37ºC incubator. The doxycyclin-inducible T-REx™-HeLa-pcDNA4-αB-
STD cell line (61) was kept in Eagle's minimal essential medium (EMEM, Lonza) 
supplemented with Glutamaxtm (Invitrogen), 10% fetal calf serum (Gibco-BRL), 5 
ug/ml Blasticidin (Invitrogen) and 200 ug/ml Zeocin (Invitrogen). The DNA fragments 
encoding the sequence of αB-crystallin wild-type, STD (Ser-19, Ser-45 and Ser-59 
replaced by Asp) and STA (Ser-19, Ser-45 and Ser-59 replaced by Ala) have been 
described elsewhere (61;115). The nuclear luciferase DNA, present in the pEGFP-N2 
vector from Clontech has been described by Nollen and coworkers (317). A β-
galactosidase expression vector was used to measure the transfection efficiency in the 
nuclear luciferase assay (318). Transfections of HeLa cells with the plasmids were 
performed by lipofection using the FuGENEtm 6 system (Roche Molecular 
Biochemicals), as described by the manufacturer. The yeast two-hybrid screen was 
performed with αB-crystallin-LexA fusion protein (bait) to select for proteins (preys) 
able to interact with αB-crystallin by screening a cDNA library from HeLa cells as has 
been described before (117). 
 
Heat shock assay 
HeLa cells (1 x 106) were seeded on coverslips (18 x 18 mm2) one day prior to 
transfection with 1 μg DNA. Two days after transfection cells were untreated or heat 
shocked for 45 minutes at 45oC and recovered at 37oC for the indicated time. The cells 
were fixed in 3% paraformaldehyde for 15 minutes and permeabilized for 10 minutes 
in 0.2% Triton X-100 in phosphate-buffered saline (PBS). The cells were subsequently 
incubated with undiluted monoclonal antibody to αB-crystallin (RIKEN Cell Bank) 
and a 1:20 dilution of TRITC-conjugated rabbit anti-mouse antibody (DAKO Corp.). 
All images were obtained by confocal laser scanning microscopy (BIO-RAD 
MRC1024). 
 
Nuclear luciferase refolding assay 
HeLa cells (1 x 105) were transfected with 0.2 μg of the transfection control vector 
expressing β-galactosidase, 0.2 μg pN-luc-EGFP vector coding for nuclear luciferase 
and 0.6 μg of the pIRES vector either empty or with an αB-crystallin isoform. Three 
days after transfection, cells were supplemented with 100 μg/ml cycloheximide and 20 
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mM 3-(N-morpholino)propanesulfonic acid (MOPS) pH 7.4, 1 hour prior to heat 
shock. Cells were incubated at 45°C for 45 minutes, followed by recovery at 37°C in 
the presence of 5% CO2. Cells were washed 3 times with PBS and lysed by scraping 
the cells in 100 μl nuclear luciferase lysis buffer (25 mM Tris/H3PO4, pH 7.8, 10 mM 
MgCl2, 1% Triton X-100, 15% glycerol and 1 mM EDTA) per 106 cells. Luciferase 
activity was measured by adding 50 μl of luciferase reagent (Promega) to 10 μl of 
lysate and subsequent analysis on a Lumat LB 9507 luminometer. β-Galactosidase 
activity was determined by first incubating 10 μl lysate for 30 minutes with 100 μl of 
β-galactosidase reagent buffer (1:100 Galacton (Tropix) in 100 mM phosphate buffer 
pH 8.1, 5 mM MgCl2) and then adding 150 μl light emission accelerator (Tropix) for 
the analysis on a Lumat LB 9507 luminometer. 
 
Co-Immunoprecipitations 
HeLa cells (1 x 106) were transfected with 1 μg pIRES vector either empty or with an 
αB-crystallin isoform. Cells were harvested by trypsinization and washed once with 
DMEM containing 10% fetal calf serum and twice with cold PBS, and suspended in 1 
ml lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, and 0.5% Nonidet P-40) at 
4°C. Cell lysates were cleared by centrifugation at 16,000 g for 30 minutes at 4°C and 
subsequently incubated with protein G-agarose beads (Roche Molecular Biochemicals) 
coupled with monoclonal antibody to αB-crystallin (RIKEN Cell Bank). After 
incubation at 4°C, beads were washed three times with buffer (50 mM Tris-HCl pH 
7.5, 100 mM NaCl, and 0.05% Nonidet P-40) and boiled in sample buffer (1% SDS, 
0.063 M Tris-HCl pH 6.8, 10% glycerol, 0.01% β-mercaptoethanol, 0.02% 
bromophenol blue) and analyzed by western blotting. 
 
In vitro import assay (319) 
HeLa cells grown on coverslips to 80-90% confluence were washed twice with PBS 
and once with P-buffer (50 mM HEPES/KOH pH 7.5, 50 mM KAc, 8 mM MgAc2, 2 
mM EGTA, 1 mM DTT, protease inhibitors cocktail (Roche)). The cells were 
permeabilized for 5 minutes at room temperature with 40 mg/ml digitonin (Sigma) in 
T-buffer (20 mM HEPES/KOH pH 7.5, 50 mM KAc, 4 mM MgAc2, 1mM DTT, 
protease inhibitors cocktail (Roche) and subsequently washed three times with T-
buffer. The permeabilized cells were incubated with 50 μl reaction buffer (T-buffer 
containing 1 mM ATP, 0.2 mM GTP, 5 mM phosphocreatine, 0.2 mg/ml 
creatinephosphokinase, 10 mg/ml BSA, 0.25 M sucrose), which was mixed with 5 μl 
reticulocyte lysate (Promega) and 400 μg purified recombinant αB-crystallin (117), 
labeled with FITC (Fluorescein isothiocyanate, Pierce) according to the protocol 
described by the manufacturer, and incubated for 60 minutes at room temperature. 
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After incubation, the cells were washed three times with T-buffer and fixed with 3% 
paraformaldehyde and mounted on glass slides with Fluorescent Mounting Medium 
(Dakocytomation). Images of the cells were obtained by confocal laser scanning 
microscopy (Bio-Rad MRC1024). Immunodepletion reticulocyte lysate was performed 
by incubating 20 μl lysate for 30 minutes with protein G beads alone or with protein G 
beads coupled with Gemin3 or SMN protein antibodies, after which the beads were 
removed by centrifugation. Nuclear import was reconstituted by adding 50 ng SMN 
complex, which was purified from HeLa cells stably overexpressing Flag-tagged SMN 
(320) (see Figure S2). 
 
siRNA transfection assay 
T-REx™-HeLa-pcDNA4-αB-STD cell line was seeded on coverslips (10 mm2) in the 
absence of antibiotics. At 40% confluency, cells were transfected with 0.1 ng siRNA 
per coverslip (n=2 per sample) using Lipofectaminetm 2000 Reagent according to 
manufacturers’ protocol (Invitrogen). Six different siRNA’s were used: two negative 
control siRNAs: si-Luciferase (CGUACGCGGAAUACUUCGAdTdT), si-Pop1 
(GAAUUUAACCGUAGACAAAdTdT) (321), two Gemin2 specific siRNA’s: si-
Gemin2.1 (CCCAACACUUCAAUGGCAAdTdT), si-Gemin2.2 
(CUGGAAUAGAUUAUGUACAdTdT) and two Gemin3 specific siRNAs: si-
Gemin3.1 (GAGGAGUACUGGAGAGCUUdTdT), si-Gemin3.2 
(GCAAAGGAAAUAAGUCAUAdTdT). The medium was refreshed 5 hours after 
transfection and 24 hours after transfection 1 µg/µl doxycyclin (Invitrogen) was added. 
After 16 hours culturing with doxycyclin, cells were washed twice with PBS and fixed 
for 20 minutes at RT in 2% paraformaldehyde (Merck) in PBS and subsequently 
washed with PBS-G (PBS supplemented with 1.5 g/l glycine (MP Biomedicals)). Cells 
were permeabilized by 10 minutes incubation at RT with 0.1% Triton X100 (USB) in 
PBS-G. Slides were incubated with  monoclonal antibody to αB-crystallin (RIKEN 
Cell Bank) for 1 hour at 37oC, 10-fold diluted in PBS-GT, (PBS-G, containing 0.05% 
Tween-20 (Fluka)), washed three times with PBS-G and incubated with goat-α-mouse-
Alexa Fluor 488 (LI-COR) for 1 hour at 37oC, 1:150 diluted in PBS-GT. Coverslips 
were washed three times with PBS-G and mounted using MOWIOL (Calbiochem). 
Analysis was performed with a fluorescence microscope (Axioskop, Zeiss). Per glass 
slide, 3 fields were selected randomly and per siRNA an average of 110 cells were 
counted. Speckle positive and negative nuclei were scored by eye by two independent 
evaluators. Statistical analysis was performed using One-way ANOVA and Tukey’s 
Multiple Comparison Test. To check for transfection efficiency, cells were transfected 
using 1.25 ng siRNA/T25 flask. The cells were harvest by trypsinization, washed two 
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times with PBS and denatured by 5 minutes heating in 40 μl sample buffer and 
analyzed by western blotting. 
 
Western blotting 
Protein samples were separated by electrophoresis on a 12.5% SDS-polyacrylamide gel 
and transferred to nitrocellulose membranes (Protran) or Hybond-P membranes 
(Amersham Biosciences). The membranes were blocked with 5% non-fat dried milk 
(Campina) + 0.05% Tween-20 (Merck) in PBS for an hour. The membranes were 
incubated O/N in 2% non-fat dried milk in PBS containing monoclonal mouse-anti-
human-αB-crystallin (RIKEN), mouse-anti-human-gamma-tubulin (Sigma-Aldrich), 
mouse-anti-human-gemin2 (E6, Santa Cruz Biotechnology), mouse-anti-human-
gemin3 (12H12, Santa Cruz Biotechnology), rabbit-anti-human-αB-crystallin (38), 
rabbit-anti-human-SMN (Santa Cruz Biotechnology) or rabbit-anti-human-Skp1 
(Neomarkers). After washing three times ten minutes with PBS complemented with 
0.1% Tween-20, blots were incubated for one hour with goat-anti-mouse IRDye® 
800CW (LI-COR) or horseradish peroxidase conjugated goat-anti-mouse secondary 
antibodies or swine-anti-rabbit secondary antibodies (DAKO Corp.) to allow 
visualization of the bound antibodies with the Odyssey scanner (LI-COR) or by 
enhanced chemoluminescence (Pierce Chemical Co.). 
 
 
RESULTS 
 
Speckle-localized pseudophosphorylated αB-crystallin serves as a chaperone 
depot 
Under normal physiological conditions αB-crystallin is mainly present in the 
cytoplasm, but upon phosphorylation at Ser-59 and Ser-45 accumulates in nuclear 
speckles (311). To investigate whether αB-crystallin remains in the nuclear speckles 
upon heat shock, the pseudophosphorylated αB-crystallin mutant αB-STD was used. 
This mutant, besides being present in the cytoplasm, abundantly accumulates in the 
nuclear speckles (311). HeLa cells transfected with pIRES αB-STD vector were 
subjected to a heat shock (45 min) and subsequently allowed to recover for 0, 6 and 24 
hours at 37°C. As expected, nuclear αB-STD of non-heat shocked cells was found 
predominantly in speckles. However, heat-shocked cells examined directly or 6 hours 
after the heat shock showed diffuse nuclear staining (Figure 1). Speckle localization 
was restored 24 hours after heat shock. These results suggest that during heat stress 
nuclear αB-crystallin exerts its chaperone function in the nucleoplasm. 
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Figure 1. Relocalization of nuclear pseudophosphorylated αB-crystallin in response to 
heat-shock. Transiently transfected HeLa cells expressing αB-STD were mock-treated or 
subjected to heat-shock and allowed to recover for 6 or 24 hours. The localization of αB-
STD was visualized by immunofluorescence, using a monoclonal antibody against αB-
crystallin. 
 
 
Pseudophosphorylated αB-crystallin is a nuclear chaperone 
To determine whether αB-crystallin can assist in the refolding of proteins present in the 
nucleus we used a nuclear targeted luciferase-EGFP fusion protein (N-luc-EGFP) (317) 
as a heat-sensitive reporter. This reporter protein shows a diffuse nuclear staining in 
non-stressed cells. HeLa cells were transfected with the empty pIRES vector or with 
pIRES constructs coding for αB-crystallin or mutants thereof, together with the nuclear 
luciferase construct. In every transfection a β-galactosidase construct was included to 
be able to correct for variations in transfection efficiency. After three days the cells 
were exposed to a heat shock to denature the luciferase. The luciferase activity was 
measured before, directly after and six hours after heat shock. During the recovery 
period the translation inhibitor cycloheximide was present to prevent de novo synthesis 
of luciferase. As can be seen in Figure 2, directly after heat shock the activity of 
luciferase was strongly reduced in cells transfected with pIRES, wild-type or non-
phosphorylatable αB-crystallin (αB-STA) and somewhat less pronounced in the cells 
transfected with αB-STD. Six hours after heat shock a significant recovery of luciferase 
activity was observed in the αB-STD transfected cells (8.7%), whereas the pIRES, 
wild-type or αB-STA transfected cells showed almost no or much less recovery of 
luciferase activity (0.3, 2.2 and 1.0%, respectively). These data demonstrate that 
pseudophosphorylated αB-crystallin participates in nuclear chaperoning activity during 
and directly after heat shock. 
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Figure 2. Pseudophosphorylated αB-crystallin enhances refolding of heat-inactivated 
nuclear luciferase. Transiently transfected HeLa cells expressing nuclear luciferase were 
heated (45 min at 45oC) and subsequently lysed directly or 6 hours thereafter. 
Cycloheximide was added just prior to heating to prevent de novo luciferase synthesis. 
Recovery of luciferase activity is indicated for cells cotransfected with empty pIRES vector 
(pIRES), or constructs encoding wild-type (WT), non-phosphorylatable αB-crystallin (αB-
STA) or pseudophosphorylated αB-crystallin (αB-STD). The luciferase activity was 
determined and compared with the initial luciferase activity before heat shock. All 
transfections were corrected for the transfection efficiency as measured by the β-
galactosidase activity resulting from a cotransfected β-galactosidase expression vector. The 
results represent the mean values of 6 independent experiments; error bars indicate the 
standard deviation. A western blot illustrating the expression of αB-crystallin is shown in 
Figure S1. 
 
 
Pseudophosphorylated αB-crystallin interacts with Gemin3 
Pseudophosphorylated αB-crystallin does not contain a canonical nuclear localization 
signal and likely enters the nucleus via an alternative route by binding to a specific 
adaptor complex. In a yeast two-hybrid system we found that wild-type αB-crystallin is 
able to interact with the C-terminal 246 residues of Gemin3 (data not shown). Gemin3 
is a subunit of the SMN complex (322) and we have previously shown that αB-STD, 
but not the non-phosphorylatable αB-STA, can interact with the SMN protein, another 
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subunit of the same complex (311). The SMN complex facilitates the assembly of 
snRNPs and their import into the nucleus (315), to allow partial accumulation in 
nuclear speckles. Since αB-STD also localizes in these speckles, we hypothesized that 
the interaction with this complex facilitates the nuclear accumulation of αB-STD (311). 
To confirm the interaction of αB-crystallin with Gemin3, a co-immunoprecipitation 
experiment was performed, using lysates of HeLa cells cotransfected with different αB-
crystallin expression constructs. The wild-type and mutant αB-crystallin were 
efficiently precipitated with anti-αB-crystallin antibody (Figure 3 lower panel).  
Gemin3 co-immunoprecipitated with wild-type αB-crystallin (Figure 3 upper panel), 
which confirms the interaction observed in the two-hybrid system. The efficiency of 
the coprecipitation of Gemin3 with αB-STA was similar as that observed for the wild-
type αB-crystallin, but appeared to be much higher with αB-STD. These results show 
that αB-crystallin is able to interact with Gemin3 and suggest that the affinity of this 
interaction is increased by the phosphorylation of αB-crystallin. 
 
 
 
Figure 3. Co-immunoprecipitation of Gemin3 with αB-crystallin. Extracts of HeLa 
cells, transfected with pIRES as a control or pIRES constructs coding for wild-type (WT), 
non-phosphorylatable αB-crystallin (αB-STA) or pseudophosphorylated αB-crystallin (αB-
STD) were subjected to immunoprecipitation with a monoclonal antibody against αB-
crystallin. The immunoprecipitates were analyzed by immunoblotting using a mouse 
monoclonal antibody against Gemin3 and rabbit polyclonal antibodies to αB-crystallin. 
Note that Gemin3 shows two bands, of which the lower band is likely a degradation 
product. 
207528-L-bw-Schootbrugge
 
PSEUDOPHOSPHORYLATED αB-CRYSTALLIN IS A NUCLEAR CHAPERONE 
IMPORTED INTO THE NUCLEUS WITH HELP OF THE SMN COMPLEX 
 
100 
 
Nuclear localization of pseudophosphorylated αB-crystallin is facilitated by 
Gemin3 and Gemin2 
To investigate whether nuclear speckle localization of αB-STD is Gemin3-dependent, 
stably transfected HeLa αB-STD cells were used with doxycyclin-inducible expression 
of αB-STD. The expression of αB-STD was induced 24 hours after transfection with 
siRNAs directed against Gemin3. αB-crystallin was visualized by immunostaining and 
the number of cells containing αB-crystallin-positive nuclear speckles was determined. 
As can be seen in figure 4b and 4c, 84% and 85% of cells that were treated with 
unrelated control siRNAs (Luciferase and POP1) showed nuclear speckle staining. This 
was comparable to cells that were not transfected with siRNA, indicating that siRNA 
treatment did not influence the presence of αB-STD in the nuclei (results not shown). 
Two distinct siRNAs (Gemin3.1 and Gemin3.2) resulted in down-regulation of 
Gemin3 expression, as demonstrated by western blotting (Fig. 4a). Knockdown of 
Gemin3 with these two siRNAs resulted in a significant reduction of cells containing 
αB-STD positive speckles (Figure 4b and 4c, 35% and 61%, respectively). To confirm 
the involvement of the SMN complex in αB-STD import (323), also Gemin2 
expression was down-regulated with two different siRNAs (Figure 4a). Gemin2 
depletion also resulted in decreased numbers of cells containing αB-STD positive 
speckles (Figure 4b and 4c, 52% and 56% respectively). These results strongly suggest 
that the SMN complex is involved in nuclear speckle localization of 
pseudophosphorylated αB-crystallin.  
 
Nuclear import of pseudophosphorylated αB-crystallin is facilitated by the 
SMN complex 
To obtain additional evidence for the involvement of complete SMN complex in 
nuclear import of αB-STD, an in vitro nuclear import system with digitonin-
permeabilized HeLa cells was used (324). Digitonin permeabilizes the cell membrane, 
whilst the nuclear membrane remains intact, allowing to reconstitute nuclear import by 
reticulocyte lysate containing ATP and GTP. First, we tested whether fluorescently 
labeled recombinant αB-STD was indeed imported into the nucleus in this system. The 
results showed that αB-STD was not only imported into the nucleus, but was also 
targeted to nuclear speckles (Fig. 5A), which was confirmed by the colocalization with 
the nuclear speckle marker SC35 (data not shown). Thus, the in vitro localization of 
αB-STD is similar to that observed in transiently transfected cell lines (61). The in vitro 
nuclear import of αB-STD is an active process, as shown by the inhibition of import at 
4°C (Figure 5a). In contrast to αB-STD, fluorescently labeled wild-type and non-
phosphorylatable αB-crystallin (αB-STA) only showed background staining in the 
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Figure 4. The effect of 
knockdown of Gemin3 and 
Gemin2 on the nuclear import 
of pseudophosphorylated αB-
STD. Doxycyclin-inducible T-
REx™-HeLa-αB-STD cells 
were treated with two different 
Gemin3 siRNAs, two different 
Gemin2 siRNAs and two 
negative control siRNAs (LUC 
and POP1). After 24 hours 1 
µg/µl doxycyclin was added to 
induce αB-STD expression and 
16 hours later the cells were 
analyzed. (A) Knockdown of 
Gemin3 and Gemin2 was 
assessed by western blotting 
analysis. αB-crystallin and γ-
tubulin were used as loading 
controls (a). T-REx™-HeLa-
αB-STD cells treated with the 
different siRNAs were stained 
for αB-crystallin (b). The 
percentages of the siRNA-
treated cells containing αB-
crystallin-positive speckles in 
the nucleus were determined 
and are shown in the graph (c). 
Statistical analysis was 
performed using One-way 
ANOVA and Tukey’s Multiple 
Comparison Test. *** P<0.001, 
** 0.001<P<0.01, * 
0.01<P<0.05. 
 
(b) 
(a) 
(c) 
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nucleus, indicating that these proteins were not imported into the nucleus, which agrees 
with previous in situ results (61). To test whether import of pseudophosphorylated αB-
crystallin depends on the SMN complex we immunodepleted reticulocyte lysates from 
this complex using antibodies directed to SMN and Gemin3. As can be seen in Figure 
5c, the Gemin3- and SMN-depleted lysates indeed contained strongly reduced levels of 
Gemin3 and SMN. Importantly, Gemin3 depletion resulted in efficient co-depletion of 
SMN, and vice versa, consistent with the removal of the complete SMN complex by 
this procedure. The SMN-depleted lysates resulted in a significant reduction of the 
accumulation of αB-STD in nuclear speckles (Figure 5b). To confirm that these effects 
were due to depletion of the SMN complex, purified SMN complex was added to the 
SMN-depleted reticulocyte lysate. The addition of the SMN complex indeed rescued 
the import and speckle localization of αB-STD (Figure 5b). These results show that 
nuclear import of pseudophosphorylated αB-crystallin is facilitated by the SMN 
complex. 
 
 
DISCUSSION 
 
Differential phosphorylation of αB-crystallin is required for nuclear localization (311) 
and occurs depending on cell cycle and cellular status (56;57). Nuclear speckle 
accumulation of αB-crystallin can be enhanced by mimicking phosphorylation at three 
phosphorylation sites (311). Here we show that upon heat shock, the 
pseudophosphorylated αB-crystallin does not reside in nuclear speckles, but is 
distributed over the nucleoplasm and re-accumulates in the speckles after release from 
stress. This is in concurrence with findings of Van den IJssel and coworkers, who 
showed that the speckle-localized endogenous αB-crystallin in U373 cells significantly 
diminished after heat shock (309). Nucleoplasmic αB-crystallin is able to protect 
nuclear proteins, as shown by the ability of pseudophosphorylated αB-crystallin to 
enhance the refolding of heat-shock-denatured nuclear luciferase. These results suggest 
that nuclear speckle-localized αB-crystallin, besides acting as a molecular chaperone 
for nuclear speckle proteins under non-stressed conditions, serves as a depot to allow a 
rapid increase of αB-crystallin in the nucleoplasm to respond to heat stress. Nuclear 
αB-crystallin has been shown to help to prevent methylglyoxal-induced apoptosis in 
retinal pigment epithelial cells, indicating that nuclear αB-crystallin also has a 
protective role under other stress conditions (325).  
αB-crystallin does not play an active role in the refolding of partially unfolded proteins, 
though it has been proposed to keep substrate proteins in a folding-competent state,  
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Figure 5. In vitro nuclear import of pseudophosphorylated αB-crystallin is dependent 
on the SMN complex. In vitro nuclear import assays were conducted by incubating 
digitonin-permeabilized HeLa cells for 1 hour at room temperature with reticulocyte lysates 
containing ATP and GTP. Import reactions were performed with FITC-labeled recombinant 
wild-type αB-crystallin (WT), non-phosphorylatable αB-crystallin (αB-STA) and 
pseudophosphorylated αB-crystallin (αB-STD). As a negative control the import assay with 
αB-STD was conducted at 4°C (STD 4°C) (a). Import reactions of αB-STD with rabbit 
reticulocyte lysates immunodepleted with anti-Gemin3 antibodies (ΔGemin3), anti-SMN 
antibodies (ΔSMN) and control-depleted (Cntr). The impaired import of αB-STD with 
SMN-depleted reticulocyte lysate could be rescued by addition of purified SMN complex 
(ΔSMN+ SMN complex) (b). The immunodepleted reticulocyte lysates were analyzed by 
western blot to assess depletion. Skp1 was used as a loading control (c). Dotted circles 
indicate the position of the nuclei. 
(a) 
(b) 
(c) 
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thereby facilitating ATP-dependent refolding by other molecular chaperones, such as 
Hsp70 (78). During heat stress, importin β-mediated nucleocytoplasmic trafficking is 
strongly reduced, thereby preventing the active import of cytoplasmic proteins into the 
nucleus. In contrast to most cytoplasmic proteins, nuclear import of Hsp70 is 
upregulated during heat shock (326), which is mediated by a novel nuclear import 
carrier, named Hikeshi (327;328). The nuclear Hsp70 might subsequently act in 
concert with αB-crystallin to restore heat shock-induced damage inside the nucleus. 
αB-crystallin forms polydisperse complexes containing 10 to 40 subunits. 
Pseudophosphorylation reduces the size of the oligomeric complex of αB-crystallin 
(60;307;329), but these complexes are still too large to allow passive diffusion into the 
nucleus, as shown by the lack of nuclear import of αB-STD at 4°C (Figure 5a). 
Because of the absence of a recognizable nuclear localization signal sequence (312), 
the nuclear import of αB-crystallin is expected to be mediated by an alternative import 
carrier. A clue for such a carrier came from yeast-two-hybrid experiments, which 
demonstrated that αB-crystallin interacts with the C-terminal 246 residues of Gemin3. 
Although the non-phosphorylated αB-crystallin can interact with Gemin3, in co-
immunoprecipitation experiments, Gemin3 was more efficiently pulled down by 
pseudophosphorylated αB-crystallin, suggesting that hyperphosphorylation increases 
the affinity for Gemin3. Pseudophosphorylation reduces the interaction between the 
αB-crystallin subunits (329), which might facilitate the binding to Gemin3. Consistent 
with the involvement of Gemin3, as a subunit of the SMN complex, in subcellular 
transport processes (323), Gemin3 appeared to mediate nuclear import of 
pseudophosphorylated αB-crystallin. This activity of Gemin3 is probably related to its 
association with the SMN complex, as demonstrated by additional experiments in 
which the levels of Gemin2 and SMN were reduced. These data strongly suggest that 
the SMN complex is responsible for nuclear import of αB-STD. SMN is able to 
directly interact with importin β, as shown in a GST-pulldown assay (330), which 
might facilitate the interaction with the nuclear pore complex to stimulate the nuclear 
import of the complex (331). Since SMN colocalizes with phosphorylated αB-
crystallin in the nuclear speckles (311), it is likely that this complex is also involved in 
the accumulation of nuclear αB-crystallin in speckles. 
Besides αB-crystallin, the C-terminus of Gemin3 is also able to interact with another 
member of the small heat shock protein family, HspB8 (332). However, so far no 
evidence for the accumulation of HspB8 in nuclear speckles has been obtained (312).  
Two other small heat shock proteins have been described to localize to nuclear 
speckles, HspB1 and HspB7. V5-tagged HspB7 constitutively localizes to nuclear 
speckles, indicating that posttranslational modifications are not involved or are 
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constitutively present. The nuclear speckle localization signal is situated in the N-
terminus of HspB7, but it is not known whether this part is able to interact with 
Gemin3. Speckle-localized HspB7 does not enhance refolding of heat-denatured 
nuclear firefly luciferase, suggesting that the association with the nuclear speckles is 
not related to protein refolding (312).  
The accumulation of HspB1 in nuclear speckles depends on more than one signal. 
Upon stress HspB1 is phosphorylated by the mitogen-activated protein kinase (MAPK) 
pathway. Phosphorylation of HspB1 has been shown to be necessary for recruitment to 
speckles, but by itself is not sufficient to support nuclear import (333). Therefore, the 
phosphorylation of HspB1 may have a similar function as the Ser-45 phosphorylation 
of αB-crystallin (311). Heat stress induces entrance of HspB1 into the nucleus, which 
suggests the involvement of a heat shock activated nuclear import factor. αB-STD is 
able to recruit endogenous HspB1 to nuclear speckles without an additional heat shock 
(unpublished data), indicating that αB-crystallin is capable to stimulate nuclear import 
of HspB1. Since heat stress stimulates nuclear accumulation of αB-crystallin (334), it is 
possible that αB-crystallin in part is responsible for the heat shock-induced nuclear 
accumulation of HspB1. Nuclear HspB1 has been shown to contribute to increased 
chaperone capacity in the nucleus under stress conditions, which, similar to the activity 
of αB-crystallin, seems to be localized outside the nuclear speckles (79).  
In summary, our data suggest that phosphorylated αB-crystallin present in nuclear 
speckles of unstressed cells temporarily moves to the nucleoplasm upon heat shock, 
providing a rapid increase in chaperone capacity to bind unfolded proteins. The import 
of phosphorylated αB-crystallin into the nucleus is facilitated by the SMN complex via 
the interaction with Gemin3. Further investigations are needed to shed more light on 
the functional activities of αB-crystallin and other small heat-shock proteins in the 
nucleus, both under normal and under stress conditions.  
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SUPPLEMENTARY FIGURES 
 
 
 
Figure S1. αB-crystallin expression. Expression of wild-type αB-crystallin (WT), non-
phosphorylatable αB-crystallin (αB-STA) or pseudophosphorylated αB-crystallin (αB-
STD) in transiently transfected HeLa cells. αB-crystallin expression was analyzed by 
immunoblotting using a monoclonal antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Composition of purified SMN complex. The purified SMN complex was 
separated by SDS-polyacrylamide gel electrophoresis, followed by silver staining. The 
SMN complex was purified form HeLa cells stably expressing Flag-tagged SMN protein 
using anti-FLAG-tag antibodies. The complex was eluted with an excess of Flag-tag 
peptide. The control lane (Cntr) contains proteins isolated in parallel by the same procedure 
from control HeLa cells. 
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As described in Chapter 1 αB-crystallin can exert the ‘classical’ sHSP chaperoning 
function during cellular stress. Unfolding proteins are captured by large oligomeric 
complexes formed by homomeric interactions between αB-crystallin subunits and by 
heteromeric interactions with other sHSPs, thereby preventing further unfolding and 
stimulating recovery. Also non-protein recovery related functions are described for this 
protein, like interaction with the apoptosis-inducing proteins to influence their activity 
and cytoskeletal proteins to stimulate proper formation of cytoskeletal structures. 
Moreover, αB-crystallin is implicated in various diseases, including several solid 
tumors, like hepatocellular carcinoma (240), breast cancer (126;222), renal cell 
carcinoma (335;336) and several brain tumor types (337-339). Increased expression of 
αB-crystallin in these cancers is often correlated with poor clinical outcome. The 
predictive value of αB-crystallin upregulation in HNSCC for disease survival rates, 
however, was subject to debate (220;221). To improve the understanding of the 
predictive value we analyzed the αB-crystallin expression levels in a HNSCC cohort of 
which 38 biopsies were available. Our results show that high αB-crystallin expression 
levels correlate with a shorter disease-free survival (DFS) (Chapter 3).  
 
 
7.1 αB-CRYSTALLIN EXPRESSION IS CORRELATED WITH METASTASIS 
FORMATION 
 
To get a better understanding of the mechanisms leading to shorter DFS upon αB-
crystallin expression, we looked into two major factors that determine DFS: metastasis 
formation and local-regional recurrence. Local-regional recurrence refers to a 
recurrence of a tumor localized in the area of the primary tumor site and/or the lymph 
nodes. For a cell to become tumorigenic, evasion of apoptosis is essential (Chapter 2). 
As αB-crystallin can interact with apoptotic proteins (Chapter 1), high αB-crystallin 
expression could lead to enhanced cell survival after radiation or chemotherapy, 
thereby leading to tumor regrowth and thus local-regional failure. Remarkably, we did 
not find any correlation with local-regional recurrence, showing that interaction with 
apoptotic proteins probably is not the mode of action leading to worse prognosis of the 
HNSCC patients in this cohort.  
Our data indicated, however, that high αB-crystallin expression correlates with 
metastasis formation (Chapter 3). One of the steps necessary for cancers to 
metastasize, is enhanced cell invasion and migration (Chapter 2). As described in 
Chapter 3, HNSCC UT-SCC-15 cell migration is reduced upon αB-crystallin 
knockdown. Furthermore, the motility of HeLa cells was faster upon overexpression of 
αB-crystallin and slower upon use of αB-crystallin siRNA (Figure 1). These data show 
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Figure 1. Cell motility of T-REx™-HeLa-pcDNA4-αB-crystallin wild type cell. 
Doxycyclin (DOX)-induced expression of αB-crystallin in the T-REx™-HeLa-pcDNA4-
αB-crystallin wild type cell line resulted in a 7-fold increase of of αB-crystallin mRNA 
(unpaired t-test p < 0.05) (a). Cell motility (gap closure) assay (for details see Chapter 3). 
Doxycyclin treated cells showed a tendency of faster gap closure, which was not significant 
compared to untreated or luciferase-siRNA (Mock) treated controls (b). A significant 
difference in gap closure rate was observed between DOX treated cells and cells in which 
αB-crystallin was knocked-down by siRNA transfection (p < 0.05 using One-way ANOVA 
and Tukey’s Multiple Comparison Test). 
 
 
that αB-crystallin expression can have an effect on cell motility. As this is a very 
complex multifactorial process, the mechanism of action of αB-crystallin in this 
process remains to be elucidated. 
Cell migration is dependent on cytoskeletal structures (340). Cell movement is initiated 
at the leading edge of a cell, where protrusions are formed composed of a branched 
filamentous (F)-actin filament network, known as lamellipodia. At the termini of these 
filaments filopodia are formed, which are antennae-like structures containing tight 
bundles of F-actin. During cellular extension, focal adhesions are formed; flat 
structures, which contact the surface. αB-crystallin is able to interact with actin 
filaments and other cytoskeletal structures (Chapter 1) (62), which are important for 
maintaining the integrity of the filaments, especially under stressful circumstances 
(Chapter 1). We hypothesized that αB-crystallin functionally interacts with the 
cytoskeletal network of filopodia during cell migration. Previously, it was found that 
inmigrating porcine lens epithelial cells a fraction of αB-crystallinis localized to the 
leading edges of the cell membrane or in the lamellipodia (62), indicating that αB-
crystallin indeed can have a function in cell motility. We investigated whether αB-
crystallin affects filopodia formation in HNSCC and other cell lines, by analyzing their 
quantity and shape upon overexpression or knock-down of αB-crystallin. No effect was 
 
(a.)               (b.) 
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observed. These data suggest that the effect of αB-crystallin is not mediated via 
filopodia formation or is very subtle, thereby making it difficult to visualize. 
 
 
7.2 VEGF SECRETION IS INFLUENCED BY αB-CRYSTALLIN EXPRESSION 
 
As described in Chapter 1, αB-crystallin can be phosphorylated at S45 by mitogen-
activated protein kinases (MAPK) ERK1/2, via an unknown mitogen activated protein 
kinase-activated protein kinase (MK), and at S59 by MK2, which is specifically 
targeted by the MAPK p38 pathway (Figure 2). Interestingly, Aggeli and coworkers 
reported that upon oxidative stress, αB-crystallin can be phosphorylated at S59 by 
MSK1 as well (Figure 2) (341), which means that ERK1/2 may also lead to αB-
crystallin phosphorylation on S59, via MSK1 (Figure 2) (226;342) and could therefore 
alter functioning of αB-crystallin, related to phosphorylation of either S45 or S59.  
By using two mouse models of intraocular disease, oxygen-induced retinopathy and 
laser-induced choroidal neovascularization, Kase and coworkers found that under 
hypoxic conditions, phosphorylation of αB-crystallin at S59 is upregulated and also 
chaperone activity was increased (226;227). Immunoprecipitation studies showed that 
αB-crystallin can bind to VEGF. Moreover, it was shown that αB-crystallin and VEGF 
are colocalized in the endoplasmic reticulum (ER) under chemical hypoxia. The 
localization of αB-crystallin in the ER has only been reported in lens epithelial cells, 
thus the significance of this finding in other types of cells is currently unknown. In the 
ER, proteins can be properly refolded and eventually secreted via the Golgi system 
(226;227). A more efficient rescue of unfolded VEGF in a tumorigenic context could 
lead to enhanced tumor vascularisation and metastatic potential (Chapter 2) 
(229;230;343-345). In Chapter 3 we show that αB-crystallin knockdown reduced 
VEGF secretion in HNSCC cells. Furthermore, upon overexpression of wild type αB-
crystallin in stably transffected TREx HeLa cells, VEGF secretion was found to be 
upregulated under normoxic as well as hypoxic culturing conditions (Figure 3). In the 
T-REx™-HeLa-pcDNA4-αB-Crystallin wild type cell line, VEGF secretion was 
increased compared to the negative control T-REx-HeLa-pcDNA4 cell line, also in the 
absence of doxycyclin (DOX) treatment. This can be explained by leakage expression 
of αB-Crystallin, which is not visible on western blot. Quantitative RT-PCR using 
HEK293 cells containing the same control and αB-crystallin constructs show αB-
crystallin expression levels that are elevated in cells containing the αB-crystallin 
construct not treated with DOX, compared to cells with the control construct. These 
levels, however, were not as high as when αB-crystallin expression was induced with 
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DOX (personal communication). 
As VEGF secretion is linked to tumor progression (Chapter 2), this indicates that αB-
crystallin expression might influence VEGF secretion in a tumorigenic context, but it is 
unknown if this accomplished via increased chaperoning of VEGF in the ER. 
Therefore, it would be interesting to determine if αB-crystallin and VEGF colocalize in 
the endoplasmic reticulum (ER) of HNSCC cell lines as well. 
A common phenomenon in HNSCC and triple negative/basal-like breast cancer is 
EGFR overexpression, which leads to enhanced EGFR signaling, and this predicts poor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regulation of αB-crystallin phosphoryl-ation by ERK1/2 and p38. As 
described in Chapter 1, αB-crystallin can be phosphorylated at serine 45 by ERK1/2 and at 
serine 59 by MK2, which is specifically targeted by the p38 pathway and MSK1. The 
kinase responsible for phosphorylation at serine 19 is unknown. Which MK is targeted by 
the ERK1/2 pathway and ultimately is involved in the phosphorylation of serine 45 is 
unknown. Many MKs can be cross-activated by the ERK1/2 as well as the p38 pathway. 
Figure adapted from ref. (342). 
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prognosis for cancer patients (Chapter 2). Interestingly, EGFR activation, via 
activation of the ERK1/2 kinase pathway, also leads to enhanced VEGF secretion 
(346;347). As ERK1/2 can have an influence on αB-crystallin functioning, via 
phosphorylation of S45 and/or S59, and αB-crystallin phosphorylated at S59 can lead 
to increased VEGF secretion, we propose a model that αB-crystallin expression, under 
hypoxic conditions and in combination with EGFR activation, leads to significantly 
elevated levels of VEGF signaling (Figure 4).  
Drug therapies are being developed, that target EGFR as well as neutralize VEGF 
using a single IgG molecule (210). The blocking of multiple pathways reduces the 
chance of tumor survival via escape pathways (348). αB-crystallin might be a valuable 
additional target for treatment in view of its roles in (hypoxic) cancer cell survival and 
VEGF secretion (Chapter 4). Recently, Chen and co-workers developed a potent small 
molecular inhibitor, NCI-41356, which can block the interaction between αB-crystallin 
and VEGF. In in vivo human breast cancer xenograft models, this molecule 
significantly inhibits tumor growth and vasculature development. This shows that, in 
accordance with our results, αB-crystallin influences VEGF in a tumorigenic context 
(349). In aged and cataract eye lenses, a proteolytic βA1/A3-crystallin peptide 
fragment is present (SDAYHIERLMSFRPIC), which can interact with regions in the 
α-crystallin domain and C-terminus of αB-crystallin and can interfere with αB-
crystallin functioning (350). As cell penetrating peptides already have been proposed as 
anti-cancer drugs (351-353), the identified αB-crystallin-binding peptide could be 
modified into a cell penetrating peptide and could be used to target αB-crystallin 
protein itself. In contrast to the small molecular inhibitor, the peptide may interfere 
with more αB-crystallin-related functions and may therefore have a stronger inhibitory 
effect on cancer cell survival. Ultimately, the use of αB-crystallin-targeting treatments 
alongside existing treatments might lead to better outcome for the patients. 
 
 
7.3 αB-CRYSTALLIN IS UPREGULATED BY ROS-STRESS 
 
As a member of the chaperone protein family, αB-crystallin expression can be induced 
upon certain types of stress (Chapter 1). We showed in HNSCC biopsies, that more 
αB-crystallin protein is present in hypoxic tumor areas compared to normoxic areas 
(Chapter 4). To explain this phenomenon, we tested whether αB-crystallin expression 
is induced upon hypoxic incubation of HNSCC cells (Chapter 4). Surprisingly, αB-
crystallin mRNA was downregulated in hypoxic HNSCC cells as opposed to VEGF 
mRNA, which, as reported before, was upregulated (283). Only when the hypoxic 
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period was followed by reoxygenation, αB-crystallin mRNA was upregulated. In vivo 
studies have demonstrated that periods of reoxygenation are associated with transiently 
increased levels of ROS (199;200). As described in Chapter 2, intermittent hypoxia, 
cyclic periods of hypoxia and normoxia in tumor cells, might lead to the presence of 
ROS in hypoxic tumor areas. ROS formation is also observed in necrotic tumor areas, 
which are often present in the core of hypoxic areas (181; 202). To investigate whether 
αB-crystallin might be upregulated in hypoxic areas due to ROS, we either increased 
ROS levels in HNSCC cell lines or reduced ROS levels by incubating with the ROS-
scavenger N-acetylcysteine and determined αB-crystallin mRNA expression levels. 
The results showed that αB-crystallin expression levels are indeed upregulated upon 
ROS-formation, strongly suggesting that ROS plays a role in elevated αB-crystallin 
expression in hypoxic areas of HNSCC (Chapter 4). The mechanism by which αB-
crystallin expression is induced under circumstances of hypoxia and ROS is not yet 
known. We have investigated a series of factors that might be involved, including heat 
shock factor 1 (HSF1), lens epithelial derived growth factor (LEDGF), NF-E2-related 
factor 2 (NRF2) and ETS-1, in HNSCC cells by quantitative RT-PCR, but the data was 
inconclusive. The tumor microenvironment is characterized, amongst other conditions, 
by hypoxia and low-glucose concentrations (354). In Chapter 4 we show that αB- 
crystallin knockdown leads to decreased cell survival under hypoxic conditions as well 
Figure 3. Influence of αB-crystallin overexpression on VEGF secretion. The 
doxycycline-inducible T-REx™-HeLa-pcDNA4-αB-Crystallin wild type cell line and T-
REx™-HeLa-pcDNA4 control cell line were treated with doxycyclin. The protein 
expression levels were assessed by western blotting (a). VEGF secretion levels were 
determined by ELISA (b). Statistical analysis was performed using One-way ANOVA and 
Tukey’s Multiple Comparison Test. *** P < 0.001, * 0.01 < P < 0.05; a.u: absorbance units 
(a.)                 (b.) 
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as under low glucose conditions. The susceptibility of these cells for glucose stress, 
especially when combined with hypoxia, could be due to the Warburg affect. Most 
cancer cells produce energy primarily by glycolysis followed by lactic acid 
fermentation in the cytosol. In normal cells, energy is produced by a low rate of 
glycolysis followed by oxidation of pyruvate in mitochondria (355;356). Recently, Liu 
and coworkers reported that the bidirectional gene pair HspB2/αB-crystallin (described 
in Chapter 1) is a novel direct target of p53 (described in Chapter 2). Knockdown of 
HspB2 as well as αB-crystallin leads to increased glucose concentration and decreased 
lactate levels in the culture medium and to an increase of intracellular ROS (357). 
Possibly, the ROS-induced upregulation of αB-crystallin expression is part of a 
feedback loop which may contribute to the reduction of ROS levels. ‘Side-effects’ of 
ROS-induced αB-crystallin upregulation are enhanced glucose metabolism and 
(hypoxic) cell survival. As hypoxia is linked to metastasis formation via HIF-1-
upregulation of angiogenesis-inducing genes, like VEGF (Chapter 2), this could 
ultimately lead to increased metastasis potential (Chapter 3).  
 
 
7.4 αB-CRYSTALLIN AS A BIOMARKER AND TARGET FOR TREATMENT FOR 
TRIPLE-NEGATIVE/BASAL-LIKE CANCERS 
 
Triple-negative/basal-like breast cancer remains a complicated disease to treat. A study 
by Dent at al. shows that women with a triple-negative breast cancer are more likely to 
die during follow-up than women with other types of breast cancers (42% versus 28%). 
Median time to death was 4.2 years versus 6 years. These women also experienced 
higher rates of distant recurrence (34% versus 20%) and these occurred sooner after 
diagnosis (2.6 versus 5.0 years) (358). A better understanding of the heterogeneity in 
gene expression of triple-negative/basal-like breast cancer is desired as this may help 
the development of patient subgroup-specific therapies (359). 
Tsang et al. showed that αB-crystallin could be a useful biomarker for triple negative 
and basal breast cancers (292) and Moyano et al. found that overexpression of αB-
crystallin in MCF-10A mammary epithelial cells led to malignant progression and 
upregulated expression of ERK1/2 and phospho-ERK1/2 (pERK1/2), AKT and 
phospho-AKT (pAKT). In Chapter 5 we show that αB-crystallin expression is 
correlated with triple negative and basal-like markers. Recently, this was found as well 
by Koletsa and coworkers. Analysis of 940 tumors showed that in their tumor 
microarray (TMA) αB-crystallin was expressed more frequently in triple-negative 
breast carcinomas (45% vs. 15%) and its expression correlated with basal cytokeratin 
protein expression (360). In our breast cancer TMA, we also found a correlation 
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between αB-crystallin expression with pERK1/2 expression. However, when triple 
negative breast cell lines are depleted of αB-crystallin, this does not affect pERK1/2. 
Therefore, it is not clear yet whether αB-crystallin-induced malignant progression is 
modulated via the ERK1/2 pathway (293). 
An ideal biomarker for clinical use has a sensitivity and specificity of more than 90% 
(361). Basal-like marker smooth muscle actin (SMA) has a specificity of 70% and a 
sensitivity of 100% and basal-like marker cytokeratin (CK)5/6 shows 76% specificity 
and 33% sensitivity. In our cohort, the specificity and sensitivity of αB-crystallin as a 
biomarker for triple negativity is 72% and 55%, respectively, which is similar to 
CK5/6. Although not ideal, αB-crystallin might be useful as an additional biomarker in 
a clinical setting. In addition, as explained above for HNSCC, αB-crystallin might be 
an interesting additional target for therapy, especially since estrogen receptor (ER), 
progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2)-targeted 
therapy does not work for triple negative breast cancer (Chapter 2).  
Basal-like and triple-negative breast cancers are regarded similar in literature, as the 
majority of triple negative cancers are of basal-like phenotype and the majority of 
tumors expressing ‘basal’ markers are triple negative (Chapter 2) (362). 
An indication that elevated αB-crystallin expression might be specifically correlated 
with the basal-like subgroup of triple negative breast cancers, was obtained by 
analyzing the αB-crystallin expression in four triple-negative cell lines, MDA-MB231, 
MDA-MB436, MDA-MB468 and HCC1937. Using gene expression profiling, 
Lehmann and coworkers showed that MDA-MB231 and MDA-MB436 are of the 
mesenchymal-like subtype and MDA-MB468 and HCC1937 are basal-like (363). αB-
crystallin protein expression was only detectable in MDA-MB468 and HCC1937, 
substantiating the possibility that αB-crystallin represents a specific marker for the 
basal-like breast cancer and not for triple negativity per se. Interestingly, the pattern of 
metastatic spread of tumors with a basal-like phenotype seems to be different from that 
of non-basal-like cancers: they less frequently metastasize to axillary nodes and bones 
and they favor a hematogenous spread, leading to distant metastasis formation (364-
367). In our HNSCC cohort, we did also find that αB-crystallin was correlated with 
distant metastasis formation and not with loco-regional recurrence. Hypothetically, the 
presence of αB-crystallin might have a role in the preference of distant metastatic 
spread of basal-like breast cancer. More support for the association of αB-crystallin 
expression with basal-like breast cancer might be obtained by analyzing whether αB-
crystallin also correlates with other basal/myoepithelial markers in breast cancer 
tissues, like CD10, maspin, calponin, p63 or p75 (368;369). Whether the 
basal/myoepithelial-like cancers originate from myoepithelial cells, already expressing 
207528-L-bw-Schootbrugge
 
 
CHAPTER 7 
 
119 
 
these markers, or are derived from a pluripotent stem cell, ultimately expressing these 
markers during cancer progression, is still under discussion (289;370-373). More 
knowledge about the development basal-like and other types of breast cancer and about 
the differences, e.g. in the metastatic spread, may ultimately lead to improvement of 
the treatment. 
 
7.5 αB-CRYSTALLIN CAN FUNCTION AS A NUCLEAR CHAPERONE 
 
In HNSCC biopsies stained with αB-crystallin antibodies, some nuclear αB-crystallin 
staining was observed (unpublished results). In the last experimental chapter of this 
thesis (Chapter 6), we describe how αB-crystallin can be transported into the nucleus 
via interaction with Gemin3, a component of the SMN complex. The SMN complex is 
well-known for its function in the assembly of spliceosomal small nuclear 
ribonucleoproteins (snRNPs), consisting of small nuclear RNAs (snRNAs) U1, U2, 
U5, andU4/U6, the Sm proteins (B/B', D1, D2,D3, E, F, and G), and a number of U 
snRNP-specific proteins. The snRNAs are exported from the nucleus to the cytoplasm 
via interaction with CRM1 (374), where the SMN complex directly recognizes both the 
Sm proteins and snRNAs and facilitates their assembly into snRNPs. The snRNP 
import factor snurportin 1 binds the snRNPs, facilitating importin β-mediated nuclear 
import (375;376). In the nucleus, the snRNPs assemble into spliceosomes, together 
with many other proteins and are responsible for the removal of introns from pre-
mRNA (377).  
Narayanan et al. showed that snurportin 1 interacts with (cytoplasmic) SMN and 
Gemin3, which are both components of the SMN complex (330), and that this 
facilitates the nuclear uptake of snRNPs (315). In non-stressed cells, a fraction of 
phosphorylated αB-crystallin is present in nuclear speckles, which contain, besides 
SC35 and other splicing factors (61;310) also snRNPs (378). Since phosphorylated αB-
crystallin can also interact with the SMN complex (311), we hypothesized that the 
nuclear import of αB-crystallin might be facilitated by this complex. In Chapter 6 we 
show that αB-crystallin directly interacts with Gemin3 in a yeast two-hybrid system.  
Knockdown of Gemin3 strongly reduced the accumulation of αB-STD, a mutant that 
mimics the phosphorylation αB-crystallin, in nuclear speckles. Furthermore, depletion 
of SMN inhibited nuclear import of fluorescently labeled recombinant αB-STD, which 
could be restored by the supplementation with the purified SMN complex. These 
results indicate that the SMN-complex facilitates the accumulation of phosphorylated 
αB-crystallin in nuclear speckles. Via its interaction with Gemin3 αB-crystallin may 
influence the functions of the SMN complex. As described by Cauchi, components of 
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Figure 4. The influence of αB-crystallin expression and phosphorylation under 
hypoxia and in tumors expressing EGFR. Under hypoxic circumstances, VEGF 
expression is upregulated by binding of HIF1 to the VEGF promoter. Correctly folded 
VEGF is transported to the Golgi-apparatus and secreted, where it can induce autocrine 
(and paracrine) signaling, when binding to the VEGF receptor (VEGFR). Misfolded protein 
will be degraded by the proteasome (a). If αB-crystallin is present in a tumor, this protein 
can bind the misfolded VEGF, preventing breakdown, and direct endoplasmic VEGF to the 
reticulum (ER), where it is correctly refolded and eventually secreted via the Golgi 
apparatus leading to enhanced signaling (b). In case a tumor expresses EGFR (which can 
occur in combination with hypoxia), ERK1/2 becomes activated and the expression of 
VEGF and VEGFR is induced. Moreover, if αB-crystallin is present, it can become 
hyperphosphorylated at S59 by ERK1/2, leading to rescue of more VEGF and thus even 
more VEGF can be secreted than under hypoxic conditions alone. Moreover, as VEGFR is 
upregulated as well, VEGFR signaling is enhanced massively. Therefore, a combination of 
EGFR expression, αB-crystallin expression and hypoxia could result in enhanced tumor 
progression (c). This figure is based on illustrations in the following references 
(227;346;347). 
 
 
the SMN complex are not only involved in snRNPs biosynthesis (379). Gemin3 can 
perform important cellular functions independent of the SMN complex. Gemin3 is 
present in mRNP and miRNP complexes containing AGO2, which are responsible for 
gene silencing. Gemin3 can also interact with SF-1, a nuclear receptor essential for the 
development of gonads, the adrenal gland and the ventromedialhypothalamic nucleus, 
leading to repression of the transcriptional activity of SF-1. Also interaction with 
METS has been described, which is a repressor of Ets target genes, involved in Ras-
dependent proliferation. The interaction with Gemin3 is essential for the anti-
proliferative effects of METS. αB-crystallin might affect these different activities of 
Gemin3 by affecting the interaction with the other Gemin3 interacting proteins.  
The function of αB-crystallin in the nuclear speckles is currently unknown. In Chapter 
6, we show that upon heat-shock, αB-crystallin speckle localization is lost and this 
protein is localized diffusely throughout the nucleus. Moreover, αB-crystallin can 
perform the classical chaperoning function, as shown by the refolding of nuclear 
luciferase after heat stress. αB-crystallin may also have more specific functions in the 
nucleus, as it has been shown that by inhibiting the activation of nuclear caspases, 
nuclear αB-crystallin has anti-apoptotic activity in retinal pigment epithelial cells 
(113;325). αB-crystallin also colocalizes with nuclear lamin A/C (334;380). The intra-
nuclear lamina network has an important function, since it is involved in the regulation 
of many processes, such as gene regulation, DNA replication, chromatin organization, 
nuclear architecture and nuclear assembly (381-383). Therefore, it is not surprising that 
(c) 
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altered lamin expression has also been observed in various cancers, frequently 
correlating with tumorigenic potential and malignant transformation (384;385). A 
functional role of αB-crystallin in the nuclear lamin network has not been demonstrated 
so far. We hypothesize that increase accumulation of αB-crystallin in the nucleus might 
drive cancer formation by improving lamin-functioning.  
 
 
7.6 CONCLUDING REMARKS 
 
It is evident that αB-crystallin is a very versatile protein, exerting functions in the 
cytoplasm as well as in the nucleus. It is also clear that this protein can assist in tumor 
formation and development of metastasis. This thesis provides suggestions in which 
direction we have to look for the cellular processes in which αB-crystallin is involved, 
i.e. enhancing cell motility and VEGF expression and helping in hypoxic cell survival, 
ultimately leading to worse prognosis for (HNSCC) patients. The exact molecular 
mechanisms of the action of αB-crystallin in these processes remain to be elucidated. 
Therefore, it is important to investigate the involvement of αB-crystallin in more detail. 
A better understanding of these processes may reveal whether αB-crystallin is indeed a 
feasible target for anti-cancer treatments. 
  
207528-L-bw-Schootbrugge
 
 
CHAPTER 7 
 
123 
 
  
207528-L-bw-Schootbrugge
 
 
 
 
124 
 
  
207528-L-bw-Schootbrugge
 
 
 
 
125 
 
REFERENCE LIST 
 
 (1)  Mörner CT. (1894) Untersuchung der Proteinsubstanzen in den sichtbrechenden Medien 
de Auges. Hoppe-Seyler's Z Physiol.Chemie , 16.  
 (2)  van der Ouderaa F.J., de Jong W.W., Groenendijk G.W., Bloemendal H. (1974) Sequence 
of the first 68 residues of the alpha B2 chain of bovine alpha-crystallin. Biochem 
Biophys Res Commun 57: 112. 
 (3)  van der Ouderaa F.J., de Jong W.W., Bloemendal H. (1973) The amino-acid sequence of 
the alphaA2 chain of bovine alpha-crystallin. Eur J Biochem 39: 207. 
 (4)  Ingolia T.D., Craig E.A. (1982) Four small Drosophila heat shock proteins are related to 
each other and to mammalian alpha-crystallin. Proc Natl Acad Sci U S A 79: 2360. 
 (5)  Horwitz J. (1992) Alpha-crystallin can function as a molecular chaperone. Proc Natl 
Acad Sci U S A 89: 10449. 
 (6)  Pasta S.Y., Raman B., Ramakrishna T., Rao C. (2004) The IXI/V motif in the C-terminal 
extension of alpha-crystallins: alternative interactions and oligomeric assemblies. Mol 
Vis 10: 655. 
 (7)  Pasta S.Y., Raman B., Ramakrishna T., Rao C. (2003) Role of the conserved 
SRLFDQFFG region of alpha-crystallin, a small heat shock protein. Effect on oligomeric 
size, subunit exchange, and chaperone-like activity. J Biol Chem 278: 51159. 
 (8)  Iwaki A., Nagano T., Nakagawa M., Iwaki T., Fukumaki Y. (1997) Identification and 
characterization of the gene encoding a new member of the alpha-crystallin/small hsp 
family, closely linked to the alphaB-crystallin gene in a head-to-head manner. Genomics 
45: 386. 
 (9)  Elicker K.S., Hutson L.D. (2007) Genome-wide analysis and expression profiling of the 
small heat shock proteins in zebrafish. Gene 403: 60. 
 (10)  Franck E., Madsen O., van Rheede T., Ricard G., Huynen M.A., de Jong W.W. (2004) 
Evolutionary diversity of vertebrate small heat shock proteins. J Mol Evol 59: 792. 
 (11)  Thompson J.D., Higgins D.G., Gibson T.J. (1994) CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence weighting, 
position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673. 
 (12)  Nicholas K.B. Nicholas H.B., Deerfield DW, editors (1997) GeneDoc: Analysis and 
Visualization of Genetic Variation. EMBNEW.NEWS 14.  
 (13)  Jehle S., van Rossum B., Stout J.R., Noguchi S.M., Falber K., Rehbein K., et al. (2009) 
alphaB-crystallin: a hybrid solid-state/solution-state NMR investigation reveals 
structural aspects of the heterogeneous oligomer. J Mol Biol 385: 1481. 
 (14)  van de Schootbrugge C., Boelens W.C. (2010). Introduction to Small Heat Shock 
Proteins. In: Simon S, Arrigo AP, editors. Small Stress Proteins and Human Diseases. 
Nova Science Publishers. 
 (15)  Guindon S., Gascuel O. (2003) A simple, fast, and accurate algorithm to estimate large 
phylogenies by maximum likelihood. Syst Biol 52: 696. 
 (16)  Gusev N.B., Bogatcheva N.V., Marston S.B. (2002) Structure and properties of small 
heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry 
(Mosc ) 67: 511. 
 (17)  Mymrikov E.V., Seit-Nebi A.S., Gusev N.B. (2011) Heterooligomeric complexes of 
human small heat shock proteins. Cell Stress Chaperones. 
 (18)  van den Oetelaar P.J., van Someren P.F., Thomson J.A., Siezen R.J., Hoenders H.J. 
(1990) A dynamic quaternary structure of bovine alpha-crystallin as indicated from 
intermolecular exchange of subunits. Biochemistry 29: 3488. 
 (19)  Bova M.P., Ding L.L., Horwitz J., Fung B.K. (1997) Subunit exchange of alphaA-
207528-L-bw-Schootbrugge
 
 
 
 
126 
 
crystallin. J Biol Chem 272: 29511. 
 (20)  Delbecq S.P., Jehle S., Klevit R. (2012) Binding determinants of the small heat shock 
protein, alphaB-crystallin: recognition of the 'IxI' motif. EMBO J 31: 4587. 
 (21)  Sudnitsyna M.V., Mymrikov E.V., Seit-Nebi A.S., Gusev N.B. (2012) The role of 
intrinsically disordered regions in the structure and functioning of small heat shock 
proteins. Curr Protein Pept Sci 13: 76. 
 (22)  de Jong W.W., Caspers G.J., Leunissen J.A. (1998) Genealogy of the alpha-crystallin--
small heat-shock protein superfamily. Int J Biol Macromol 22: 151. 
 (23)  Koteiche H.A., Mchaourab H.S. (1999) Folding pattern of the alpha-crystallin domain in 
alphaA-crystallin determined by site-directed spin labeling. J Mol Biol 294: 561. 
 (24)  Morris A.M., Treweek T.M., Aquilina J.A., Carver J.A., Walker M.J. (2008) Glutamic 
acid residues in the C-terminal extension of small heat shock protein 25 are critical for 
structural and functional integrity. FEBS J 275: 5885. 
 (25)  van Montfort R.L., Basha E., Friedrich K.L., Slingsby C., Vierling E. (2001) Crystal 
structure and assembly of a eukaryotic small heat shock protein. Nat Struct Biol 8: 1025. 
 (26)  Li Y., Schmitz K.R., Salerno J.C., Koretz J.F. (2007) The role of the conserved COOH-
terminal triad in alphaA-crystallin aggregation and functionality. Mol Vis 13: 1758. 
 (27)  Saji H., Iizuka R., Yoshida T., Abe T., Kidokoro S., Ishii N., et al. (2008) Role of the 
IXI/V motif in oligomer assembly and function of StHsp14.0, a small heat shock protein 
from the acidothermophilic archaeon, Sulfolobus tokodaii strain 7. Proteins 71: 771. 
 (28)  Jehle S., Vollmar B.S., Bardiaux B., Dove K.K., Rajagopal P., Gonen T., et al. (2011) N-
terminal domain of alphaB-crystallin provides a conformational switch for 
multimerization and structural heterogeneity. Proc Natl Acad Sci U S A 108: 6409. 
 (29)  Aquilina J.A., Benesch J.L., Bateman O.A., Slingsby C., Robinson C.V. (2003) 
Polydispersity of a mammalian chaperone: mass spectrometry reveals the population of 
oligomers in alphaB-crystallin. Proc Natl Acad Sci U S A 100: 10611. 
 (30)  Delbecq S.P., Klevit R.E. (2013) One size does not fit all: The oligomeric states of 
alphaB crystallin. FEBS Lett 587: 1073. 
 (31)  Braun N., Zacharias M., Peschek J., Kastenmuller A., Zou J., Hanzlik M., et al. (2011) 
Multiple molecular architectures of the eye lens chaperone alphaB-crystallin elucidated 
by a triple hybrid approach. Proc Natl Acad Sci U S A 108: 20491. 
 (32)  Dillmann W.H. (1999) Small heat shock proteins and protection against injury. Ann N Y 
Acad Sci 874: 66. 
 (33)  Tallot P., Grongnet J.F., David J.C. (2003) Dual perinatal and developmental expression 
of the small heat shock proteins [FC12]aB-crystallin and Hsp27 in different tissues of the 
developing piglet. Biol Neonate 83: 281. 
 (34)  Ciocca D.R., Oesterreich S., Chamness G.C., McGuire W.L., Fuqua S.A. (1993) 
Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J 
Natl Cancer Inst 85: 1558. 
 (35)  Efthymiou C.A., Mocanu M.M., de Belleroche J., Wells D.J., Latchmann D.S., Yellon 
D.M. (2004) Heat shock protein 27 protects the heart against myocardial infarction. 
Basic Res Cardiol 99: 392. 
 (36)  Lutsch G., Vetter R., Offhauss U., Wieske M., Grone H.J., Klemenz R., et al. (1997) 
Abundance and location of the small heat shock proteins HSP25 and alphaB-crystallin in 
rat and human heart. Circulation 96: 3466. 
 (37)  Verschuure P., Tatard C., Boelens W.C., Grongnet J.F., David J.C. (2003) Expression of 
small heat shock proteins HspB2, HspB8, Hsp20 and cvHsp in different tissues of the 
perinatal developing pig. Eur J Cell Biol 82: 523. 
 (38)  van de Klundert F.A., Gijsen M.L., van den IJssel P.R., Snoeckx L.H., de Jong W.W. 
(1998) alpha B-crystallin and hsp25 in neonatal cardiac cells--differences in cellular 
207528-L-bw-Schootbrugge
 
 
 
 
127 
 
localization under stress conditions. Eur J Cell Biol 75: 38. 
 (39)  Srinivasan A.N., Nagineni C.N., Bhat S.P. (1992) alpha A-crystallin is expressed in non-
ocular tissues. J Biol Chem 267: 23337. 
 (40)  Egwuagu C.E., Chepelinsky A.B. (1997) Extralenticular expression of the alpha A-
crystallin promoter/gamma interferon transgene. Exp Eye Res 64: 491. 
 (41)  Dubin R.A., Wawrousek E.F., Piatigorsky J. (1989) Expression of the murine alpha B-
crystallin gene is not restricted to the lens. Mol Cell Biol 9: 1083. 
 (42)  Bhat S.P., Nagineni C.N. (1989) alpha B subunit of lens-specific protein alpha-crystallin 
is present in other ocular and non-ocular tissues. Biochem Biophys Res Commun 158: 
319. 
 (43)  Swamynathan S.K., Piatigorsky J. (2007) Regulation of the mouse alphaB-crystallin and 
MKBP/HspB2 promoter activities by shared and gene specific intergenic elements: the 
importance of context dependency. Int J Dev Biol 51: 689. 
 (44)  Doerwald L., van Rheede T., Dirks R.P., Madsen O., Rexwinkel R., van Genesen S.T., et 
al. (2004) Sequence and functional conservation of the intergenic region between the 
head-to-head genes encoding the small heat shock proteins alphaB-crystallin and HspB2 
in the mammalian lineage. J Mol Evol 59: 674. 
 (45)  de T.A., Le M.A., Mezger V. (2012) Transcriptional regulation of small HSP-HSF1 and 
beyond. Int J Biochem Cell Biol 44: 1593. 
 (46)  Taylor R.P., Benjamin I.J. (2005) Small heat shock proteins: a new classification scheme 
in mammals. J Mol Cell Cardiol 38: 433. 
 (47)  Golenhofen N., Ness W., Wawrousek E.F., Drenckhahn D. (2002) Expression and 
induction of the stress protein alpha-B-crystallin in vascular endothelial cells. Histochem 
Cell Biol 117: 203. 
 (48)  Yu A.L., Fuchshofer R., Birke M., Priglinger S.G., Eibl K.H., Kampik A., et al. (2007) 
Hypoxia/reoxygenation and TGF-beta increase alphaB-crystallin expression in human 
optic nerve head astrocytes. Exp Eye Res 84: 694. 
 (49)  Omar R., Pappolla M. (1993) Oxygen free radicals as inducers of heat shock protein 
synthesis in cultured human neuroblastoma cells: relevance to neurodegenerative 
disease. Eur Arch Psychiatry Clin Neurosci 242: 262. 
 (50)  Hawse J.R., Cumming J.R., Oppermann B., Sheets N.L., Reddy V.N., Kantorow M. 
(2003) Activation of metallothioneins and alpha-crystallin/sHSPs in human lens 
epithelial cells by specific metals and the metal content of aging clear human lenses. 
Invest Ophthalmol Vis Sci 44: 672. 
 (51)  Boluyt M.O., Brevick J.L., Rogers D.S., Randall M.J., Scalia A.F., Li Z.B. (2006) 
Changes in the rat heart proteome induced by exercise training: Increased abundance of 
heat shock protein hsp20. Proteomics 6: 3154. 
 (52)  Vissing K., Bayer M.L., Overgaard K., Schjerling P., Raastad T. (2008) Heat shock 
protein translocation and expression response is attenuated in response to repeated 
eccentric exercise. Acta Physiol (Oxf). 
 (53)  Wilhelmus M.M., Otte-Holler I., Wesseling P., de Waal R.M., Boelens W.C., Verbeek 
M.M. (2006) Specific association of small heat shock proteins with the pathological 
hallmarks of Alzheimer's disease brains. Neuropathol Appl Neurobiol 32: 119. 
 (54)  Arrigo A.P., Simon S., Gibert B., Kretz-Remy C., Nivon M., Czekalla A., et al. (2007) 
Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett 581: 
3665. 
 (55)  Golenhofen N., Ness W., Koob R., Htun P., Schaper W., Drenckhahn D. (1998) 
Ischemia-induced phosphorylation and translocation of stress protein alpha B-crystallin 
to Z lines of myocardium. Am J Physiol 274: H1457-H1464. 
 (56)  Ito H., Okamoto K., Nakayama H., Isobe T., Kato K. (1997) Phosphorylation of alphaB-
207528-L-bw-Schootbrugge
 
 
 
 
128 
 
crystallin in response to various types of stress. J Biol Chem 272: 29934. 
 (57)  Kato K., Ito H., Kamei K., Inaguma Y., Iwamoto I., Saga S. (1998) Phosphorylation of 
alphaB-crystallin in mitotic cells and identification of enzymatic activities responsible for 
phosphorylation. J Biol Chem 273: 28346. 
 (58)  Ito H., Kamei K., Iwamoto I., Inaguma Y., Nohara D., Kato K. (2001) Phosphorylation-
induced change of the oligomerization state of alpha B-crystallin. J Biol Chem 276: 
5346. 
 (59)  Kato K., Hasegawa K., Goto S., Inaguma Y. (1994) Dissociation as a result of 
phosphorylation of an aggregated form of the small stress protein, hsp27. J Biol Chem 
269: 11274. 
 (60)  Ahmad M.F., Raman B., Ramakrishna T., Rao C. (2008) Effect of phosphorylation on 
alpha B-crystallin: differences in stability, subunit exchange and chaperone activity of 
homo and mixed oligomers of alpha B-crystallin and its phosphorylation-mimicking 
mutant. J Mol Biol 375: 1040. 
 (61)  den Engelsman J., Bennink E.J., Doerwald L., Onnekink C., Wunderink L., Andley U.P., 
et al. (2004) Mimicking phosphorylation of the small heat-shock protein alphaB-
crystallin recruits the F-box protein FBX4 to nuclear SC35 speckles. Eur J Biochem 271: 
4195. 
 (62)  Maddala R., Rao V.P. (2005) alpha-Crystallin localizes to the leading edges of migrating 
lens epithelial cells. Exp Cell Res 306: 203. 
 (63)  Launay N., Goudeau B., Kato K., Vicart P., Lilienbaum A. (2006) Cell signaling 
pathways to alphaB-crystallin following stresses of the cytoskeleton. Exp Cell Res 312: 
3570. 
 (64)  Gupta R., Srivastava O.P. (2004) Deamidation affects structural and functional 
properties of human alphaA-crystallin and its oligomerization with alphaB-crystallin. J 
Biol Chem 279: 44258. 
 (65)  Kamei A., Iwase H., Masuda K. (1997) Cleavage of amino acid residue(s) from the N-
terminal region of alpha A- and alpha B-crystallins in human crystalline lens during 
aging. Biochem Biophys Res Commun 231: 373. 
 (66)  Takeuchi N., Ouchida A., Kamei A. (2004) C-terminal truncation of alpha-crystallin in 
hereditary cataractous rat lens. Biol Pharm Bull 27: 308. 
 (67)  Chen S.J., Sun T.X., Akhtar N.J., Liang J.J. (2001) Oxidation of human lens recombinant 
alphaA-crystallin and cysteine-deficient mutants. J Mol Biol 305: 969. 
 (68)  Blakytny R., Carver J.A., Harding J.J., Kilby G.W., Sheil M.M. (1997) A spectroscopic 
study of glycated bovine alpha-crystallin: investigation of flexibility of the C-terminal 
extension, chaperone activity and evidence for diglycation. Biochim Biophys Acta 1343: 
299. 
 (69)  Nagaraj R.H., Oya-Ito T., Padayatti P.S., Kumar R., Mehta S., West K., et al. (2003) 
Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. 
Biochemistry 42: 10746. 
 (70)  Satish K.M., Mrudula T., Mitra N., Bhanuprakash R.G. (2004) Enhanced degradation 
and decreased stability of eye lens alpha-crystallin upon methylglyoxal modification. Exp 
Eye Res 79: 577. 
 (71)  Seidler N.W., Yeargans G.S., Morgan T.G. (2004) Carnosine disaggregates glycated 
alpha-crystallin: an in vitro study. Arch Biochem Biophys 427: 110. 
 (72)  Fujii N., Matsumoto S., Hiroki K., Takemoto L. (2001) Inversion and isomerization of 
Asp-58 residue in human alphaA-crystallin from normal aged lenses and cataractous 
lenses. Biochim Biophys Acta 1549: 179. 
 (73)  Stromer T., Ehrnsperger M., Gaestel M., Buchner J. (2003) Analysis of the interaction of 
small heat shock proteins with unfolding proteins. J Biol Chem 278: 18015. 
207528-L-bw-Schootbrugge
 
 
 
 
129 
 
 (74)  Quinlan R.A., Brenner M., Goldman J.E., Messing A. (2007) GFAP and its role in 
Alexander disease. Exp Cell Res 313: 2077. 
 (75)  Outeiro T.F., Klucken J., Strathearn K.E., Liu F., Nguyen P., Rochet J.C., et al. (2006) 
Small heat shock proteins protect against alpha-synuclein-induced toxicity and 
aggregation. Biochem Biophys Res Commun 351: 631. 
 (76)  Sharma M.C., Goebel H.H. (2005) Protein aggregate myopathies. Neurol India 53: 273. 
 (77)  Haslbeck M., Franzmann T., Weinfurtner D., Buchner J. (2005) Some like it hot: the 
structure and function of small heat-shock proteins. Nat Struct Mol Biol 12: 842. 
 (78)  Lee G.J., Vierling E. (2000) A small heat shock protein cooperates with heat shock 
protein 70 systems to reactivate a heat-denatured protein. Plant Physiol 122: 189. 
 (79)  Bryantsev A.L., Kurchashova S.Y., Golyshev S.A., Polyakov V.Y., Wunderink H.F., 
Kanon B., et al. (2007) Regulation of stress-induced intracellular sorting and chaperone 
function of Hsp27 (HspB1) in mammalian cells. Biochem J 407: 407. 
 (80)  Matuszewska M., Kuczynska-Wisnik D., Laskowska E., Liberek K. (2005) The small 
heat shock protein IbpA of Escherichia coli cooperates with IbpB in stabilization of 
thermally aggregated proteins in a disaggregation competent state. J Biol Chem 280: 
12292. 
 (81)  Mogk A., Deuerling E., Vorderwulbecke S., Vierling E., Bukau B. (2003) Small heat 
shock proteins, ClpB and the DnaK system form a functional triade in reversing protein 
aggregation. Mol Microbiol 50: 585. 
 (82)  Haslbeck M., Miess A., Stromer T., Walter S., Buchner J. (2005) Disassembling protein 
aggregates in the yeast cytosol. The cooperation of Hsp26 with Ssa1 and Hsp104. J Biol 
Chem 280: 23861. 
 (83)  Cashikar A.G., Duennwald M., Lindquist S.L. (2005) A chaperone pathway in protein 
disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation 
by Hsp104. J Biol Chem 280: 23869. 
 (84)  Arrigo A.P. (2013) Human small heat shock proteins: Protein interactomes of homo- and 
hetero-oligomeric complexes: An update. FEBS Lett. 
 (85)  Zantema A., Verlaan-De Vries M., Maasdam D., Bol S., van der E.A. (1992) Heat shock 
protein 27 and alpha B-crystallin can form a complex, which dissociates by heat shock. J 
Biol Chem 267: 12936. 
 (86)  Kato K., Goto S., Inaguma Y., Hasegawa K., Morishita R., Asano T. (1994) Purification 
and characterization of a 20-kDa protein that is highly homologous to alpha B crystallin. 
J Biol Chem 269: 15302. 
 (87)  Sugiyama Y., Suzuki A., Kishikawa M., Akutsu R., Hirose T., Waye M.M., et al. (2000) 
Muscle develops a specific form of small heat shock protein complex composed of 
MKBP/HSPB2 and HSPB3 during myogenic differentiation. J Biol Chem 275: 1095. 
 (88)  Sun X., Welsh M.J., Benndorf R. (2006) Conformational changes resulting from 
pseudophosphorylation of mammalian small heat shock proteins--a two-hybrid study. 
Cell Stress Chaperones 11: 61. 
 (89)  Lelj-Garolla B., Mauk A.G. (2006) Self-association and chaperone activity of Hsp27 are 
thermally activated. J Biol Chem 281: 8169. 
 (90)  Bukach O.V., Glukhova A.E., Seit-Nebi A.S., Gusev N.B. (2008) Heterooligomeric 
complexes formed by human small heat shock proteins HspB1 (Hsp27) and HspB6 
(Hsp20). Biochim Biophys Acta. 
 (91)  Charette S.J., Lavoie J.N., Lambert H., Landry J. (2000) Inhibition of Daxx-mediated 
apoptosis by heat shock protein 27. Mol Cell Biol 20: 7602. 
 (92)  Fu L., Liang J.J. (2002) Detection of protein-protein interactions among lens crystallins 
in a mammalian two-hybrid system assay. J Biol Chem 277: 4255. 
 (93)  Pipkin W., Johnson J.A., Creazzo T.L., Burch J., Komalavilas P., Brophy C. (2003) 
207528-L-bw-Schootbrugge
 
 
 
 
130 
 
Localization, macromolecular associations, and function of the small heat shock-related 
protein HSP20 in rat heart. Circulation 107: 469. 
 (94)  Fontaine J.M., Sun X., Benndorf R., Welsh M.J. (2005) Interactions of HSP22 (HSPB8) 
with HSP20, alphaB-crystallin, and HSPB3. Biochem Biophys Res Commun 337: 1006. 
 (95)  Sun X., Fontaine J.M., Rest J.S., Shelden E.A., Welsh M.J., Benndorf R. (2004) 
Interaction of human HSP22 (HSPB8) with other small heat shock proteins. J Biol Chem 
279: 2394. 
 (96)  Irobi J., Van Impe K., Seeman P., Jordanova A., Dierick I., Verpoorten N., et al. (2004) 
Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature 
Genetics 36: 597. 
 (97)  Kato K., Shinohara H., Goto S., Inaguma Y., Morishita R., Asano T. (1992) 
Copurification of small heat shock protein with alpha B crystallin from human skeletal 
muscle. J Biol Chem 267: 7718. 
 (98)  Benndorf R., Sun X., Gilmont R.R., Biederman K.J., Molloy M.P., Goodmurphy C.W., et 
al. (2001) HSP22, a new member of the small heat shock protein superfamily, interacts 
with mimic of phosphorylated HSP27 ((3D)HSP27). J Biol Chem 276: 26753. 
 (99)  Mounier N., Arrigo A.P. (2002) Actin cytoskeleton and small heat shock proteins: how 
do they interact? Cell Stress Chaperones 7: 167. 
 (100)  Brown D.D., Christine K.S., Showell C., Conlon F.L. (2007) Small heat shock protein 
Hsp27 is required for proper heart tube formation. Genesis 45: 667. 
 (101)  Perng M.D., Cairns L., van den I.J., Prescott A., Hutcheson A.M., Quinlan R.A. (1999) 
Intermediate filament interactions can be altered by HSP27 and alphaB-crystallin. J Cell 
Sci 112 ( Pt 13): 2099. 
 (102)  Bennardini F., Wrzosek A., Chiesi M. (1992) Alpha B-crystallin in cardiac tissue. 
Association with actin and desmin filaments. Circ Res 71: 288. 
 (103)  Nicholl I.D., Quinlan R.A. (1994) Chaperone activity of alpha-crystallins modulates 
intermediate filament assembly. EMBO J 13: 945. 
 (104)  Bova M.P., Yaron O., Huang Q., Ding L., Haley D.A., Stewart P.L., et al. (1999) 
Mutation R120G in alphaB-crystallin, which is linked to a desmin-related myopathy, 
results in an irregular structure and defective chaperone-like function. Proc Natl Acad 
Sci U S A 96: 6137. 
 (105)  Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. (1998) A missense 
mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat 
Genet 20: 92. 
 (106)  Hagemann T.L., Boelens W.C., Wawrousek E.F., Messing A. (2009) Suppression of 
GFAP toxicity by {alpha}B-crystallin in mouse models of Alexander disease. Hum Mol 
Genet. 
 (107)  Arai H., Atomi Y. (1997) Chaperone activity of alpha B-crystallin suppresses tubulin 
aggregation through complex formation. Cell Struct Funct 22: 539. 
 (108)  Kato K., Ito H., Inaguma Y., Okamoto K., Saga S. (1996) Synthesis and accumulation of 
alphaB crystallin in C6 glioma cells is induced by agents that promote the disassembly of 
microtubules. J Biol Chem 271: 26989. 
 (109)  Xi J.H., Bai F., McGaha R., Andley U.P. (2006) Alpha-crystallin expression affects 
microtubule assembly and prevents their aggregation. FASEB J 20: 846. 
 (110)  Houck S.A., Clark J.I. (2010) Dynamic subunit exchange and the regulation of 
microtubule assembly by the stress response protein human alphaB crystallin. PLoS One 
5: e11795. 
 (111)  Mao Y.W., Liu J.P., Xiang H., Li D.W. (2004) Human alphaA- and alphaB-crystallins 
bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine-induced 
apoptosis. Cell Death Differ 11: 512. 
207528-L-bw-Schootbrugge
 
 
 
 
131 
 
 (112)  Kamradt M.C., Chen F., Cryns V.L. (2001) The small heat shock protein alpha B-
crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of 
caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276: 16059. 
 (113)  Stegh A.H., Kesari S., Mahoney J.E., Jenq H.T., Forloney K.L., Protopopov A., et al. 
(2008) Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct 
mechanisms in glioblastoma. Proc Natl Acad Sci U S A 105: 10703. 
 (114)  Li R., Reiser G. (2011) Phosphorylation of Ser45 and Ser59 of alphaB-crystallin and 
p38/extracellular regulated kinase activity determine alphaB-crystallin-mediated 
protection of rat brain astrocytes from C2-ceramide- and staurosporine-induced cell 
death. J Neurochem 118: 354. 
 (115)  den Engelsman J., Keijsers V., de Jong W.W., Boelens W.C. (2003) The small heat-
shock protein alpha B-crystallin promotes FBX4-dependent ubiquitination. J Biol Chem 
278: 4699. 
 (116)  Lin D.I., Barbash O., Kumar K.G., Weber J.D., Harper J.W., Klein-Szanto A.J., et al. 
(2006) Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB 
crystallin) complex. Mol Cell 24: 355. 
 (117)  Boelens W.C., Croes Y., de Jong W.W. (2001) Interaction between alphaB-crystallin 
and the human 20S proteasomal subunit C8/alpha7. Biochim Biophys Acta 1544: 311. 
 (118)  Dehle F.C., Ecroyd H., Musgrave I.F., Carver J.A. (2010) alphaB-Crystallin inhibits the 
cell toxicity associated with amyloid fibril formation by kappa-casein and the amyloid-
beta peptide. Cell Stress Chaperones 15: 1013. 
 (119)  Shammas S.L., Waudby C.A., Wang S., Buell A.K., Knowles T.P., Ecroyd H., et al. 
(2011) Binding of the molecular chaperone alphaB-crystallin to Abeta amyloid fibrils 
inhibits fibril elongation. Biophys J 101: 1681. 
 (120)  Vos M.J., Zijlstra M.P., Kanon B., van Waarde-Verhagen M.A., Brunt E.R., Oosterveld-
Hut H.M., et al. (2010) HSPB7 is the most potent polyQ aggregation suppressor within 
the HSPB family of molecular chaperones. Hum Mol Genet 19: 4677. 
 (121)  Bruinsma I.B., Bruggink K.A., Kinast K., Versleijen A.A., Segers-Nolten I.M., 
Subramaniam V., et al. (2011) Inhibition of alpha-synuclein aggregation by small heat 
shock proteins. Proteins 79: 2956. 
 (122)  Sun Y., MacRae T.H. (2005) Small heat shock proteins: molecular structure and 
chaperone function. Cell Mol Life Sci 62: 2460. 
 (123)  Perng M.D., Wen S.F., van den I.J., Prescott A.R., Quinlan R.A. (2004) Desmin 
aggregate formation by R120G alphaB-crystallin is caused by altered filament 
interactions and is dependent upon network status in cells. Mol Biol Cell 15: 2335. 
 (124)  Sanbe A., Osinska H., Villa C., Gulick J., Klevitsky R., Glabe C.G., et al. (2005) 
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl 
Acad Sci U S A 102: 13592. 
 (125)  Sacconi S., Feasson L., Antoine J.C., Pecheux C., Bernard R., Cobo A.M., et al. (2011) A 
novel CRYAB mutation resulting in multisystemic disease. Neuromuscul Disord. 
 (126)  Moyano J.V., Evans J.R., Chen F., Lu M., Werner M.E., Yehiely F., et al. (2006) 
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast 
cancer. J Clin Invest 116: 261. 
 (127)  Oesterreich S., Weng C.N., Qiu M., Hilsenbeck S.G., Osborne C.K., Fuqua S.A. (1993) 
The small heat shock protein hsp27 is correlated with growth and drug resistance in 
human breast cancer cell lines. Cancer Res 53: 4443. 
 (128)  Rocchi P., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L., et al. (2004) Heat 
shock protein 27 increases after androgen ablation and plays a cytoprotective role in 
hormone-refractory prostate cancer. Cancer Res 64: 6595. 
 (129)  Oesterreich S., Schunck H., Benndorf R., Bielka H. (1991) Cisplatin induces the small 
207528-L-bw-Schootbrugge
 
 
 
 
132 
 
heat shock protein hsp25 and thermotolerance in Ehrlich ascites tumor cells. Biochem 
Biophys Res Commun 180: 243. 
 (130)  Geiger T.R., Peeper D.S. (2009) Metastasis mechanisms. Biochim Biophys Acta 1796: 
293. 
 (131)  Folkman J., Shing Y. (1992) Angiogenesis. J Biol Chem 267: 10931. 
 (132)  Hudson T.J., Anderson W., Artez A., Barker A.D., Bell C., Bernabe R.R., et al. (2010) 
International network of cancer genome projects. Nature 464: 993. 
 (133)  Stratton M.R., Campbell P.J., Futreal P.A. (2009) The cancer genome. Nature 458: 719. 
 (134)  Cairns R.A., Harris I.S., Mak T.W. (2011) Regulation of cancer cell metabolism. Nat Rev 
Cancer 11: 85. 
 (135)  Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. (2008) An 
integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807. 
 (136)  Hanahan D., Weinberg R.A. (2000) The hallmarks of cancer. Cell 100: 57. 
 (137)  Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell 86: 353. 
 (138)  Hanahan D., Weinberg R.A. (2011) Hallmarks of cancer: the next generation. Cell 144: 
646. 
 (139)  Spandidos D.A. (2007) Oncogenes and tumor suppressor genes as paradigms in 
oncogenesis. J BUON 12 Suppl 1: S9. 
 (140)  Munger K. (2002) Disruption of oncogene/tumor suppressor networks during human 
carcinogenesis. Cancer Invest 20: 71. 
 (141)  Chinnam M., Goodrich D.W. (2011) RB1, development, and cancer. Curr Top Dev Biol 
94: 129. 
 (142)  Ozaki T., Nakagawara A. (2011) p53: the attractive tumor suppressor in the cancer 
research field. J Biomed Biotechnol 2011: 603925. 
 (143)  Gutierrez C., Schiff R. (2011) HER2: biology, detection, and clinical implications. Arch 
Pathol Lab Med 135: 55. 
 (144)  Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. (2011) Cyclin D 
as a therapeutic target in cancer. Nat Rev Cancer 11: 558. 
 (145)  Clapp R.W., Jacobs M.M., Loechler E.L. (2008) Environmental and occupational causes 
of cancer: new evidence 2005-2007. Rev Environ Health 23: 1. 
 (146)  Clapp R.W., Howe G.K., Jacobs M.M. (2007) Environmental and occupational causes of 
cancer: a call to act on what we know. Biomed Pharmacother 61: 631. 
 (147)  Calabrese P., Tavare S., Shibata D. (2004) Pretumor progression: clonal evolution of 
human stem cell populations. Am J Pathol 164: 1337. 
 (148)  Oliveira P.A., Colaco A., Chaves R., Guedes-Pinto H., De-La-Cruz P.L., Lopes C. (2007) 
Chemical carcinogenesis. An Acad Bras Cienc 79: 593. 
 (149)  Kamangar F., Dores G.M., Anderson W.F. (2006) Patterns of cancer incidence, 
mortality, and prevalence across five continents: defining priorities to reduce cancer 
disparities in different geographic regions of the world. J Clin Oncol 24: 2137. 
 (150)  Parkin D.M., Bray F., Ferlay J., Pisani P. (2005) Global cancer statistics, 2002. CA 
Cancer J Clin 55: 74. 
 (151)  Rothenberg S.M., Ellisen L.W. (2012) The molecular pathogenesis of head and neck 
squamous cell carcinoma. J Clin Invest 122: 1951. 
 (152)  Brandsma J.L., Abramson A.L. (1989) Association of papillomavirus with cancers of the 
head and neck. Arch Otolaryngol Head Neck Surg 115: 621. 
 (153)  Scully C. (1993) Oncogenes, tumor suppressors and viruses in oral squamous 
carcinoma. J Oral Pathol Med 22: 337. 
 (154)  Lund V.J., Howard D.J. (1990) Head and neck cancer in the young: a prognostic 
conundrum? J Laryngol Otol 104: 544. 
207528-L-bw-Schootbrugge
 
 
 
 
133 
 
 (155)  Derynck R. (1992) The physiology of transforming growth factor-alpha. Adv Cancer Res 
58: 27. 
 (156)  Todd R., Chou M.Y., Matossian K., Gallagher G.T., Donoff R.B., Wong D.T. (1991) 
Cellular sources of transforming growth factor-alpha in human oral cancer. J Dent Res 
70: 917. 
 (157)  Wong D.T., Todd R., Tsuji T., Donoff R.B. (1996) Molecular biology of human oral 
cancer. Crit Rev Oral Biol Med 7: 319. 
 (158)  Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., et al. (1984) 
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein 
sequences. Nature 307: 521. 
 (159)  Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., et al. (1984) 
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the 
amplified gene in A431 epidermoid carcinoma cells. Nature 309: 418. 
 (160)  Wells A., Bishop J.M., Helmeste D. (1988) Amplified gene for the epidermal growth 
factor receptor in a human glioblastoma cell line encodes an enzymatically inactive 
protein. Mol Cell Biol 8: 4561. 
 (161)  Di M.E., Pierce J.H., Fleming T.P., Kraus M.H., Molloy C.J., Aaronson S.A., et al. 
(1989) Autocrine interaction between TGF alpha and the EGF-receptor: quantitative 
requirements for induction of the malignant phenotype. Oncogene 4: 831. 
 (162)  Di Fiore P.P., Pierce J.H., Fleming T.P., Hazan R., Ullrich A., King C.R., et al. (1987) 
Overexpression of the human EGF receptor confers an EGF-dependent transformed 
phenotype to NIH 3T3 cells. Cell 51: 1063. 
 (163)  Liao Y.M., Kim C., Yen Y. (2011) Mammalian target of rapamycin and head and neck 
squamous cell carcinoma. Head Neck Oncol 3: 22. 
 (164)  Reis-Filho J.S., Pusztai L. (2011) Gene expression profiling in breast cancer: 
classification, prognostication, and prediction. Lancet 378: 1812. 
 (165)  Turaga K., Acs G., Laronga C. (2010) Gene expression profiling in breast cancer. 
Cancer Control 17: 177. 
 (166)  Rastelli F., Biancanelli S., Falzetta A., Martignetti A., Casi C., Bascioni R., et al. (2010) 
Triple-negative breast cancer: current state of the art. Tumori 96: 875. 
 (167)  Osborne C., Wilson P., Tripathy D. (2004) Oncogenes and tumor suppressor genes in 
breast cancer: potential diagnostic and therapeutic applications. Oncologist 9: 361. 
 (168)  Leong A.S., Zhuang Z. (2011) The changing role of pathology in breast cancer diagnosis 
and treatment. Pathobiology 78: 99. 
 (169)  Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. (2012) Strategies for the 
discovery and development of therapies for metastatic breast cancer. Nat Rev Drug 
Discov 11: 479. 
 (170)  Kong D., Li Y., Wang Z., Sarkar F.H. (2011) Cancer Stem Cells and Epithelial-to-
Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers 
(Basel) 3: 716. 
 (171)  Thiery J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer 2: 442. 
 (172)  Geiger T.R., Peeper D.S. (2005) The neurotrophic receptor TrkB in anoikis resistance 
and metastasis: a perspective. Cancer Res 65: 7033. 
 (173)  Zhu Z., Sanchez-Sweatman O., Huang X., Wiltrout R., Khokha R., Zhao Q., et al. (2001) 
Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 61: 1707. 
 (174)  Dvorak H.F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma 
generation and wound healing. N Engl J Med 315: 1650. 
 (175)  Kim M., Gans J.D., Nogueira C., Wang A., Paik J.H., Feng B., et al. (2006) Comparative 
oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125: 1269. 
207528-L-bw-Schootbrugge
 
 
 
 
134 
 
 (176)  Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., et al. (2008) Rac 
activation and inactivation control plasticity of tumor cell movement. Cell 135: 510. 
 (177)  Guo W., Giancotti F.G. (2004) Integrin signalling during tumour progression. Nat Rev 
Mol Cell Biol 5: 816. 
 (178)  Bergers G., Benjamin L.E. (2003) Tumorigenesis and the angiogenic switch. Nat Rev 
Cancer 3: 401. 
 (179)  Kalluri R. (2003) Basement membranes: structure, assembly and role in tumour 
angiogenesis. Nat Rev Cancer 3: 422. 
 (180)  Roskoski R., Jr. (2007) Vascular endothelial growth factor (VEGF) signaling in tumor 
progression. Crit Rev Oncol Hematol 62: 179. 
 (181)  Harris A.L. (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 
2: 38. 
 (182)  Lu X., Kang Y. (2010) Hypoxia and hypoxia-inducible factors: master regulators of 
metastasis. Clin Cancer Res 16: 5928. 
 (183)  Semenza G.L. (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721. 
 (184)  Bussink J., van der Kogel A.J., Kaanders J.H. (2008) Patterns and levels of hypoxia in 
head and neck squamous cell carcinomas and their relationship to patient outcome: in 
regard to Evans et al. (Int J Radiat Oncol Biol Phys 2007;69:1024-1031). Int J Radiat 
Oncol Biol Phys 70: 1616. 
 (185)  Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., Bussink J. 
(2008) Molecular aspects of tumour hypoxia. Mol Oncol 2: 41. 
 (186)  Harrison L.B., Chadha M., Hill R.J., Hu K., Shasha D. (2002) Impact of tumor hypoxia 
and anemia on radiation therapy outcomes. Oncologist 7: 492. 
 (187)  Chaudary N., Hill R.P. (2009) Increased expression of metastasis-related genes in 
hypoxic cells sorted from cervical and lymph nodal xenograft tumors. Lab Invest 89: 587. 
 (188)  Raghunand N., Gatenby R.A., Gillies R.J. (2003) Microenvironmental and cellular 
consequences of altered blood flow in tumours. Br J Radiol 76 Spec No 1: S11-S22. 
 (189)  Ahn G.O., Brown M. (2007) Targeting tumors with hypoxia-activated cytotoxins. Front 
Biosci 12: 3483. 
 (190)  Semenza G.L. (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 
1. Semin Cancer Biol 19: 12. 
 (191)  Bristow R.G., Hill R.P. (2008) Hypoxia and metabolism. Hypoxia, DNA repair and 
genetic instability. Nat Rev Cancer 8: 180. 
 (192)  Lunt S.J., Chaudary N., Hill R.P. (2009) The tumor microenvironment and metastatic 
disease. Clin Exp Metastasis 26: 19. 
 (193)  Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., et al. (2006) 
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value 
of its measurement in the management of cancer therapy. Int J Radiat Biol 82: 699. 
 (194)  Liu Y., Song X., Wang X., Wei L., Liu X., Yuan S., et al. (2010) Effect of chronic 
intermittent hypoxia on biological behavior and hypoxia-associated gene expression in 
lung cancer cells. J Cell Biochem 111: 554. 
 (195)  Jain R.K. (2009) A new target for tumor therapy. N Engl J Med 360: 2669. 
 (196)  Fukumura D., Duda D.G., Munn L.L., Jain R.K. (2010) Tumor microvasculature and 
microenvironment: novel insights through intravital imaging in pre-clinical models. 
Microcirculation 17: 206. 
 (197)  Mazzone M., Dettori D., Leite de O.R., Loges S., Schmidt T., Jonckx B., et al. (2009) 
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via 
endothelial normalization. Cell 136: 839. 
 (198)  Toffoli S., Michiels C. (2008) Intermittent hypoxia is a key regulator of cancer cell and 
endothelial cell interplay in tumours. FEBS J 275: 2991. 
207528-L-bw-Schootbrugge
 
 
 
 
135 
 
 (199)  Zhu X., Zuo L., Cardounel A.J., Zweier J.L., He G. (2007) Characterization of in vivo 
tissue redox status, oxygenation, and formation of reactive oxygen species in 
postischemic myocardium. Antioxid Redox Signal 9: 447. 
 (200)  Prabhakar N.R., Kumar G.K., Nanduri J., Semenza G.L. (2007) ROS signaling in 
systemic and cellular responses to chronic intermittent hypoxia. Antioxid Redox Signal 
9: 1397. 
 (201)  Sandin A., Dagnell M., Gonon A., Pernow J., Stangl V., Aspenstrom P., et al. (2011) 
Hypoxia followed by re-oxygenation induces oxidation of tyrosine phosphatases. Cell 
Signal 23: 820. 
 (202)  Morgan M.J., Kim Y.S., Liu Z.G. (2008) TNFalpha and reactive oxygen species in 
necrotic cell death. Cell Res 18: 343. 
 (203)  Hussain S.P., Hofseth L.J., Harris C.C. (2003) Radical causes of cancer. Nat Rev Cancer 
3: 276. 
 (204)  Wu W.S. (2006) The signaling mechanism of ROS in tumor progression. Cancer 
Metastasis Rev 25: 695. 
 (205)  Masuda S. (2012) Breast cancer pathology: the impact of molecular taxonomy on 
morphological taxonomy. Pathol Int 62: 295. 
 (206)  Elston C.W. (1984) The assessment of histological differentiation in breast cancer. Aust 
N Z J Surg 54: 11. 
 (207)  Boscolo-Rizzo P., Maronato F., Marchiori C., Gava A., Da Mosto M.C. (2008) Long-
term quality of life after total laryngectomy and postoperative radiotherapy versus 
concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 118: 300. 
 (208)  Vergeer M.R., Doornaert P.A., Rietveld D.H., Leemans C.R., Slotman B.J., Langendijk 
J.A. (2009) Intensity-modulated radiotherapy reduces radiation-induced morbidity and 
improves health-related quality of life: results of a nonrandomized prospective study 
using a standardized follow-up program. Int J Radiat Oncol Biol Phys 74: 1. 
 (209)  Ross G.M. (1999) Induction of cell death by radiotherapy. Endocr Relat Cancer 6: 41. 
 (210)  Zhang N., Erjala K., Kulmala J., Qiu X., Sundvall M., Elenius K., et al. (2009) 
Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head 
and neck in vitro. Radiother Oncol 92: 388. 
 (211)  Borek C. (2004) Antioxidants and radiation therapy. J Nutr 134: 3207S. 
 (212)  Fang Y.Z., Yang S., Wu G. (2002) Free radicals, antioxidants, and nutrition. Nutrition 
18: 872. 
 (213)  Kaanders J.H., Bussink J., van der Kogel A.J. (2004) Clinical studies of hypoxia 
modification in radiotherapy. Semin Radiat Oncol 14: 233. 
 (214)  Bache M., Kappler M., Said H.M., Staab A., Vordermark D. (2008) Detection and 
specific targeting of hypoxic regions within solid tumors: current preclinical and clinical 
strategies. Curr Med Chem 15: 322. 
 (215)  Vincenzi B., Zoccoli A., Pantano F., Venditti O., Galluzzo S. (2010) Cetuximab: from 
bench to bedside. Curr Cancer Drug Targets 10: 80. 
 (216)  Mehra R., Cohen R.B., Burtness B.A. (2008) The role of cetuximab for the treatment of 
squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6: 742. 
 (217)  Goerner M., Seiwert T.Y., Sudhoff H. (2010) Molecular targeted therapies in head and 
neck cancer--an update of recent developments-. Head Neck Oncol 2: 8. 
 (218)  Seiwert T.Y., Cohen E.E. (2008) Targeting angiogenesis in head and neck cancer. Semin 
Oncol 35: 274. 
 (219)  Steelman L.S., Chappell W.H., Abrams S.L., Kempf R.C., Long J., Laidler P., et al. 
(2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling 
growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 
3: 192. 
207528-L-bw-Schootbrugge
 
 
 
 
136 
 
 (220)  Chin D., Boyle G.M., Williams R.M., Ferguson K., Pandeya N., Pedley J., et al. (2005) 
Alpha B-crystallin, a new independent marker for poor prognosis in head and neck 
cancer. Laryngoscope 115: 1239. 
 (221)  Boslooper K., King-Yin L.A., Gao J., Weinstein S., Johnson N. (2008) The 
clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head 
and neck squamous cell carcinoma. Pathology 40: 500. 
 (222)  Sitterding S.M., Wiseman W.R., Schiller C.L., Luan C., Chen F., Moyano J.V., et al. 
(2008) AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast 
carcinomas. Ann Diagn Pathol 12: 33. 
 (223)  Kim H.S., Lee Y., Lim Y.A., Kang H.J., Kim L.S. (2011) alphaB-Crystallin is a Novel 
Oncoprotein Associated with Poor Prognosis in Breast Cancer. J Breast Cancer 14: 14. 
 (224)  Gruvberger-Saal S.K., Parsons R. (2006) Is the small heat shock protein alphaB-
crystallin an oncogene? J Clin Invest 116: 30. 
 (225)  Ghosh J.G., Shenoy A.K., Jr., Clark J.I. (2007) Interactions between important 
regulatory proteins and human alphaB crystallin. Biochemistry 46: 6308. 
 (226)  Kase S., He S., Sonoda S., Kitamura M., Spee C., Wawrousek E., et al. (2010) alphaB-
crystallin regulation of angiogenesis by modulation of VEGF. Blood 115: 3398. 
 (227)  Kerr B.A., Byzova T.V. (2010) alphaB-crystallin: a novel VEGF chaperone. Blood 115: 
3181. 
 (228)  Martiny-Baron G., Marme D. (1995) VEGF-mediated tumour angiogenesis: a new target 
for cancer therapy. Curr Opin Biotechnol 6: 675. 
 (229)  Hu Z., Fan C., Livasy C., He X., Oh D.S., Ewend M.G., et al. (2009) A compact VEGF 
signature associated with distant metastases and poor outcomes. BMC Med 7: 9. 
 (230)  Bremnes R.M., Camps C., Sirera R. (2006) Angiogenesis in non-small cell lung cancer: 
the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours 
and blood. Lung Cancer 51: 143. 
 (231)  Leemans C.R., Braakhuis B.J., Brakenhoff R.H. (2011) The molecular biology of head 
and neck cancer. Nat Rev Cancer 11: 9. 
 (232)  Hoogsteen I.J., Marres H.A., Wijffels K.I., Rijken P.F., Peters J.P., van den Hoogen F.J., 
et al. (2005) Colocalization of carbonic anhydrase 9 expression and cell proliferation in 
human head and neck squamous cell carcinoma. Clin Cancer Res 11: 97. 
 (233)  Troost E.G., Bussink J., Slootweg P.J., Peeters W.J., Merkx M.A., van der Kogel A.J., et 
al. (2010) Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in 
squamous cell carcinoma of the oral cavity. J Nucl Med 51: 713. 
 (234)  Rijken P.F., Bernsen H.J., Peters J.P., Hodgkiss R.J., Raleigh J.A., van der Kogel A.J. 
(2000) Spatial relationship between hypoxia and the (perfused) vascular network in a 
human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol 
Biol Phys 48: 571. 
 (235)  Yaromina A., Zips D., Thames H.D., Eicheler W., Krause M., Rosner A., et al. (2006) 
Pimonidazole labelling and response to fractionated irradiation of five human squamous 
cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in 
biomarker studies. Radiother Oncol 81: 122. 
 (236)  Span P.N., Grebenchtchikov N., Geurts-Moespot J., Westphal J.R., Lucassen A.M., 
Sweep C.G. (2000) EORTC Receptor and Biomarker Study Group Report: a sandwich 
enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and 
tumor tissue extracts. Int J Biol Markers 15: 184. 
 (237)  Zusterzeel P.L., Span P.N., Dijksterhuis M.G., Thomas C.M., Sweep F.C., Massuger L.F. 
(2009) Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. 
J Cancer Res Clin Oncol 135: 283. 
 (238)  Geback T., Schulz M.M., Koumoutsakos P., Detmar M. (2009) TScratch: a novel and 
207528-L-bw-Schootbrugge
 
 
 
 
137 
 
simple software tool for automated analysis of monolayer wound healing assays. 
Biotechniques 46: 265. 
 (239)  Goplen D., Bougnaud S., Rajcevic U., Boe S.O., Skaftnesmo K.O., Voges J., et al. (2010) 
alphaB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. 
Am J Pathol 177: 1618. 
 (240)  Tang Q., Liu Y.F., Zhu X.J., Li Y.H., Zhu J., Zhang J.P., et al. (2009) Expression and 
prognostic significance of the alpha B-crystallin gene in human hepatocellular 
carcinoma. Hum Pathol 40: 300. 
 (241)  Cicek M., Samant R.S., Kinter M., Welch D.R., Casey G. (2004) Identification of 
metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and 
metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clin Exp Metastasis 21: 
149. 
 (242)  Ivanov O., Chen F., Wiley E.L., Keswani A., Diaz L.K., Memmel H.C., et al. (2008) 
alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in 
breast cancer. Breast Cancer Res Treat 111: 411. 
 (243)  Hicklin D.J., Ellis L.M. (2005) Role of the vascular endothelial growth factor pathway in 
tumor growth and angiogenesis. J Clin Oncol 23: 1011. 
 (244)  Christopoulos A., Ahn S.M., Klein J.D., Kim S. (2010) Biology of vascular endothelial 
growth factor and its receptors in head and neck cancer: Beyond angiogenesis. Head 
Neck. 
 (245)  Dimberg A., Rylova S., Dieterich L.C., Olsson A.K., Schiller P., Wikner C., et al. (2008) 
alphaB-crystallin promotes tumor angiogenesis by increasing vascular survival during 
tube morphogenesis. Blood 111: 2015. 
 (246)  Ruan Q., Han S., Jiang W.W., Boulton M.E., Chen Z.J., Law B.K., et al. (2011) 
{alpha}B-crystallin, a effecter of unfolded protein response, confers anti-VEGF 
resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. Mol 
Cancer Res. 
 (247)  Naresh K.N., Nerurkar A.Y., Borges A.M. (2001) Angiogenesis is redundant for tumour 
growth in lymph node metastases. Histopathology 38: 466. 
 (248)  Kyzas P.A., Stefanou D., Batistatou A., Agnantis N.J. (2005) Prognostic significance of 
VEGF immunohistochemical expression and tumor angiogenesis in head and neck 
squamous cell carcinoma. J Cancer Res Clin Oncol 131: 624. 
 (249)  Endo K., Shirai A., Furukawa M., Yoshizaki T. (2006) Prognostic value of cell motility 
activation factors in patients with tongue squamous cell carcinoma. Hum Pathol 37: 
1111. 
 (250)  Ho P.Y., Chueh S.C., Chiou S.H., Wang S.M., Lin W.C., Lee I.L., et al. (2012) alphaB-
Crystallin in clear cell renal cell carcinoma: Tumor progression and prognostic 
significance. Urol Oncol. 
 (251)  Benke E.M., Ji Y., Patel V., Wang H., Miyazaki H., Yeudall W.A. (2010) VEGF-C 
contributes to head and neck squamous cell carcinoma growth and motility. Oral Oncol 
46: e19-e24. 
 (252)  Lucas J.T., Jr., Salimath B.P., Slomiany M.G., Rosenzweig S.A. (2010) Regulation of 
invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 
29: 4449. 
 (253)  Singh B.N., Rao K.S., Ramakrishna T., Rangaraj N., Rao C. (2007) Association of 
alphaB-crystallin, a small heat shock protein, with actin: role in modulating actin 
filament dynamics in vivo. J Mol Biol 366: 756. 
 (254)  Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. (1997) Tumor 
hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat 
Oncol Biol Phys 38: 285. 
207528-L-bw-Schootbrugge
 
 
 
 
138 
 
 (255)  Ralph S.J., Rodriguez-Enriquez S., Neuzil J., Saavedra E., Moreno-Sanchez R. (2010) 
The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic 
transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 31: 
145. 
 (256)  Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. (2003) Oxidative DNA damage: 
mechanisms, mutation, and disease. FASEB J 17: 1195. 
 (257)  Parcellier A., Schmitt E., Brunet M., Hammann A., Solary E., Garrido C. (2005) Small 
heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic 
functions. Antioxid Redox Signal 7: 404. 
 (258)  Kamradt M.C., Chen F., Sam S., Cryns V.L. (2002) The small heat shock protein alpha 
B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting 
caspase-3 activation. J Biol Chem 277: 38731. 
 (259)  Tallot P., Grongnet J.F., David J.C. (2003) Dual perinatal and developmental expression 
of the small heat shock proteins [FC12]aB-crystallin and Hsp27 in different tissues of the 
developing piglet. Biol Neonate 83: 281. 
 (260)  Mao Y., Zhang D.W., Lin H., Xiong L., Liu Y., Li Q.D., et al. (2012) Alpha B-crystallin 
is a new prognostic marker for laryngeal squamous cell carcinoma. J Exp Clin Cancer 
Res 31: 101. 
 (261)  van de Schootbrugge C., Bussink J., Span P.N., Sweep F.C., Grenman R., Stegeman H., 
et al. (2013) alphaB-crystallin stimulates VEGF secretion and tumor cell migration and 
correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. 
BMC Cancer 13: 128. 
 (262)  Chelouche-Lev D., Kluger H.M., Berger A.J., Rimm D.L., Price J.E. (2004) alphaB-
crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 100: 
2543. 
 (263)  Nefti O., Grongnet J.F., David J.C. (2005) Overexpression of alphaB crystallin in the 
gastrointestinal tract of the newborn piglet after hypoxia. Shock 24: 455. 
 (264)  Louapre P., Grongnet J.F., Tanguay R.M., David J.C. (2005) Effects of hypoxia on stress 
proteins in the piglet heart at birth. Cell Stress Chaperones 10: 17. 
 (265)  Wessel G.M., McClay D.R. (1986) Two embryonic, tissue-specific molecules identified 
by a double-label immunofluorescence technique for monoclonal antibodies. J Histochem 
Cytochem 34: 703. 
 (266)  Rademakers S.E., Lok J., van der Kogel A.J., Bussink J., Kaanders J.H. (2011) Metabolic 
markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, 
HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11: 167. 
 (267)  Li C., Jackson R.M. (2002) Reactive species mechanisms of cellular hypoxia-
reoxygenation injury. Am J Physiol Cell Physiol 282: C227-C241. 
 (268)  Onozuka H., Tsuchihara K., Esumi H. (2011) Hypoglycemic/hypoxic condition in vitro 
mimicking the tumor microenvironment markedly reduced the efficacy of anticancer 
drugs. Cancer Sci 102: 975. 
 (269)  Malhotra R., Brosius F.C., III. (1999) Glucose uptake and glycolysis reduce hypoxia-
induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 274: 12567. 
 (270)  Sandulache V.C., Ow T.J., Pickering C.R., Frederick M.J., Zhou G., Fokt I., et al. (2011) 
Glucose, not glutamine, is the dominant energy source required for proliferation and 
survival of head and neck squamous carcinoma cells. Cancer 117: 2926. 
 (271)  Meijer T.W., Kaanders J.H., Span P.N., Bussink J. (2012) Targeting hypoxia, HIF-1, and 
tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18: 5585. 
 (272)  Perez-Perri J.I., Acevedo J.M., Wappner P. (2011) Epigenetics: new questions on the 
response to hypoxia. Int J Mol Sci 12: 4705. 
 (273)  Johnson A.B., Denko N., Barton M.C. (2008) Hypoxia induces a novel signature of 
207528-L-bw-Schootbrugge
 
 
 
 
139 
 
chromatin modifications and global repression of transcription. Mutat Res 640: 174. 
 (274)  Imura T., Shimohama S., Sato M., Nishikawa H., Madono K., Akaike A., et al. (1999) 
Differential expression of small heat shock proteins in reactive astrocytes after focal 
ischemia: possible role of beta-adrenergic receptor. J Neurosci 19: 9768. 
 (275)  Li T., Mo X., Jiang Z., He W., Lu W., Zhang H., et al. (2012) Study of alphaB-crystallin 
expression in Gerbil BCAO model of transient global cerebral ischemia. Oxid Med Cell 
Longev 2012: 945071. 
 (276)  Bertuzzi A., Fasano A., Gandolfi A., Sinisgalli C. (2010) Necrotic core in EMT6/Ro 
tumour spheroids: Is it caused by an ATP deficit? J Theor Biol 262: 142. 
 (277)  Takahashi E. (2008) Anoxic cell core can promote necrotic cell death in cardiomyocytes 
at physiological extracellular PO2. Am J Physiol Heart Circ Physiol 294: H2507-H2515. 
 (278)  Naranjo-Suarez S., Carlson B.A., Tsuji P.A., Yoo M.H., Gladyshev V.N., Hatfield D.L. 
(2012) HIF-independent regulation of thioredoxin reductase 1 contributes to the high 
levels of reactive oxygen species induced by hypoxia. PLoS One 7: e30470. 
 (279)  Bennewith K.L., Raleigh J.A., Durand R.E. (2002) Orally administered pimonidazole to 
label hypoxic tumor cells. Cancer Res 62: 6827. 
 (280)  Bennewith K.L., Durand R.E. (2004) Quantifying transient hypoxia in human tumor 
xenografts by flow cytometry. Cancer Res 64: 6183. 
 (281)  Yaung J., Jin M., Barron E., Spee C., Wawrousek E.F., Kannan R., et al. (2007) alpha-
Crystallin distribution in retinal pigment epithelium and effect of gene knockouts on 
sensitivity to oxidative stress. Mol Vis 13: 566. 
 (282)  Vaupel P. (2004) Tumor microenvironmental physiology and its implications for 
radiation oncology. Semin Radiat Oncol 14: 198. 
 (283)  Jung J.E., Lee H.G., Cho I.H., Chung D.H., Yoon S.H., Yang Y.M., et al. (2005) STAT3 
is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma 
cells. FASEB J 19: 1296. 
 (284)  Rofstad E.K., Gaustad J.V., Egeland T.A., Mathiesen B., Galappathi K. (2010) Tumors 
exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and 
metastatic dissemination. Int J Cancer 127: 1535. 
 (285)  Chaudary N., Hill R.P. (2007) Hypoxia and metastasis. Clin Cancer Res 13: 1947. 
 (286)  Volkmann J., Reuning U., Rudelius M., Hafner N., Schuster T., AB V.R., et al. (2012) 
High expression of crystallin alphaB represents an independent molecular marker for 
unfavourable ovarian cancer patient outcome and impairs T. Int J Cancer. 
 (287)  Toft D.J., Cryns V.L. (2011) Minireview: Basal-like breast cancer: from molecular 
profiles to targeted therapies. Mol Endocrinol 25: 199. 
 (288)  Chacon R.D., Costanzo M.V. (2010) Triple-negative breast cancer. Breast Cancer Res 
12 Suppl 2: S3. 
 (289)  Da S.L., Clarke C., Lakhani S.R. (2007) Demystifying basal-like breast carcinomas. J 
Clin Pathol 60: 1328. 
 (290)  Kobayashi S. (2008) Basal-like subtype of breast cancer: a review of its unique 
characteristics and their clinical significance. Breast Cancer 15: 153. 
 (291)  Podo F., Buydens L.M., Degani H., Hilhorst R., Klipp E., Gribbestad I.S., et al. (2010) 
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 4: 
209. 
 (292)  Tsang J.Y., Lai M.W., Wong K.H., Chan S.K., Lam C.C., Tsang A.K., et al. (2012) 
alphaB-crystallin is a useful marker for triple negative and basal breast cancers. 
Histopathology 61: 378. 
 (293)  Jechlinger M., Grunert S., Beug H. (2002) Mechanisms in epithelial plasticity and 
metastasis: insights from 3D cultures and expression profiling. J Mammary Gland Biol 
Neoplasia 7: 415. 
207528-L-bw-Schootbrugge
 
 
 
 
140 
 
 (294)  Oh H.Y., Lee E.J., Yoon S., Chung B.H., Cho K.S., Hong S.J. (2007) Cholesterol level of 
lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through 
EGFR-mediated Akt and ERK signal transduction. Prostate 67: 1061. 
 (295)  Kashyap A.S., Hollier B.G., Manton K.J., Satyamoorthy K., Leavesley D.I., Upton Z. 
(2011) Insulin-like growth factor-I:vitronectin complex-induced changes in gene 
expression effect breast cell survival and migration. Endocrinology 152: 1388. 
 (296)  Nagelkerke A., van Kuijk S.J., Sweep F.C., Nagtegaal I.D., Hoogerbrugge N., Martens 
J.W., et al. (2011) Constitutive expression of gamma-H2AX has prognostic relevance in 
triple negative breast cancer. Radiother Oncol 101: 39. 
 (297)  Wennemers M., Bussink J., Grebenchtchikov N., Sweep F.C., Span P.N. (2011) TRIB3 
protein denotes a good prognosis in breast cancer patients and is associated with 
hypoxia sensitivity. Radiother Oncol 101: 198. 
 (298)  Hudis C.A., Gianni L. (2011) Triple-negative breast cancer: an unmet medical need. 
Oncologist 16 Suppl 1: 1. 
 (299)  Allen L.F., Sebolt-Leopold J., Meyer M.B. (2003) CI-1040 (PD184352), a targeted 
signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30: 105. 
 (300)  Umemura S., Yoshida S., Ohta Y., Naito K., Osamura R.Y., Tokuda Y. (2007) Increased 
phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 98: 1889. 
 (301)  Chrestensen C.A., Shuman J.K., Eschenroeder A., Worthington M., Gram H., Sturgill 
T.W. (2007) MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. J 
Biol Chem 282: 4243. 
 (302)  Alvarez R.H., Valero V., Hortobagyi G.N. (2010) Emerging targeted therapies for breast 
cancer. J Clin Oncol 28: 3366. 
 (303)  Morrison L.E., Hoover H.E., Thuerauf D.J., Glembotski C.C. (2003) Mimicking 
phosphorylation of alphaB-crystallin on serine-59 is necessary and sufficient to provide 
maximal protection of cardiac myocytes from apoptosis. Circ Res 92: 203. 
 (304)  Inaguma Y., Hasegawa K., Goto S., Ito H., Kato K. (1995) Induction of the synthesis of 
hsp27 and alpha B crystallin in tissues of heat-stressed rats and its suppression by 
ethanol or an alpha 1-adrenergic antagonist. J Biochem 117: 1238. 
 (305)  Acunzo J., Katsogiannou M., Rocchi P. (2012) Small heat shock proteins HSP27 
(HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int 
J Biochem Cell Biol. 
 (306)  Wettstein G., Bellaye P.S., Micheau O., Bonniaud P. (2012) Small heat shock proteins 
and the cytoskeleton: an essential interplay for cell integrity? Int J Biochem Cell Biol 44: 
1680. 
 (307)  Ecroyd H., Meehan S., Horwitz J., Aquilina J.A., Benesch J.L., Robinson C.V., et al. 
(2007) Mimicking phosphorylation of alphaB-crystallin affects its chaperone activity. 
Biochem J 401: 129. 
 (308)  Koteiche H.A., Mchaourab H.S. (2003) Mechanism of chaperone function in small heat-
shock proteins. Phosphorylation-induced activation of two-mode binding in alphaB-
crystallin. J Biol Chem 278: 10361. 
 (309)  van den IJssel P., Wheelock R., Prescott A., Russell P., Quinlan R.A. (2003) Nuclear 
speckle localisation of the small heat shock protein alpha B-crystallin and its inhibition 
by the R120G cardiomyopathy-linked mutation. Exp Cell Res 287: 249. 
 (310)  van Rijk A.E., Stege G.J., Bennink E.J., May A., Bloemendal H. (2003) Nuclear staining 
for the small heat shock protein alphaB-crystallin colocalizes with splicing factor SC35. 
Eur J Cell Biol 82: 361. 
 (311)  den Engelsman J., Gerrits D., de Jong W.W., Robbins J., Kato K., Boelens W.C. (2005) 
Nuclear import of {alpha}B-crystallin is phosphorylation-dependent and hampered by 
hyperphosphorylation of the myopathy-related mutant R120G. J Biol Chem 280: 37139. 
207528-L-bw-Schootbrugge
 
 
 
 
141 
 
 (312)  Vos M.J., Kanon B., Kampinga H.H. (2009) HSPB7 is a SC35 speckle resident small 
heat shock protein. Biochim Biophys Acta 1793: 1343. 
 (313)  Spector D.L., Lamond A.I. (2011) Nuclear speckles. Cold Spring Harb Perspect Biol 3. 
 (314)  Fischer U., Liu Q., Dreyfuss G. (1997) The SMN-SIP1 complex has an essential role in 
spliceosomal snRNP biogenesis. Cell 90: 1023. 
 (315)  Narayanan U., Achsel T., Luhrmann R., Matera A.G. (2004) Coupled in vitro import of U 
snRNPs and SMN, the spinal muscular atrophy protein. Mol Cell 16: 223. 
 (316)  Otter S., Grimmler M., Neuenkirchen N., Chari A., Sickmann A., Fischer U. (2007) A 
comprehensive interaction map of the human survival of motor neuron (SMN) complex. J 
Biol Chem 282: 5825. 
 (317)  Nollen E.A., Salomons F.A., Brunsting J.F., Want J.J., Sibon O.C., Kampinga H.H. 
(2001) Dynamic changes in the localization of thermally unfolded nuclear proteins 
associated with chaperone-dependent protection. Proc Natl Acad Sci U S A 98: 12038. 
 (318)  Heldens L., Dirks R.P., Hensen S.M., Onnekink C., van Genesen S.T., Rustenburg F., et 
al. (2010) Co-chaperones are limiting in a depleted chaperone network. Cell Mol Life 
Sci 67: 4035. 
 (319)  Adam S.A., Marr R.S., Gerace L. (1990) Nuclear protein import in permeabilized 
mammalian cells requires soluble cytoplasmic factors. J Cell Biol 111: 807. 
 (320)  Pellizzoni L., Yong J., Dreyfuss G. (2002) Essential role for the SMN complex in the 
specificity of snRNP assembly. Science 298: 1775. 
 (321)  Mattijssen S., Hinson E.R., Onnekink C., Hermanns P., Zabel B., Cresswell P., et al. 
(2011) Viperin mRNA is a novel target for the human RNase MRP/RNase P 
endoribonuclease. Cell Mol Life Sci 68: 2469. 
 (322)  Charroux B., Pellizzoni L., Perkinson R.A., Shevchenko A., Mann M., Dreyfuss G. 
(1999) Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular 
atrophy gene product, and is a component of gems. J Cell Biol 147: 1181. 
 (323)  Todd A.G., Morse R., Shaw D.J., McGinley S., Stebbings H., Young P.J. (2010) SMN, 
Gemin2 and Gemin3 associate with beta-actin mRNA in the cytoplasm of neuronal cells 
in vitro. J Mol Biol 401: 681. 
 (324)  Dingwall C., Palacios I. (1998) In vitro systems for the reconstitution of snRNP and 
protein nuclear import. Methods Cell Biol 53: 517. 
 (325)  Jeong W.J., Rho J.H., Yoon Y.G., Yoo S.H., Jeong N.Y., Ryu W.Y., et al. (2012) 
Cytoplasmic and Nuclear Anti-Apoptotic Roles of alphaB-Crystallin in Retinal Pigment 
Epithelial Cells. PLoS One 7: e45754. 
 (326)  Lamian V., Small G.M., Feldherr C.M. (1996) Evidence for the existence of a novel 
mechanism for the nuclear import of Hsc70. Exp Cell Res 228: 84. 
 (327)  Kodiha M., Chu A., Matusiewicz N., Stochaj U. (2004) Multiple mechanisms promote 
the inhibition of classical nuclear import upon exposure to severe oxidative stress. Cell 
Death Differ 11: 862. 
 (328)  Kose S., Furuta M., Imamoto N. (2012) Hikeshi, a nuclear import carrier for Hsp70s, 
protects cells from heat shock-induced nuclear damage. Cell 149: 578. 
 (329)  Aquilina J.A., Benesch J.L., Ding L.L., Yaron O., Horwitz J., Robinson C.V. (2004) 
Phosphorylation of alphaB-crystallin alters chaperone function through loss of dimeric 
substructure. J Biol Chem 279: 28675. 
 (330)  Narayanan U., Ospina J.K., Frey M.R., Hebert M.D., Matera A.G. (2002) SMN, the 
spinal muscular atrophy protein, forms a pre-import snRNP complex with snurportin1 
and importin beta. Hum Mol Genet 11: 1785. 
 (331)  Hamada M., Haeger A., Jeganathan K.B., van Ree J.H., Malureanu L., Walde S., et al. 
(2011) Ran-dependent docking of importin-beta to RanBP2/Nup358 filaments is essential 
for protein import and cell viability. J Cell Biol 194: 597. 
207528-L-bw-Schootbrugge
 
 
 
 
142 
 
 (332)  Sun X., Fontaine J.M., Hoppe A.D., Carra S., DeGuzman C., Martin J.L., et al. (2010) 
Abnormal interaction of motor neuropathy-associated mutant HspB8 (Hsp22) forms with 
the RNA helicase Ddx20 (gemin3). Cell Stress Chaperones 15: 567. 
 (333)  Bryantsev A.L., Chechenova M.B., Shelden E.A. (2007) Recruitment of phosphorylated 
small heat shock protein Hsp27 to nuclear speckles without stress. Exp Cell Res 313: 
195. 
 (334)  Adhikari A.S., Sridhar R.K., Rangaraj N., Parnaik V.K., Mohan R.C. (2004) Heat stress-
induced localization of small heat shock proteins in mouse myoblasts: intranuclear lamin 
A/C speckles as target for alphaB-crystallin and Hsp25. Exp Cell Res 299: 393. 
 (335)  Shi T., Dong F., Liou L.S., Duan Z.H., Novick A.C., DiDonato J.A. (2004) Differential 
protein profiling in renal-cell carcinoma. Mol Carcinog 40: 47. 
 (336)  Holcakova J., Hernychova L., Bouchal P., Brozkova K., Zaloudik J., Valik D., et al. 
(2008) Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by 
SELDI-TOF MS. Int J Biol Markers 23: 48. 
 (337)  Aoyama A., Steiger R.H., Frohli E., Schafer R., von D.A., Wiestler O.D., et al. (1993) 
Expression of alpha B-crystallin in human brain tumors. Int J Cancer 55: 760. 
 (338)  Iwaki T., Iwaki A., Miyazono M., Goldman J.E. (1991) Preferential expression of alpha 
B-crystallin in astrocytic elements of neuroectodermal tumors. Cancer 68: 2230. 
 (339)  Odreman F., Vindigni M., Gonzales M.L., Niccolini B., Candiano G., Zanotti B., et al. 
(2005) Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome 
Res 4: 698. 
 (340)  Mattila P.K., Lappalainen P. (2008) Filopodia: molecular architecture and cellular 
functions. Nat Rev Mol Cell Biol 9: 446. 
 (341)  Aggeli I.K., Beis I., Gaitanaki C. (2008) Oxidative stress and calpain inhibition induce 
alpha B-crystallin phosphorylation via p38-MAPK and calcium signalling pathways in 
H9c2 cells. Cell Signal 20: 1292. 
 (342)  Roux P.P., Blenis J. (2004) ERK and p38 MAPK-activated protein kinases: a family of 
protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320. 
 (343)  Aldridge S.E., Lennard T.W., Williams J.R., Birch M.A. (2005) Vascular endothelial 
growth factor acts as an osteolytic factor in breast cancer metastases to bone. Br J 
Cancer 92: 1531. 
 (344)  Konecny G.E., Meng Y.G., Untch M., Wang H.J., Bauerfeind I., Epstein M., et al. (2004) 
Association between HER-2/neu and vascular endothelial growth factor expression 
predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10: 1706. 
 (345)  Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., et al. (1997) 
Prognostic significance of vascular endothelial growth factor protein in node-negative 
breast carcinoma. J Natl Cancer Inst 89: 139. 
 (346)  Larsen A.K., Ouaret D., El O.K., Petitprez A. (2011) Targeting EGFR and VEGF(R) 
pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131: 80. 
 (347)  Lichtenberger B.M., Tan P.K., Niederleithner H., Ferrara N., Petzelbauer P., Sibilia M. 
(2010) Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote 
epithelial cancer development. Cell 140: 268. 
 (348)  Ciardiello F., Troiani T., Bianco R., Orditura M., Morgillo F., Martinelli E., et al. (2006) 
Interaction between the epidermal growth factor receptor (EGFR) and the vascular 
endothelial growth factor (VEGF) pathways: a rational approach for multi-target 
anticancer therapy. Ann Oncol 17 Suppl 7: vii109-vii114. 
 (349)  Chen Z., Ruan Q., Han S., Xi L., Jiang W., Jiang H., et al. (2014) Discovery of structure-
based small molecular inhibitor of alphaB-crystallin against basal-like/triple-negative 
breast cancer development in vitro and in vivo. Breast Cancer Res Treat 145: 45. 
 (350)  Rao G., Santhoshkumar P., Sharma K.K. (2008) Anti-chaperone betaA3/A1(102-117) 
207528-L-bw-Schootbrugge
 
 
 
 
143 
 
peptide interacting sites in human alphaB-crystallin. Mol Vis 14: 666. 
 (351)  Li Z.J., Cho C.H. (2012) Peptides as targeting probes against tumor vasculature for 
diagnosis and drug delivery. J Transl Med 10 Suppl 1: S1. 
 (352)  Macewan S.R., Chilkoti A. (2012) Harnessing the power of cell-penetrating peptides: 
activatable carriers for targeting systemic delivery of cancer therapeutics and imaging 
agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 
 (353)  Moktan S., Raucher D. (2012) Anticancer activity of proapoptotic peptides is highly 
improved by thermal targeting using elastin-like polypeptides. Int J Pept Res Ther 18: 
227. 
 (354)  Lee Y.J., Moon M.S., Kwon S.J., Rhee J.G. (2005) Hypoxia and low glucose 
differentially augments TRAIL-induced apoptotic death. Mol Cell Biochem 270: 89. 
 (355)  Gatenby R.A., Gillies R.J. (2004) Why do cancers have high aerobic glycolysis? Nat Rev 
Cancer 4: 891. 
 (356)  Alfarouk K.O., Muddathir A.K., Shayoub M.E. (2011) Tumor acidity as evolutionary 
spite. Cancers (Basel) 3: 408. 
 (357)  Liu S., Yan B., Lai W., Chen L., Xiao D., Xi S., et al. (2014) As a novel p53 direct 
target, bidirectional gene HspB2/alphaB-crystallin regulates the ROS level and Warburg 
effect. Biochim Biophys Acta 1839: 592. 
 (358)  Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. (2007) 
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer 
Res 13: 4429. 
 (359)  Shastry M., Yardley D.A. (2013) Updates in the treatment of basal/triple-negative breast 
cancer. Curr Opin Obstet Gynecol 25: 40. 
 (360)  Koletsa T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A.G., et al. 
(2014) alphaB-crystallin is a marker of aggressive breast cancer behavior but does not 
independently predict for patient outcome: a combined analysis of two randomized 
studies. BMC Clin Pathol 14: 28. 
 (361)  Brower V. (2011) Biomarkers: Portents of malignancy. Nature 471: S19-S21. 
 (362)  Badve S., Dabbs D.J., Schnitt S.J., Baehner F.L., Decker T., Eusebi V., et al. (2011) 
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the 
implications for pathologists and oncologists. Mod Pathol 24: 157. 
 (363)  Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. 
(2011) Identification of human triple-negative breast cancer subtypes and preclinical 
models for selection of targeted therapies. J Clin Invest 121: 2750. 
 (364)  Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A., et al. (2007) 
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and 
long-term survival. Breast Cancer Res 9: R4. 
 (365)  Rodriguez-Pinilla S.M., Sarrio D., Honrado E., Hardisson D., Calero F., Benitez J., et al. 
(2006) Prognostic significance of basal-like phenotype and fascin expression in node-
negative invasive breast carcinomas. Clin Cancer Res 12: 1533. 
 (366)  Tsuda H., Takarabe T., Hasegawa F., Fukutomi T., Hirohashi S. (2000) Large, central 
acellular zones indicating myoepithelial tumor differentiation in high-grade invasive 
ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg 
Pathol 24: 197. 
 (367)  Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. 
(2006) Breast cancers with brain metastases are more likely to be estrogen receptor 
negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J 
Surg Pathol 30: 1097. 
 (368)  Dewar R., Fadare O., Gilmore H., Gown A.M. (2011) Best practices in diagnostic 
immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med 
207528-L-bw-Schootbrugge
 
 
 
 
144 
 
135: 422. 
 (369)  Sopel M. (2010) The myoepithelial cell: its role in normal mammary glands and breast 
cancer. Folia Morphol (Warsz ) 69: 1. 
 (370)  Leibl S., Gogg-Kammerer M., Sommersacher A., Denk H., Moinfar F. (2005) 
Metaplastic breast carcinomas: are they of myoepithelial differentiation?: 
immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial 
markers. Am J Surg Pathol 29: 347. 
 (371)  Gusterson B. (2009) Do 'basal-like' breast cancers really exist? Nat Rev Cancer 9: 128. 
 (372)  Boecker W., Buerger H. (2003) Evidence of progenitor cells of glandular and 
myoepithelial cell lineages in the human adult female breast epithelium: a new 
progenitor (adult stem) cell concept. Cell Prolif 36 Suppl 1: 73. 
 (373)  Petersen O.W., Polyak K. (2010) Stem cells in the human breast. Cold Spring Harb 
Perspect Biol 2: a003160. 
 (374)  Fornerod M., Ohno M., Yoshida M., Mattaj I.W. (1997) CRM1 is an export receptor for 
leucine-rich nuclear export signals. Cell 90: 1051. 
 (375)  Strasser A., Dickmanns A., Schmidt U., Penka E., Urlaub H., Sekine M., et al. (2004) 
Purification, crystallization and preliminary crystallographic data of the m3G cap-
binding domain of human snRNP import factor snurportin 1. Acta Crystallogr D Biol 
Crystallogr 60: 1628. 
 (376)  Mitrousis G., Olia A.S., Walker-Kopp N., Cingolani G. (2008) Molecular basis for the 
recognition of snurportin 1 by importin beta. J Biol Chem 283: 7877. 
 (377)  Kolb S.J., Battle D.J., Dreyfuss G. (2007) Molecular functions of the SMN complex. J 
Child Neurol 22: 990. 
 (378)  Morimoto M., Boerkoel C.F. (2013) The Role of Nuclear Bodies in Gene Expression and 
Disease. Biology (Basel) 2: 976. 
 (379)  Cauchi R.J. (2010) SMN and Gemins: 'we are family' ... or are we?: insights into the 
partnership between Gemins and the spinal muscular atrophy disease protein SMN. 
Bioessays 32: 1077. 
 (380)  Dechat T., Pfleghaar K., Sengupta K., Shimi T., Shumaker D.K., Solimando L., et al. 
(2008) Nuclear lamins: major factors in the structural organization and function of the 
nucleus and chromatin. Genes Dev 22: 832. 
 (381)  Gruenbaum Y., Margalit A., Goldman R.D., Shumaker D.K., Wilson K.L. (2005) The 
nuclear lamina comes of age. Nat Rev Mol Cell Biol 6: 21. 
 (382)  Gonzalez-Suarez I., Redwood A.B., Gonzalo S. (2009) Loss of A-type lamins and 
genomic instability. Cell Cycle 8: 3860. 
 (383)  Warren D.T., Shanahan C.M. (2011) Defective DNA-damage repair induced by nuclear 
lamina dysfunction is a key mediator of smooth muscle cell aging. Biochem Soc Trans 
39: 1780. 
 (384)  Ho C.Y., Lammerding J. (2012) Lamins at a glance. J Cell Sci 125: 2087. 
 (385)  Foster C.R., Przyborski S.A., Wilson R.G., Hutchison C.J. (2010) Lamins as cancer 
biomarkers. Biochem Soc Trans 38: 297. 
 
 
 
207528-L-bw-Schootbrugge
 
 
 
 
145 
 
  
207528-L-bw-Schootbrugge
 
 
 
 
146 
 
SUMMARY 
 
αB-Crystallin, also known as HSPB5, is a member of the small heat shock family. In 
human, this family consists of 10 different members (HSPB1-10). Already in 1894 it 
was discovered that αB-crystallin is highly expressed in the eye lens of mammals. 
Later, it turned out that this protein is present in almost every tissue, especially in heart 
and muscle. Over the years, the function of this protein has been clarified. Cells contain 
many different proteins, which can be seen as 'the machines of the cell' that help the 
cells to perform their function. They can only work when they are folded in the correct 
way and may lose their proper folding when the cell is exposed to stress. Misfolded 
proteins are dangerous to the cell and are therefore trapped by chaperone proteins, 
which can refold these proteins or help them to be degraded via the ubiquitin-
proteasome-system. When this system malfunctions, the misfolded proteins can 
accumulate and aggregate, leading to a dysfunctional cell. Eventually, this can lead to 
diseases such as Parkinson’s, Huntington’s and Alzheimer’s disease. 
αB-Crystallin expression is increased in cells that are exposed to several kinds of 
stress, like heat stress, osmotic stress, hypoxia/reoxygenation stress, oxidative stress 
and stress caused by exposure to heavy metals (Chapter 1). The elevated expression 
levels are beneficial as αB-crystallin, alone or together with other HSPBs, is capable of 
binding (partly) unfolded proteins. These proteins can then be refolded by other 
chaperone proteins (for example HSP40 and HSP70), which prevents the breakdown of 
these proteins (Chapter 1). In this way, cells may function normally again as soon as 
the stress is over. Because αB-crystallin is beneficial for a cell, it is also connected to 
the pathogenesis of cancer. A tumor is formed when cells exhibit uncontrolled cell 
division and do not want to die in a proper way. Tumors can be benign or malignant. 
Characteristics of benign tumors are their low grow rates, their inability to invade other 
tissues and their lack of spreading to other parts of the body. Malignant tumors have 
the propensity to grow fast and invade surrounding tissues causing damage. The first 
tumor that forms is called the primary tumor. Tumors that later appear in other parts of 
the body are called secondary tumors or metastases (Chapter 2). In Chapter 3 we 
investigated whether and how αB-crystallin is involved in the development of head and 
neck squamous cell carcinoma (HNSCC). Previously, two studies were published 
about the presence of αB-crystallin in HNSCC and in both studies semi-quantitative 
methods were applied. One study showed that the presence of αB-crystallin could 
predict shorter survival of HNSCC patients, compared to patients with little or no αB-
crystallin in their tumors. In the other study the amount of αB-crystallin did not affect 
the prognosis of the patient. To obtain more certainty about the role of αB-crystallin, a 
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quantitative method was used to determine whether or not the amount of αB-crystallin 
correlated with a worse prognosis for the patient. During a period of 10 years patients 
were followed to investigate whether the primary tumor recurred, tumors were formed 
nearby the primary tumor or metastases were formed. We found that patients with high 
levels of αB-crystallin in their tumor biopsies had a shorter life-span as they had a 
higher chance of metastasis formation. In Chapter 2 the steps necessary for metastasis 
formation are explained, including cell migration through blood vessels from one part 
of the body to another. To facilitate this, important steps are increased cell motility and 
the formation of blood vessels (under influence of the VEGF protein). Previous 
research showed that αB-crystallin was present in the region of migrating pig epithelial 
lens cells and that it was necessary for cell migration. αB-Crystallin could therefore 
have an influence on cell motility. It had been shown before that more blood vessels 
were formed in damaged retina of mice when αB-crystallin was present in the cells, 
which was dependent on VEGF. To investigate this further, we determined if a 
decrease of the amount of αB-crystallin protein would influence the capacity of 
HNSCC cells to migrate or secrete VEGF. It was shown that the cells moved slower 
and secreted less VEGF when there was less αB-crystallin present. In other cells (HeLa 
cells) we increased the amount of αB-crystallin and these cells moved faster and 
secreted more VEGF. Thus, in case of a tumor, the presence of αB-crystallin might be 
associated with faster moving cells, which secrete more VEGF. This could contribute 
to metastasis formation. 
Most solid tumors contain areas that are not well oxygenated (termed hypoxia), as 
described in Chapter 2. This is due to a lack of or poorly developed blood vessels in 
the tumors. A shortage of oxygen is stressful for the cell. As the expression of αB-
crystallin can be upregulated due to several kinds of stress, we analyzed the presence of 
αB-crystallin in hypoxic areas in HNSCC biopsies using two fluorescent dyes, one 
indicative for αB-crystallin and one for hypoxia, in Chapter 4. As high proportions of 
the two dyes overlapped, we determined the influence of hypoxia on the expression of 
αB-crystallin mRNA and protein in HNSCC cells. We found that the amount of αB-
crystallin decreased instead of increased. As explained in Chapter 2 it is possible that 
sometimes blood flow stops and resumes in the poorly constructed blood vessels. This 
phenomenon is called hypoxia/reoxygenation. As a result of the sudden flow of 
oxygen, reactive oxygen species (ROS) can be formed. In Chapter 4 experiments are 
described in which we first exposed HNSCC cells to hypoxia and then reoxygenated 
the cells. The amount of αB-crystallin mRNA and protein decreased upon hypoxia and 
increased again upon reoxygenation. To determine whether the increase is due to ROS, 
HNSCC cells were exposed to higher levels of ROS by adding H2O2 or lower levels by 
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adding a reagent that captures ROS. The amount of αB-crystallin mRNA was increased 
under influence of ROS and decreased when ROS was captured. When ROS was 
captured during the reoxygenation phase, the amount of αB-crystallin mRNA increased 
to a lesser extent. This means that αB-crystallin expression during the reoxygenation 
phase indeed can be upregulated by ROS. Next, we showed that αB-crystallin can help 
cells to survive hypoxia. It was already known that tumors with a high amount of 
hypoxic cells are prone to form metastases (Chapter 2). As αB-crystallin can help to 
retain cells in the hypoxic regions, αB-crystallin could also contribute to the formation 
of metastases in this way.  
Another common type of cancer is breast cancer, which represents a very diverse group 
of tumors (Chapter 2). By studying the genes that are expressed in the breast tumor, a 
broad distinction can be made: tumors that show an expression pattern similar to 
normal breast cells, luminal A, luminal B, enriched for HER2 and the expression of 
basal-like genes (Chapter 2). These biomarkers are used to diagnose in an early stage 
or to improve treatment. Another subdivision that is used is based on the expression of 
certain types of receptors in the cells: the estrogen receptor (ER), the progesterone 
receptor (PR) and the HER2 receptor (Chapter 2). There are breast tumors that do not 
express any receptor, these are called 'triple-negative'. The triple-negative tumors often 
show a basal-like gene expression pattern and patients often have a worse prognosis. 
As described above, the presence of αB-crystallin also is an indication for a worse 
prognosis. In Chapter 5 we determined if the expression of αB-crystallin correlates 
with the expression of genes which are linked to the development of tumors (pERK1/2, 
pAKT, pmTOR, EGFR and IGF-1R). It was studied as well if αB-crystallin correlates 
with triple-negativity and the expression of basal-like genes (CK5/6 and SMA). For 
this purpose we used tissue microarrays (TMA), which allow analyzing different 
biopsies simultaneously. αB-Crystallin indeed correlated with both triple-negativity 
and the expression of basal-like genes. This could mean that patients with a high 
amount of αB-crystallin in their tumor biopsies would not benefit from medication 
directed against the ER, PR and/or the HER2-receptor, as chances are high that these 
receptors are not present in those tumors. For these patients another therapy could be 
considered. As the cells do contain αB-crystallin, the therapy could be directed against 
this protein. Recently, a peptide was developed, that can disrupt the interaction 
between αB-crystallin and VEGF (Chapter 7). This peptide slowed down tumor 
growth and the development of blood vessels. Possibly, this approach could be applied 
in the treatment of (breast) cancer.  
The function of proteins can be altered by amendments in the proteins, called post-
translation modifications. The function of the αB-crystallin protein can be amended by 
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adding a phosphate group at three different positions in the protein, serine 19, 45 and 
59 (Chapter 1). When serine 59 becomes phosphorylated, αB-crystallin is transported 
from the cytoplasm to the nucleus. Phosphorylation of serine 45 results in the 
accumulation of αB-crystallin in certain nuclear structures, called speckles. How αB-
crystallin is translocated to the nucleus and what the function is in the speckles was not 
known. In Chapter 6, we first analyzed how αB-crystallin ends up in the nucleus. 
Using a technique called 'yeast two-hybrid screening', we found that αB-crystallin, of 
which the phosphorylation of the three serine residues was mimicked (αB-STD), can 
bind a protein called Gemin3. This protein is part of the so-called SMN complex. This 
complex was already known to be involved in nuclear import of proteins. A decrease of 
the amount of Gemin2 (another protein in the SMN complex) and Gemin3 resulted in 
less αB-STD speckles in the nucleus. To obtain information about the function of the 
speckles, we studied what the result of cell stress was on the distribution of αB-
crystallin in the nucleus. We overexpressed αB-STD in HeLa cells and heated the cells 
for 45 minutes at 45oC (heat-shock) after which the cells were returned to 37oC. 
Directly and 6 hours after heat shock, αB-STD was diffusely distributed throughout the 
nucleus. After 24 hours, αB-STD was present in the speckles again. To determine 
whether nuclear αB-crystallin has chaperone activity, another protein (luciferase) was 
overexpressed in the nucleus. After heat-shock, the function of this protein was 
restored faster when αB-STD was present. These results suggest that phosphorylated 
αB-crystallin is stored in the speckles until it is needed. Under the influence of stress it 
is released from the speckles and can bind poorly-folded proteins. This way nuclear 
αB-crystallin helps these proteins to become re-folded and functional again. 
It is clear that αB-crystallin is a very versatile protein that can function in the 
cytoplasm as well as the nucleus. It is also clear that this protein can contribute to 
metastasis formation of (HNSCC) tumors. In this thesis, cellular processes are 
described that can be involved: increase of cell motility, increase of VEGF secretion 
and helping cell survival after hypoxia. The molecular mechanisms still have to be 
elucidated. It is therefore important that the contribution of αB-crystallin in these 
processes will be studied further. 
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SAMENVATTING 
 
αB-Crystalline, ook wel HSPB5 genoemd, behoort tot de familie van kleine 'heat-
shock' eiwitten. Bij de mens bestaat deze familie uit 10 verschillende leden (HSPB1-
10). Al in 1894 is ontdekt dat αB-crystalline veel voorkomt in de ooglens van 
zoogdieren. Later is gebleken dat αB-crystalline in bijna elk weefsel aanwezig is, met 
name in het hart en in spieren. De functie van dit eiwit werd in de loop der jaren 
opgehelderd. Cellen bevatten zeer veel verschillende eiwitten, die de 'machines van de 
cel' worden genoemd en ervoor zorgen dat de cel kan functioneren. Ze kunnen hun 
werk slechts doen als ze op de juiste manier gevouwen zijn. Ze kunnen echter hun 
structuur verliezen wanneer de cel blootgesteld wordt aan stress. Slecht gevouwen 
eiwitten zijn gevaarlijk voor de cel en worden daarom opgevangen door zogeheten 
chaperonne eiwitten, die proberen de eiwitten te hervouwen of af te laten breken door 
middel van het zogenaamde ubiquitine-proteasoom-systeem. Als dit niet goed gebeurt 
kunnen de slecht gevouwen eiwitten zich gaan ophopen en samenklonteren, waardoor 
de cel niet meer normaal functioneert. Uiteindelijk kunnen hierdoor ziektes ontstaan, 
zoals de ziekte van Parkinson, Huntington en Alzheimer.  
αB-Crystalline komt verhoogd tot expressie in cellen die blootgesteld zijn aan 
verschillende soorten stress, zoals hittestress, osmotische stress, hypoxie/reoxygenering 
stress, oxidatieve stress en stress veroorzaakt door de blootstelling aan zware metalen 
(Hoofdstuk 1). De verhoogde aanwezigheid bij stress is gunstig, omdat αB-crystalline, 
alleen of in samenwerking met andere HSPBs, in staat is om (deels) ontvouwen 
eiwitten te binden. Hierna kunnen deze eiwitten door andere chaperonne eiwitten 
(bijvoorbeeld HSP40 en HSP70) weer teruggevouwen worden in de juiste structuur en 
hoeven dus niet te worden afgebroken (Hoofdstuk 1). De cel is op deze manier na 
blootstelling aan stress zo snel als mogelijk weer in staat normaal te functioneren. 
Omdat de aanwezigheid van αB-crystalline gunstig is voor de cel wordt dit ook in 
verband gebracht met het ontstaan van verschillende soorten kanker. Kanker ontstaat 
wanneer de celdeling op hol slaat en cellen niet op de reguliere manier doodgaan. 
Tumoren kunnen goedaardig en kwaadaardig zijn. Kenmerken van goedaardige 
tumoren zijn dat ze langzaam groeien, ze geen andere weefsels binnendringen en zich 
niet verder verspreiden in het lichaam. Kwaadaardige tumoren hebben de neiging om 
heel snel te groeien. Ze dringen ook de nabijgelegen weefsels en organen binnen, 
waardoor deze beschadigd raken. De tumor die zich het eerst ontwikkelt, heet de 
primaire tumor. Tumoren die zich later ontwikkelen in andere delen van het lichaam 
(uitzaaien) heten secundaire tumoren of metastasen (Hoofdstuk 2). In Hoofdstuk 3 van 
dit proefschrift hebben we gekeken of en hoe het eiwit αB-crystalline een rol kan 
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spelen bij de ontwikkeling van kwaadaardige hoofd-/halskanker (in het Engels head 
and neck squamous cell carcinoma genoemd, afgekort HNSCC). Over het voorkomen 
van αB-crystalline in HNSCC tumoren zijn al twee studies gepubliceerd, waarbij 
gebruik is gemaakt van semi-kwantitatieve analysemethoden. Een van deze studies liet 
zien dat de aanwezigheid van αB-crystalline zou kunnen voorspellen dat patiënten met 
HNSCC korter leven dan patiënten met weinig of geen αB-crystalline in hun tumoren. 
In de andere studie werd het verband tussen prognose en de hoeveelheid aB-crystalline 
niet gevonden. Om meer duidelijkheid te krijgen over de rol van αB-crystalline is in 
Hoofdstuk 3 op een kwantitatieve manier geanalyseerd of de hoeveelheid αB-
crystalline in een primair tumorbiopt correleerde met een slechtere prognose voor de 
patiënt. Er is bij patiënten met HNSCC gedurende een periode van 10 jaar onderzocht 
of de primaire tumor terugkeerde, of er tumoren in de buurt van de primaire tumor 
werden gevormd, of dat er metastasen gevormd werden. Het bleek dat patiënten met 
veel αB-crystalline in het primaire tumorbiopt korter leefden, omdat ze een grotere 
kans hadden om metastasen te ontwikkelen. In Hoofdstuk 2 wordt uitgelegd welke 
stappen er nodig zijn voor de vorming van metastasen, waaronder celmigratie door 
bloedvaten van de ene plek naar de andere plek in het lichaam. Onder andere 
verhoogde celmotiliteit (vermogen tot beweging van een cel) en de aanmaak van 
bloedvaten (onder invloed van onder andere het VEGF eiwit) zijn hiervoor belangrijk. 
Uit eerder onderzoek is gebleken dat αB-crystalline aanwezig was op plekken in 
migrerende varkenslens epitheelcellen die nodig zijn voor de celmigratie. αB-
Crystalline zou dus invloed kunnen hebben op celmotiliteit. Verder is er reeds een 
onderzoek uitgevoerd dat liet zien dat er meer nieuwe bloedvatvorming in beschadigde 
retina van muizen plaatsvond wanneer er αB-crystalline in deze cellen aanwezig was. 
Deze bloedvatvorming was afhankelijk van VEGF. Om dit verder te onderzoeken is 
door ons geanalyseerd of een verlaging van de hoeveelheid αB-crystalline zowel 
invloed had op het vermogen van HNSCC cellen om te migreren als op het vermogen 
om VEGF uit te scheiden. De cellen bleken langzamer te bewegen en minder VEGF uit 
te scheiden wanneer er minder αB-crystalline aanwezig was. In andere cellen (HeLa 
cellen) is de hoeveelheid αB-crystalline juist verhoogd. Deze cellen bleken sneller te 
bewegen en meer VEGF uit te scheiden. In het geval van een tumor zou de 
aanwezigheid van veel αB-crystalline dus ook sneller bewegende cellen en een hogere 
VEGF productie kunnen betekenen, wat een bijdrage zou kunnen leveren aan de 
vorming van metastasen.  
Zoals beschreven in Hoofdstuk 2, zijn er in de meeste solide tumoren plekken 
aanwezig met weinig zuurstof (hypoxie genoemd). Dit komt doordat er te weinig of 
slecht gevormde bloedvaten in de tumoren aanwezig zijn. Een tekort aan zuurstof is 
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stressvol voor de cel en de expressie van αB-crystalline kan verhoogd worden door 
verschillende soorten stress. Daarom hebben in Hoofdstuk 4 in HNSCC biopten de 
aanwezigheid van αB-crystalline in hypoxische gebieden geanalyseerd middels het 
aankleuren van hypoxie en αB-crystalline met verschillende fluorescerende stoffen. 
Omdat er in hoge mate overlap werd gevonden, hebben we vervolgens bestudeerd 
welke invloed hypoxie heeft op de hoeveelheid αB-crystalline mRNA en αB-crystalline 
eiwit in HNSCC cellen. Het bleek dat hypoxie de hoeveelheid αB-crystalline juist 
verlaagt in plaats van verhoogt. Zoals uitgelegd in Hoofdstuk 2 kan het mogelijk zijn 
dat er toch af en toe bloed stroomt door de vaak slecht aangelegde bloedvaten in 
tumoren. Dit wordt hypoxie/reoxygenatie genoemd. Door de plotselinge toevoer van 
zuurstof kunnen reactieve zuurstofdeeltjes (reactive oxygen species, ROS genoemd) 
ontstaan. In Hoofdstuk 4 worden experimenten beschreven, waarin HNSCC cellen 
hypoxisch zijn gemaakt en daarna weer zuurstof aan de cellen is toegevoegd. De 
hoeveelheid αB-crystalline mRNA en eiwit bleek omlaag te gaan bij hypoxie en juist 
weer omhoog bij reoxygenatie. Om na te gaan of ROS de oorzaak is van deze 
verhoging, werden HNSCC cellen blootgesteld aan hogere hoeveelheden ROS door het 
toevoegen van H2O2 of aan een verlaging van de hoeveelheid door het toevoegen van 
een stofje wat ROS wegvangt. De hoeveelheid αB-crystalline mRNA in de cel bleek 
omhoog te gaan onder invloed van ROS en omlaag bij het wegvangen van ROS. Als 
ROS werd weggevangen tijdens de reoxygenatiefase ging de hoeveelheid αB-
crystalline mRNA minder omhoog. Dit wil zeggen dat αB-crystalline expressie tijdens 
reoxygenatie dus inderdaad gereguleerd kan worden door ROS. Daarna hebben we 
aangetoond dat αB-crystalline cellen die last hebben van hypoxie kan helpen 
overleven. Het was reeds bekend dat tumoren met veel hypoxische cellen vaker 
metastaseren (Hoofdstuk 2). Omdat αB-crystalline cellen in hypoxische regio's kan 
helpen overleven, zou αB-crystalline dus ook kunnen bijdragen aan de ontwikkeling 
van metastasen.  
Een andere veelvoorkomende kanker is borstkanker, die uit een heel diverse groep van 
tumoren bestaat (Hoofdstuk 2). Door na te gaan welke genen tot expressie komen in 
borsttumoren, kan er een brede onderverdeling worden gemaakt: tumoren die een 
expressiepatroon laten zien zoals normaal in de borst, luminaal A en B, verrijkt voor 
HER2 en expressie van 'basal-like' genen (Hoofdstuk 2). Deze biomarkers worden 
gebruikt om in een zo vroeg mogelijk stadium een diagnose te kunnen stellen en ook 
voor het verbeteren van de behandeling. Een andere manier voor de onderverdeling van 
borsttumoren is het aantonen van bepaalde receptoren (signaalontvangers) in de 
tumorcellen: de oestrogeenreceptor (ER), de progesteronreceptor (PR) en de HER2-
receptor (Hoofdstuk 2). Er zijn borsttumoren waarbij alle drie de receptoren niet tot 
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expressie komen. Deze tumoren worden 'triple-negatief' genoemd. De triple-negatieve 
tumoren laten vaak het basal-like genexpressiepatroon zien en patiënten met dit type 
tumor hebben een slechtere prognose. Omdat, zoals hierboven beschreven, de 
aanwezigheid van αB-crystalline ook een indicatie is voor een slechtere prognose, is in 
Hoofdstuk 5 bepaald of de expressie van αB-crystalline correleerde met de expressie 
van genen die in verband worden gebracht met het ontstaan van tumoren (pERK1/2, 
pAKT, pmTOR, EGFR en IGF-1R). Hierbij is ook geanalyseerd of αB-crystalline 
correleerde met 'triple-negativiteit' en met de expressie van basal-like genen (CK5/6 en 
SMA). Dit is gedaan met tissue microarrays (TMA), waarbij vele verschillende 
biopten tegelijkertijd aangekleurd en bestudeerd kunnen worden. αB-Crystalline 
expressie bleek inderdaad gecorreleerd met 'triple-negativiteit' en met de expressie van 
de basal-like genen. Dit zou kunnen betekenen dat patiënten met veel αB-crystalline in 
hun tumorbiopt geen baat hebben bij medicijnen die werken tegen de ER-, PR- en/of de 
HER2-receptor, omdat de kans groot is dat deze receptoren niet aanwezig zijn in de 
tumorcellen. Voor deze patiënten kan dan een andere therapie overwogen worden. 
Omdat de cellen dus αB-crystalline bevatten, zou deze therapie bijvoorbeeld tegen dit 
eiwit gericht kunnen zijn. Recentelijk is er een peptide ontwikkeld, die de binding 
tussen αB-crystalline en VEGF verstoort (Hoofdstuk 7). Deze peptide bleek de 
tumorgroei en aanmaak van bloedvaten te kunnen remmen. Mogelijk zou deze aanpak 
dus gebruikt kunnen worden bij de behandeling van (borst)kanker.  
De functie van eiwitten kan worden aangepast door kleine veranderingen aan te 
brengen, post-translationele modificaties genoemd. De functie van het αB-crystalline-
eiwit kan aangepast worden door op drie verschillende posities een fosfaatgroep te 
plaatsen (fosforylering genoemd), namelijk op serine 19, serine 45 en serine 59 
(Hoofdstuk 1). Wanneer serine 59 wordt gefosforyleerd, kan αB-crystalline verplaatst 
worden van het cytoplasma naar de nucleus. Fosforylering van serine 45 leidt ertoe, dat 
αB-crystalline zich in de kern ophoopt in bepaalde structuren, 'speckles' genoemd. Hoe 
αB-crystalline wordt verplaatst naar de kern en wat de functie is van αB-crystalline in 
de speckles was nog niet bekend. In Hoofdstuk 6 hebben we eerst geanalyseerd hoe 
αB-crystalline in de kern terecht kan komen. Door middel van een techniek die 'yeast 
two-hybrid screening' wordt genoemd, hebben we gevonden dat αB-crystalline, met 
nagebootste fosforylering op de drie eerder genoemde posities (αB-STD) kan binden 
aan een eiwit dat Gemin3 wordt genoemd. Dit eiwit maakt onderdeel uit van het 
zogenaamde SMN complex. Van dit complex was al bekend dat het betrokken is bij 
kernimport van eiwitten. Verlaging van de hoeveelheid Gemin2 eiwit (een ander eiwit 
uit het SMN complex) en Gemin3 eiwit bleek tot minder αB-STD speckles in de 
celkern te leiden. Om informatie te krijgen over de functie van αB-crystalline in de 
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celkern hebben we vervolgens bestudeerd wat celstress doet met de distributie van αB-
crystalline. We hebben dit gedaan door αB-STD tot overexpressie te brengen in HeLa 
cellen en deze 45 minuten bij 45oC te verhitten (heat-shocken) en daarna weer terug te 
brengen tot 37oC. Direct en 6 uur na de heat-shock was αB-STD diffuus vespreid door 
de kern. Na 24 uur was αB-STD weer in de speckles te vinden. Om the bepalen of αB-
crystalline in de kern ook chaperonne activiteit heeft, werd een ander eiwit (luciferase) 
in de kern tot overexpressie gebracht. Het bleek dat de functie van dit eiwit na een 
heat-shock sneller werd hersteld in aanwezigheid van αB-STD. Deze resultaten 
suggereren dat gefosforyleerd αB-crystalline in de speckles opgeslagen wordt totdat dit 
eiwit nodig is. Onder stress komt αB-crystalline dan vrij uit de speckles en kan het de 
slecht gevouwen eiwitten binden, zodat deze eiwitten uiteindelijk weer teruggevouwen 
kunnen worden in de juiste structuur en weer functioneel zijn.  
Het is duidelijk dat αB-crystalline een zeer veelzijdig eiwit is, dat zowel in het 
cytoplasma als in de celkern zijn functie kan uitoefenen. Het is ook evident dat dit 
eiwit kan bijdragen aan het uitzaaien van (HNSCC) tumoren. In dit proefschrift staan 
cellulaire processen beschreven, die hierbij betrokken kunnen zijn: verhoging van 
celmotiliteit, verhoogde uitscheiding van VEGF en het helpen van cellen bij de 
overleving van hypoxie. De moleculaire mechanismen die hiertoe leiden moeten nog 
opgehelderd worden. Het is daarom belangrijk dat de bijdrage van αB-crystalline aan 
deze processen verder bestudeerd wordt. 
  
207528-L-bw-Schootbrugge
 
 
 
 
155 
 
CURRICULUM VITAE 
 
Chantal van de Schootbrugge werd geboren op 21 augustus 1983 te Nunspeet. In 2001 
behaalde zij haar VWO-diploma aan het Nuborgh College Lambert Franckens te 
Elburg, waarna ze begon aan de studie Moleculaire Levenswetenschappen aan de 
Katholieke Universiteit Nijmegen, later Radboud Universiteit Nijmegen. Tijdens deze 
studie heeft ze tweemaal een wetenschappelijke stage gelopen, in 2004/2005 op de 
afdeling Moleculaire Dierfysiologie onder begeleiding van Prof. G. Martens en in 
2005/2006 op de afdeling Autoimmuun Biochemie (het huidige Biomoleculaire 
Chemie) onder begeleiding van Dr. G. J. M. Pruijn. In 2006 is zij cum laude 
afgestudeerd. Van 2006 tot 2007 heeft ze als onderzoeker in opleiding gewerkt op de 
afdeling Kindergeneeskunde van het Radboud Universitair Medisch Centrum. Daarna 
heeft ze van 2007 tot 2012 gewerkt als promovenda op de afdeling Biomoleculaire 
Chemie van de Radboud Universiteit Nijmegen, onder begeleiding van Prof. G. J. M. 
Pruijn en Dr. W.C. Boelens in samenwerking met de afdeling Radiotherapie van het 
Radboud Universitair Medisch Centrum onder begeleiding van Prof. J.H.A.M. 
Kaanders en Dr. J. Bussink. Gedurende deze periode werd het onderzoek verricht dat is 
beschreven in dit proefschrift. In de eerste helft van 2013 heeft ze het ‘Regulatory 
Affairs’ traineeship gevolgd bij Zwiers Regulatory Consultancy in Oss. Sinds augustus 
2013 is ze werkzaam als ‘Regulatory Project Leader’ bij het College ter Beoordeling 
van Geneesmiddelen in Utrecht. 
 
 
 
207528-L-bw-Schootbrugge
 
 
 
 
156 
 
PUBLICATIES 
 
van de Schootbrugge C., Boelens W.C. (2011): Introduction to Small Heat  Shock 
Proteins. In: Simon S., Arrigo A.P., editors. Small Stress Proteins and Human 
Diseases. Nova Science Publishers: 1  
 
van de Schootbrugge C.; Bussink J., Span P.N., Sweep F.C., Grenman R., Stegeman 
H., Pruijn G.J., Kaanders J.H.A.M., Boelens W.C. (2013): alphaB-crystallin stimulates 
VEGF secretion and tumor cell migration and correlates with enhanced distant 
metastasis in  head and neck squamous cell carcinoma. BMC Cancer 13: 128 
 
van de Schootbrugge C., van Asten F., Nagtegaal I.D., Versleijen-Jonkers Y.M., van 
Laarhoven H.W., Roeffen M.H., Sweep F.C., Bussink J., Kaanders J.H., Pruijn G.J., 
Boelens W.C., Span P.N. (2013): αB-crystallin expression is correlated with phospho-
ERK1/2 expression in human breast cancer. Int J Biol Markers  28: 365 
 
den Engelsman J., van de Schootbrugge C., Yong J, Pruijn G.J., Boelens  W.C. 
(2013): Pseudophosphorylated αB-crystallin is a nuclear chaperone imported into the 
nucleus with help of the SMN complex. PLoS One 8: 73489 
 
van de Schootbrugge C., Schults E.M., Bussink J., Span P.N., Grénman R., Pruijn 
G.J., Kaanders J.H., Boelens W.C. (2014): Effect of hypoxia on the expression of αB-
crystallin in head and neck squamous cell carcinoma. BMC Cancer 14: 252 
 
207528-L-bw-Schootbrugge
 
 
 
 
157 
 
DANKWOORD 
 
Zo. Ik ben er klaar mee. Letterlijk en figuurlijk! Maar niet voordat ik de mensen heb 
bedankt zonder wie ik dit proefschrift niet had kunnen voltooien, door de kennis die ze 
gedeeld hebben of de morele support die ze geboden hebben. 
 
Beste Wilbert, ik ken bijna geen optimistischer persoon dan jij. Waar ik 'te kritisch' kon 
zijn of resultaten 'kapot kon analyseren', zag jij altijd een mogelijkheid om verder te 
kijken, waardoor er nu uiteindelijk toch een boekje ligt. Heel erg bedankt hiervoor! En 
ik bewonder je enthousiasme voor de wetenschap! 
 
Beste Ger, heel erg bedankt dat ik na mijn stage (bij de 'oude' afdeling Autoimmuun 
Biochemie) weer aan de slag kon bij de 'nieuwe' afdeling Biomoleculaire Chemie. Een 
afdeling met zeer divers onderzoek, waardoor er toch altijd weer met een frisse blik 
naar mijn onderzoeksresultaten werd gekeken. Alle input tijdens de werkbesprekingen 
en brainstormavonden hebben enorm geholpen!  
 
Beste Lettie, hoe kan iemand nou zoveel weten? Ook bedankt voor alle input die je 
hebt gegeven! 
 
Hans en Jan, bedankt. Zonder de biopten en UT-SCC cellijnen, die ik heb mogen 
gebruiken, was een groot deel van mijn onderzoek niet mogelijk geweest. Paul, 
bedankt voor de prettige samenwerking! Dankzij jou is hoofdstuk 5 van dit proefschrift 
een feit en kon ik toch aan de 'vier gepubliceerde onderzoekshoofdstukken'-eis 
voldoen. Ook dank aan alle medewerkers van radiotherapie de me hebben geholpen bij 
mijn onderzoek. 
 
Lieve Els, het is fijn als mensen aan je denken als het goed gaat, maar nog fijner als 
iemand dat doet als het niet goed gaat! Het feit dat ik altijd alles tegen je heb kunnen 
zeggen, zonder erom veroordeeld te worden, heeft heel veel geholpen. Heel erg 
bedankt voor alle dingen die je voor me hebt gedaan, tijdens mijn 'officiële' 
promotietijd en erna! 
 
Ex-BMCers Joyce, Sanne, Lonneke, Remon (en Mariska) leuk dat we ook nu nog 
steeds contact hebben! Dames, de high teas houden we erin! (Prinses) Joyce, ik ben zo 
blij dat je je droombaan hebt gevonden in Maastricht. Lonneke, na een omzwerving via 
Italië, gelukkig weer terug in Arnhem. Misschien stranden we weer eens samen als de 
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treinen vanuit Utrecht weer eens een keer niet rijden ;-) Sanne, heel veel geluk samen 
met Walter in Mainz en bij BioNTech Diagnostics. Remon en Mariska, hoe kan ik 
jullie nu niet samen noemen . Alle geluk in jullie prachtige huis in Lithoijen enne, het 
wordt weer tijd voor een (nachtelijk) dansfeestje :-P Sandy, ook al zit je in het verre 
Amerika, dankzij Facebook lijkt het toch niet zó ver weg! Raymond, óók al zo ver weg 
daar in Kiwiland! Maar toch ook niet helemaal weg dankzij alterego 'Blehfaceboek'. 
Tamara, you seem perfectly happy back in Croatia. I hope to see you again one day, if 
only for some catching up in our old time favorite restaurant Romagna! Ook alle 
andere BMC oud-collega’s wil ik graag bedanken voor de leuke tijd op het lab én 
daarbuiten (Aesculaaf, labstap, dagjes uit, kampeertrips, filmpjes, etentjes of borrels): 
Angelique, Annemarie, Bas, Carla O., Carla W., Geurt, Helma, Ilmar, Judith, Kalok, 
Marina, Merel, Sander, Siebe en Tim. 
 
Studenten begeleiden was een aangename afwisseling met het labwerk en van jullie 
heb ik ook weer veel geleerd. Sjoerd, Simone, Floor en Elma, heel erg bedankt 
hiervoor! Elma, dankzij jouw doorzettingsvermogen hebben we hoofdstuk 4 van dit 
proefschrift toch kunnen publiceren! 
 
Ook wil ik Alex Zwiers en Karin Ruijtenbeek bedanken, omdat ze mij de kans hebben 
gegeven het ‘Regulatory Affairs’ traineeship te volgen bij Zwiers Regulatory 
Consultancy. Ik heb hier echt een heel leerzame en gezellige tijd gehad, alle 
medewerkers bedankt hiervoor! In het bijzonder wil ik natuurlijk de twee mede-
trainees Fatima en Çiğdem bedanken. Jullie hebben ook zeker wat van mijn 
proefschriftfrustraties meegekregen... Maar wat hebben we een lol gehad, met als 
hoogtepunt de bruiloft in Ankara! En uiteindelijk hebben we hier alle drie ook nog eens 
een superleuke baan aan overgehouden!  
 
Een baan bij het CBG dus. Wat een fijne organisatie om voor te mogen werken! Ik wil 
daarom mijn (farmacotherapeutische groep-2) collega's bedanken. De RPL'en voor alle 
tijd die ze in me hebben gestoken om mij het RPL vak te leren (en nog steeds!). Wat 
een ontzettend veelzijdig beroep, geen dag is hetzelfde. Heerlijk! Natuurlijk ook 
bedankt voor de gezelligheid, ik voelde me gelijk thuis in de groep. De beoordelaars 
bedankt voor de ontzettend prettige samenwerking. Door overleg is er zoveel te 
bereiken. En Jaap voor het vertrouwen om mij als 'jonge' RPL toch al veel 
verantwoordelijkheid te geven, zoals spreken op de commissie praktijkavond en 
deelname aan de Wetenschappelijk Advies commissie en Werkgroep Nationaal.  
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Gelukkig is er naast het werk ook nog zoiets als een sociaal leven, onontbeerlijk! 
Natuurlijk is er in dit dankwoord dan ook een plekje gereserveerd voor 
studievriendinnetjes Marij, Teunie, Emmy en Cynthia. Altijd geïnteresseerd hoe het 
met 'm'n boekie' stond en bereid om me op te beuren als ik het niet meer zag zitten☺. 
Ook al zijn we alle vijf heel verschillend, toch brengen we nog steeds heel wat leuke 
avondjes door met verjaardagen, etentjes en dansjes in Utrecht, Gent en Ibiza!  
 
Renske en Ronald, fijne vrienden van 'Hoogeveldt gang 27'. Ik denk nog altijd met een 
warm gevoel aan deze tijd terug en geniet nog steeds van onze bijklets- en 
saunamomenten!  
 
Lenneke, lief vriendinnetje, ook al woon je in het 'verre' Haarlem, we hebben altijd 
weer de grootste lol als we afspreken! Ook al denken we terug aan 'toen in 2011' ;-). 
 
De 'Nunspeet-gang': Edwin, Richard en Eric! Na al die jaren nog steeds contact! Af en 
toe een middagje bijkletsen in ons geliefde Nunspeet enne Eric, mijn technomaatje! 
Wat hebben we toch heerlijke dagen en nachten doorgedanst. Daar ben ik nog 
làààààààng niet klaar mee!!! 
 
Tim, Lyette, Stephanie, Remco, Leonie en Jeroen, ik kijk alweer uit naar het volgende 
(bioscoop)filmavondje, 80's/90's feestje of sushi/dans-event! 
 
Joost en Marjon, naast het samenwerken bij het CBG hebben we het daarbuiten ook erg 
gezellig met bijkletsetentjes/kroegavondjes of dansen (in Groningen). Joost, succes met 
je 'tweede fulltime baan' studeren en Marjon, ik blijf me verbazen waar je de tijd 
vandaan haalt voor je duobaan beoordelaar/onderzoeker Dermatologie bij het UMCG! 
 
Thanks Çiğdem (you Dutchy!!!) for being such a wonderful friend! I always enjoy the 
times we spend chatting, shopping and eating (cannot recall how many times we ate at 
Sumo Utrecht or Tai Soen any more) and so on! I am glad that Philipp will be coming 
to Europe soon, and we remain in touch definitely when you are moving across 
Europe. But first things first, delighted that you are still in The Netherlands and that 
you have agreed to be my paranymph! 
 
Lieve Michelle, wat hebben we samen al een hoop meegemaakt! Hele leuke, maar ook 
minder leuke dingen. Maar we slaan ons er altijd weer doorheen  Zoals je al eens 
hebt opgemerkt: ‘Wij doen niet aan zussendag, wij doen aan zussenjaar!’, van avondjes 
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kletsen en hangen op de bank, koken, terrassen, avondjes dansen tot zussenweekenden 
weg, we hebben het altijd gezellig! Ik ben trots dat je je (bijna) 'Master of Arts' mag 
noemen in Communicatie en Beïnvloeding! Zeker niet makkelijk geweest... ook hier... 
de laatste loodjes!!!! En ik ben natuurlijk superblij dat je mijn paranimf wilt zijn! 
 
Lieve Bas, ‘pas’ in oktober 2014 op mijn pad gekomen maar het lijkt al zoveel langer 
 Wat ben ik blij met jou! De laatste loodjes wegen zeker het zwaarst. Jij hebt me zo 
ontzettend gesteund! Alle keren dat ik in de avonden na werktijd en in de weekenden 
weer aan de slag moest wist je me altijd weer op te vrolijken! We hebben al zoveel 
fijne dingen gedaan en meegemaakt en daar komt nog veel meer bij! Maar ook een 
gewoon avondje thuis voor de buis is heel erg fijn met jou. HVJ! 
 
Lieve pap en mam! Wat ben ik ontzettend gek op jullie! Mam, je bent de meest lieve en 
verzorgende persoon die ik ken. Je hebt altijd zoveel voor je moeder, broers en zussen 
moeten doen en dat zonder morren. Daar heb ik heel veel respect voor. En in 2013 ook 
nog eens je MBO-diploma Verzorgende gehaald (past natuurlijk perfect bij je), 
fantastisch! En pap, niets is zo moeilijk als veranderen en toch heb je dat voor elkaar 
gekregen. Heel erg knap! Enne, als we langskomen ligt de kelder altijd weer vol met 
door jou meegenomen versnaperingen, des Schootbrugges! ‘Hmmmmm, lekker’! We 
houden allemaal van dezelfde humor en gezelligheid, daarom kom ik nog steeds altijd 
heel erg graag bij jullie langs! Kletsen, wandelen met de lieve Guc, een spelletje doen 
of een filmpje kijken, we vervelen ons nooit!  
 
Dit boekje is voor jullie, want wie had dit nu ooit gedacht, lang geleden in 1983…;-) 
 


